FM-X2215
8/19/06
3:25 PM
Page ii
Section Editors JOHN L. ATLEE, MD
TERRI G. MONK, MD
Professor of Anesthesiology Department of Anesthesiology Medical College of Wisconsin Milwaukee, Wisconsin
Professor Department of Anesthesiology Duke University Medical Center Durham, North Carolina
BRENDA A. BUCKLIN, MD
TIMOTHY E. MOREY, MD
Associate Professor of Anesthesiology Department of Anesthesiology University of Colorado Health Sciences Center Denver, Colorado
Associate Professor of Anesthesiology Department of Anesthesiology University of Florida College of Medicine Gainesville, Florida
MARK A. CHANEY, MD
MICHAEL J. MURRAY, MD, PHD
Associate Professor of Anesthesiology Department of Anesthesia and Critical Care University of Chicago Pritzker School of Medicine Chicago, Illinois
DONN M. DENNIS, MD, FAHA Joachim S. Gravenstein, MD, Professor of Anesthesiology Department of Anesthesiology University of Florida College of Medicine Gainesville, Florida Vice President-Pharmacology, ARYx Therapeutics, Inc. Santa Clara, California
JOHN ELLIS, MD Professor of Anesthesiology Department of Anesthesia and Critical Care University of Chicago Pritzker School of Medicine Chicago, Illinois
JOEL M. GUNTER, MD Professor of Clinical Anesthesia and Pediatrics Department of Anesthesia University of Cincinnati School of Medicine Attending Anesthesiologist Department of Anesthesia Children’s Hospital Medical Center Cincinnati, Ohio
ROSEMARY HICKEY, MD
Professor of Anesthesiology and Chair Department of Anesthesiology Mayo Clinic College of Medicine Jacksonville, Florida
NADER D. NADER, MD Associate Professor of Anesthesiology, Surgery and Pathology State University of New York at Buffalo School of Medicine Buffalo, New York
MICHAEL F. O’CONNOR, MD Associate Professor Department of Anesthesia and Critical Care University of Chicago Pritzker School of Medicine Chicago, Illinois
KERRI M. ROBERTSON, MD Associate Clinical Professor of Anesthesiology Chief, General, Vascular, High-Risk Transplant and Surgical Critical Care Medicine Division Chief, Transplant Services Duke University School of Medicine Department of Anesthesiology Durham, North Carolina
SCOTT R. SPRINGMAN, MD
Professor and Program Director Department of Anesthesiology University of Texas Health Science Center at San Antonio San Antonio, Texas
Professor Departments of Anesthesiology and Surgery University of Wisconsin Medical School Madison, Wisconsin
BRIAN M. ILFELD, MD
KEVIN K. TREMPER, MD
Associate Professor Department of Anesthesia University of California, San Diego San Diego, California
Professor and Chairman Department of Anesthesiology University of Michigan Medical Center Ann Arbor, Michigan
DONALD A. KROLL, MD, PHD
B. CRAIG WELDON, MD
Staff Anesthesiologist Department of Surgery Veterans Affairs Medical Center Biloxi, Mississippi
Associate Professor Department of Anesthesiology and Pediatrics Duke University School of Medicine Durham, North Carolina
FM-X2215
8/19/06
3:25 PM
Page iv
1600 John F. Kennedy Blvd. Ste 1800 Philadelphia, PA 19103-2899
COMPLICATIONS IN ANESTHESIA, 2nd edition
ISBN-13: 978-1-4160-2215-2 ISBN-10: 1-4160-2215-5
Copyright © 2007, 1999 by Saunders, an imprint of Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier’s Health Sciences Rights Department in Philadelphia, PA, USA: phone: (+1) 215 239 3804, fax: (+1) 215 239 3805, e-mail:
[email protected]. You may also complete your request on-line via the Elsevier homepage (http://www.elsevier.com), by selecting ‘Customer Support’ and then ‘Obtaining Permissions’.
Notice Knowledge and best practice in this field are constantly changing. As new research and experience broaden our knowledge, changes in practice, treatment, and drug therapy may become necessary or appropriate. Readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of the practitioner, relying on his or her own experience and knowledge of the patient, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions. To the fullest extent of the law, neither the Publisher nor the Editors assumes any liability for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this book. The Publisher
Library of Congress Cataloging-in-Publication Data Complications in anesthesia / [edited by] John L. Atlee. -- 2nd ed. p. ; cm. Includes bibliographical references and index. ISBN 1-4160-2215-5 1. Anesthesia--Complications. I. Atlee, John L. [DNLM: 1. Anesthesia--adverse effects. 2. Anesthetics--adverse effects. WO 245 C7369 2007] RD82.5.C63 2007 617.9′6041--dc22 2006040549
Executive Publisher: Natasha Andjelkovic Developmental Editor: Jean Nevius Publishing Services Manager: Tina Rebane Project Manager: Amy Norwitz Marketing Manager: Dana Butler
Printed in the United States of America Last digit is the print number: 9 8 7 6 5 4 3 2 1
FM-X2215
8/19/06
3:25 PM
Page v
To all who have contributed to this work, and to the patients we serve.
FM-X2215
8/19/06
3:25 PM
Page vii
Preface An ounce of prevention is worth a pound of cure. –ANONYMOUS The second edition of Complications in Anesthesia, like its first edition, is intended to provide all practitioners of anesthesia and critical care medicine with a comprehensive source of information for most complications that might be faced in clinical practice. Topics are addressed in ten sections: Pharmacology; General Anesthesia; Regional Anesthesia and Pain Management; Cardiothoracic and Vascular Surgery; Physiologic Imbalance and Coexisting Disease; Equipment and Monitoring; Pediatrics and Neonatology; Neurosurgery, Ophthalmology, and ENT; Other Surgical Subspecialties (subdivided into Obstetrics and Gynecology, General Surgery, Urologic Surgery, and Orthopedic Surgery); and Special Topics (subdivided into Postanesthesia Care Unit, Diagnostic or Therapeutic Intervention, and Medicolegal Aspects). Section Editors were selected based on their special expertise and knowledge of the topics addressed in each section. Each chapter is presented in a highly structured format (in accordance with problem-based learning) under the following headings and subheadings: Case Synopsis, Problem Analysis (divided into Definition, Recognition, Risk Assessment, Implications), Management, and Prevention; in chapters with more than one topic, each topic is addressed
using the same headings. Schematics, figures, and tables are used liberally to illustrate key points or to summarize important information. Key references are listed at the end of each chapter under “Further Reading,” avoiding in-text citations that might distract the reader. Some chapters contain footnotes that provide further explanations. In this way, the reader can gain useful insight into a topic of interest in the minimal amount of time and with maximal retention. Also, thumb indexing and liberal cross-referencing are intended to reduce the need for time-consuming index searches. Finally, under Further Reading, in text, or in footnotes, there are references to Web sites for more or updated information. In that way, the reader can keep abreast of new developments. I hope this unconventional treatment of complications in anesthesia and critical care will serve several purposes: first, to permit quick location and researching of topics of interest to busy practitioners in the least amount of time; second, to organize the thought processes involved in medical decisionmaking in an attractive format—i.e., akin to Sherlock Holmes’ “who done it?”; and third and most importantly, to reduce the risk to our patients for unexpected and untoward events. John L. Atlee, MD
vii
FM-X2215
8/19/06
3:25 PM
Page ix
Contributors Mark Abel, MD
Lori A. Aronson, MD, FAAP
Clinical Assistant Professor, Department of Anesthesiology, Mount Sinai Medical Center, New York, New York Vaporizers
Assistant Professor of Clinical Anesthesia and Pediatrics, Department of Anesthesia, University of Cincinnati College of Medicine; Assistant Professor, Clinical Anesthesia and Pediatrics, Department of Anesthesia, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Hypoxemia
Gaury S. Adhikary, MD, FRCA Assistant Professor, Department of Anesthesiology, University of Michigan Hospitals, Ann Arbor, Michigan Carbon Dioxide Absorbers
Maurice S. Albin, MD, MSc (Anes) Professor of Anesthesiology, Department of Anesthesiology, University of Alabama School of Medicine, Birmingham, Alabama Venous Air Embolism
Stacey L. Allen, MD Assistant Professor of Anesthesiology, Department of Anesthesiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Corneal Injury; Open Globe Injury
Steven J. Allen, MD Professor of Anesthesiology, Ohio State University College of Medicine; Chief Executive Officer, Columbus Children’s Hospital, Columbus, Ohio Autonomic Hyperreflexia
Jonathan M. Anagnostou, MD Associate Professor of Clinical Anesthesia, Department of Anesthesia, Indiana University School of Medicine; Staff Anesthesiologist, Medical Director of Respiratory Care, Department of Anesthesia, Respiratory Care, Indiana University Hospital, Indianapolis, Indiana Blood and Blood Products: Hepatitis and HIV
Maged Argalious, MD
John L. Atlee, MD Professor of Anesthesiology, Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin Adenosine; Disorders of Potassium Balance; Nonbarbiturate Anesthetics; Chemotherapeutic Agents; Cardiac Risk Assessment; Postobstruction Pulmonary Edema; Perioperative Tachyarrhythmias; Tachyarrhythmias with Ventricular Preexcitation; Long QT Syndromes and Ventricular Arrhythmias; Patients with Cardiac Rhythm Management Devices; Disorders of Water Homeostasis: Hyponatremia and Hypernatremia
Michael S. Avidan, MD Associate Professor of Anesthesiology and Surgery; Division Chief, CT Anesthesiology and CT Intensive Care, Washington University School of Medicine, St. Louis, Missouri HIV Infection and AIDS
Isaac Azar, MD Professor of Anesthesiology, Albert Einstein College of Medicine; Consultant, Department of Anesthesiology, Beth Israel Medical Center, New York, New York Scavenging Systems
James E. Baker, MD, FRCPC Assistant Professor and Anesthesiologist, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, California Postoperative Pulmonary Hypertension
Staff Anesthesiologist, Departments of General Anesthesiology and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, Ohio Complications of Trauma Surgery
Narayan Baliga, MD
George A. Arndt, MD
Shahar Bar-Yosef, MD
Professor (CHS), Department of Anesthesiology, University of Wisconsin Medical School, Madison, Wisconsin Difficult Airway: Cannot Ventilate, Cannot Intubate
Assistant Professor, Department of Anesthesiology and Critical Care, Duke University School of Medicine, Durham, North Carolina Complications of Laparoscopic Surgery
Staff Anesthesiologist, Kenosha Hospital and Medical Center, Kenosha, Wisconsin Difficult Airway: Opiate-Induced Muscle Rigidity
ix
FM-X2215
8/19/06
x
3:25 PM
Page x
Contributors
Juliana Barr, MD
Lois L. Bready, MD
Associate Professor, Department of Anesthesiology, Stanford University School of Medicine, Stanford, California; Staff Intensivist and Anesthesiologist, Veterans Affairs Palo Alto Health Care System, Anesthesiology Service, Palo Alto, California Reversal Agents: Naloxone and Flumazenil
Professor and Vice Chair, Department of Anesthesiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Corneal Injury
Curtis L. Baysinger, MD Associate Professor, Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, Tennessee Hypertensive Disorders of Pregnancy
Eric Bedell, MD Associate Professor, Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas Posterior Fossa Surgery
Joan Benca, MD Associate Professor, Department of Anesthesiology, University of Wisconsin Hospital and Clinics, Madison, Wisconsin Bronchospasm
Patrick E. Benedict, MD Assistant Professor of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Transesophageal Echocardiography
Thomas P. Broderick, MD Assistant Professor, Department of Anesthesiology, University of Wisconsin Hospital and Clinics, Madison, Wisconsin Preanesthetic Evaluation: Inadequate or Missing Test Result
David L. Brown, MD Edward Rotan Distinguished Professor and Chairman, Department of Anesthesiology and Pain Medicine, M.D. Anderson Cancer Center, Houston, Texas Celiac Plexus Block: Side Effects and Complications
Adrie Bruijinzeel, MD Assistant Professor, Department of Psychiatry, Evelyn and William McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Florida Chemical Dependency: Opioids
Brenda A. Bucklin, MD Associate Professor of Anesthesiology, Department of Anesthesiology, University of Colorado Health Sciences Center, Denver, Colorado Fetal Distress
Matthew D. Caldwell, MD David G. Bjoraker, MD Associate Professor, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida Anaphylaxis and Anaphylactoid Reactions
Assistant Professor, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Pulmonary Artery Pressure Monitoring
William R. Camann, MD Susan Black, MD Professor, Department of Anesthesiology, University of Alabama School of Medicine, Birmingham, Alabama Antidepressants
Associate Professor, Department of Anesthesia, Harvard Medical School; Director of Obstetric Anesthesia, Brigham and Women’s Hospital, Boston, Massachusetts Pulmonary Aspiration in the Parturient
Maria I. Castro, PhD William S. Blau, MD, PhD Associate Professor of Anesthesiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina Opioid Tolerance
Assistant Professor, Department of Anesthesiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas Class II Antiarrhythmic Drugs: β-Blockers—Heart Block or Bradycardia
Steffan Blumenthal, MD
Kevin P. Chan, MD
Assistant Professor, Department of Anesthesiology and Reanimation, Orthopedic University Clinic Balgrist/Zurich, Zurich, Switzerland Interscalene Nerve Block: Potential Severe Complications
Fellow in Cardiovascular Anesthesia, Stanford University School of Medicine, Stanford, California Nonbarbiturate Anesthetics
Mark A. Chaney, MD John C. Boncyk, MD Assistant Professor, Department of Anesthesiology, University of Wisconsin Hospital and Clinics, Madison, Wisconsin Perioperative Hypoxia
Associate Professor of Anesthesiology, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Perioperative Myocardial Ischemia and Infarction; Adverse Neurologic Sequelae: Central Neurologic Impairment; Hypercoagulable States: Thrombosis and Embolism
Alain Borgeat, MD Professor and Chief of Staff, Department of Anesthesiology and Reanimation, Orthopedic University Clinic Balgrist/Zurich, Zurich, Switzerland Interscalene Nerve Block: Potential Severe Complications
Amit V. Chawla, MD Consultant, Department of Anesthesia, Guy’s Hospital, London, United Kingdom Inspiratory and Expiratory Gas Monitoring
FM-X2215
8/19/06
3:25 PM
Page xi
Contributors
xi
David C. H. Cheng, MD, MSc, FRCPC
James C. Crews, MD
Professor and Chair, Department of Anesthesia and Perioperative Medicine, University of Western Ontario; Anesthesiologist in Chief, London Health Sciences Center and St. Joseph’s Health Care, London, Ontario, Canada Fast-Track Cardiac Surgery
Associate Professor of Anesthesiology, Section of Regional Anesthesia and Acute Pain Management, Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina Infectious Complications of Central Neuraxial Block
Deborah A. Davis, MD S. Devi Chiravuri, MD Assistant Professor, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Rapid Fluid and Blood Delivery Systems
Gordon Lee Collins, MD Clinical Fellow, Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri Complications after Pneumonectomy
Lois A. Connolly, MD Associate Professor, Department of Anesthesiology, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin Unstable Cervical Spine, Atlantoaxial Subluxation
D. Ryan Cook, MD Professor of Anesthesiology, Department of Anesthesiology, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania Hypoglycemia and Hyperglycemia
Clinical Professor of Anesthesiology, Department of Anesthesiology, Thomas Jefferson University – Jefferson Medical College, Philadelphia, Pennsylvania; Pediatric Anesthesiologist/Intensivist, Nemours Cardiac Center, A.I. duPont Hospital for Children, Wilmington, Delaware Pulmonary Hypertension
Martin L. De Ruyter, MD Associate Professor of Anesthesiology, Department of Anesthesiology, Kansas University School of Medicine, Kansas City, Kansas Hyperglycemia and Diabetic Ketoacidosis; Sarcoidosis
Hernando De Soto, MD Associate Professor, Department of Pediatric Anesthesia, University of Florida Health Science Center; Staff Anesthesiologist/Medical Director of the OR, Department of Anesthesiology, SHANDS Jacksonville, Jacksonville, Florida Difficult Pediatric Airway
Donn M. Dennis, MD, FAHA
Assistant Professor of Anesthesia, Department of Anesthesiology and Critical Care Medicine, University of Pennsylvania School of Medicine; Associate Anesthesiologist, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Ophthalmic Problems and Complications
Joachim S. Gravenstein, MD, Professor of Anesthesiology, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida; Vice PresidentPharmacology, ARYx Therapeutics, Inc., Santa Clara, California Class III Antiarrhythmic Drugs: Potassium Channel Blockers; Class IV Antiarrhythmic Drugs: Calcium Channel Blockers
Victoria Coon, CRNA, MS
Ronak Desai, DO
Scott D. Cook-Sather, MD
Perioperative Director and Anesthesiology Department Administrator, Kaiser Permanente, West Los Angeles, Los Angeles, California Quality Assurance; Cost Containment
Resident, CA-2, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Peripheral Vascular Surgery
John R. Cooper, Jr., MD
Cheryl DeSimone, MD
Clinical Associate Professor of Anesthesiology, University of Texas Health Science Center; Associate Chief, Cardiovascular Anesthesia; Co-Director, Cullen Cardiovascular Research Laboratories, Texas Heart Institute, Houston, Texas Troubleshooting Common Problems during Cardiopulmonary Bypass
Cyrus DeSouza, MB,BS, FANZCA
Associate Professor of Anesthesiology, Obstetrics and Gynecology, Department of Anesthesiology, Albany Medical College; Director of Obstetric Anesthesia, Albany Medical Center, Albany, New York Embolic Events of Pregnancy
Director of Clinical Research in Pediatric Anesthesia, Department of Anesthesiology, Massachusetts General Hospital, Boston, Massachusetts Sedation of Pediatric Patients
Acting Assistant Professor, Cardiothoracic Anesthesiologist, Department of Anesthesiology, University of Washington Medical Center, Seattle, Washington; Staff Specialist Anaesthetist, Department of Anaesthetics, St. Georges Hospital, Sydney, NSW, Australia Chronotropic Drugs
Douglas B. Coursin, MD
Clifford S. Deutschman, MD
Professor of Anesthesiology and Internal Medicine, Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin Adrenal Insufficiency
Professor, Department of Anesthesia and Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania Sepsis, Systemic Inflammatory Response Syndrome, and Multiple Organ Dysfunction Syndrome
Charles J. Coté, MD
FM-X2215
8/19/06
xii
3:25 PM
Page xii
Contributors
Pema Dorje, MD
Brenda G. Fahy, MD, FCCP, FCCM
Clinical Assistant Professor, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Arterial Blood Pressure Monitoring
Professor, Department of Anesthesiology, University of Kentucky; Director of Critical Care, Department of Anesthesiology, AB Chandler Medical Center, Lexington, Kentucky Disorders of Water Homeostasis: Hyponatremia and Hypernatremia
Anthony R. Doyle, BSc, MB,BS, FRCA Formerly, Visiting Instructor in Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan; Consultant Anaesthetist, Dorset County Hospital, Dorchester, United Kingdom Fires in the Operating Room
Kenneth Drasner, MD Professor, Department of Anesthesiology and Perioperative Care, University of California, San Francisco, San Francisco, California Local Anesthetic Neurotoxicity: Cauda Equina Syndrome
Catherine Drexler, MD Vice Chair, Department of Anesthesiology, ColumbiaSt. Mary’s-Milwaukee Campus, Milwaukee, Wisconsin Angioedema and Urticaria
Zhuang T. Fang, MD, MSPH Assistant Clinical Professor, Department of Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California Unanticipated Hospital Admission and Readmission
Doron Feldman, MD Associate Professor of Clinical Anesthesiology, State University of New York at Buffalo School of Medicine; Attending in Anesthesiology, Children’s Hospital of Buffalo, Buffalo, New York The Hostile-Combative Patient
Lynne R. Ferrari, MD
Ellen Duncan, MD
Associate Professor, Department of Anesthesia, Harvard Medical School; Medical Director, Perioperative Services, Children’s Hospital, Boston, Massachusetts Adenotonsillectomy
Tejas Anesthesia, San Antonio, Texas Open Globe Injury
Matthew P. Feuer, MD
Martin W. Dünser, MD Resident in Anesthesiology and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Medical University Innsbruck, Innsbruck, Austria Vasopressors: Vasoconstrictor Drugs
Jörg Dziersk, MD, FRCA Assistant Professor of Anesthesiology, Department of Anesthesiology, University of Washington School of Medicine, Seattle, Washington Vasodilator Drugs
Michael P. Eaton, MD Associate Professor, Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, New York Proportioning Systems; Patient Warming Systems
Charles E. Edmiston, Jr., MS, PhD Associate Professor, Department of Surgery; Director, Surgical Microbiology Research Laboratory, Medical College of Wisconsin, Milwaukee, Wisconsin Nosocomial Infections: Bacterial Pneumonia
Staff Anesthesiologist, Department of Anesthesiology, Virginia Mason Medical Center, Seattle, Washington Spinal Anesthesia: Post–Dural Puncture Headache
Stephanie S. F. Fischer, MD Visiting Associate in Cardiothoracic and Critical Care, Division of Pediatric Anesthesiology, Duke University School of Medicine, Durham, North Carolina Cardiomyopathies
M. Pamela Fish, MB,ChB Associate Professor, Department of Anesthesiology, Stanford University School of Medicine, Stanford, California; Staff Physician, Veterans Affairs Palo Alto Health Care System, Palo Alto, California Antiemetic Drugs
Randall Flick, MD, MPH Assistant Professor of Anesthesiology and Pediatrics, Department of Anesthesiology and Pediatrics, Mayo Clinic College of Medicine; Chair, Section of Pediatric Anesthesiology, Mayo Clinic, Rochester, Minnesota Anterior Mediastinal Mass
Michael P. Ford, MD
Professor of Anesthesiology, Mount Sinai School of Medicine, New York, New York Vaporizers
Assistant Professor of Anesthesiology, Department of Anesthesiology, University of Wisconsin Medical School, Madison, Wisconsin Preanesthetic Evaluation: False-Positive Tests; Difficult Airway: Cannot Ventilate, Cannot Intubate
John Ellis, MD
Jennifer T. Fortney, MD
Professor of Anesthesiology, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Carotid Endarterectomy; Thoracic Aortic Aneurysm
Assistant Clinical Professor, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina Fat Embolism Syndrome
James B. Eisenkraft, MD
FM-X2215
8/19/06
3:25 PM
Page xiii
Contributors
xiii
James M. T. Foster, MD
Mark S. Gold, MD
Clinical Assistant Professor of Anesthesiology, Department of Anesthesiology, State University of New York at Buffalo School of Medicine; Director of Anesthesiology Services, Kaleida Health, Buffalo, New York The Hostile-Combative Patient
Distinguished Professor and Chief, Departments of Psychiatry, Neuroscience, Anesthesiology, Community Health and Family Medicine, Evelyn and William McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Florida Chemical Dependency: Opioids; Chemical Dependency: Nonopioids
Melissa Franckowiak, MD Resident, Department of Anesthesiology, State University of New York at Buffalo School of Medicine, Buffalo, New York Cardioversion
Eugene B. Freid, MD Associate Professor, Departments of Anesthesiology and Pediatrics, University of North Carolina Hospitals, Chapel Hill, North Carolina Succinylcholine
Kimberly Frost-Pineda, MD Assistant in Psychiatry, Department of Psychiatry, Director of Public Health Research, University of Florida College of Medicine, Gainesville, Florida Chemical Dependency: Opioids; Chemical Dependency: Nonopioids
Jeffrey L. Galinkin, MD Associate Professor, Department of Anesthesia, Children’s Hospital, Denver, Colorado Fetal Intrauterine Surgery
Arjunan Ganesh, MD Assistant Professor of Anesthesia, Department of Anesthesia, University of Pennsylvania School of Medicine; Assistant Anesthesiologist, Department of Anesthesiology and Critical Care Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Upper Respiratory Tract Infection
Hind M. Gautam, MD Clinical Assistant Professor, Department of Anesthesiology, Veterans Affairs Medical Center, Buffalo, New York Magnetic Resonance Imaging
Rodolfo Gebhardt, MD
Stuart Grant, MD Assistant Professor, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina Continuous Nerve Blocks: Perineural Local Anesthetic Infusion
Glenn P. Gravlee, MD Professor, Department of Anesthesiology, Ohio State University Hospitals, Columbus, Ohio Hemodilution and Blood Conservation
Ivar Gunnarsson, MD Landspítali—háskólasjúkrahús, Reykjavik, Iceland Oxygen Flush Valve
Mary Ann Gurkowski, MD Professor of Anesthesiology, University of Texas Health Science Center at San Antonio; Clinical Staff/Director of Medical Students, Department of Anesthesiology/Crossappointed to Otorhinolaryngology, University Hospital; Attending Staff, Department of Anesthesiology, Audie Murphy Veterans Affairs Hospital, San Antonio, Texas Foreign Body Aspiration
Jacob Gutsche, MD Physician, Department of Anesthesia, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania Sepsis, Systemic Inflammatory Response Syndrome, and Multiple Organ Dysfunction Syndrome
Thomas S. Guyton, MD Staff Anesthesiologist, Methodist Healthcare of Memphis, Memphis, Tennessee Magnesium; Antibiotics
Assistant Professor of Clinical Anesthesiology, Department of Anesthesiology, Department of Clinical Anesthesiology, Veterans Affairs Medical Center, Buffalo New York Uncontrolled Pain
Ali Habibi, MD
Jeremy M. Geiduschek, MD
Saeed Habibi, MD
Clinical Professor, Department of Anesthesiology, University of Washington School of Medicine; Director, Clinical Anesthesia Services, Department of Anesthesiology, Children’s Hospital and Regional Medical Center, Seattle, Washington Intraoperative Cardiac Arrest
J. C. Gerancher, MD Associate Professor and Section Head, Regional Anesthesia and Acute Pain Management, Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina Epidural Anesthesia: Unintended Intrathecal Injection; Epidural Anesthesia: Unintended Subdural Injection
Adjunct Clinical Faculty, Anesthesiology, Stanford University School of Medicine, Stanford, California Antihistamines: H1- and H2-Blockers Chair, Department of Anesthesiology, Columbia– St. Mary’s–Milwaukee Campus, Milwaukee, Wisconsin Angioedema and Urticaria
Charles B. Hantler, MD Professor, Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri Bradyarrhythmias
H. David Hardman, MD, MBA Assistant Clinical Professor, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina Extremity Tourniquets
FM-X2215
8/19/06
xiv
3:25 PM
Page xiv
Contributors
Barry A. Harrison, MB,BS
Liana Hosu, MD
Assistant Professor of Anesthesiology, Department of Anesthesiology, Mayo Clinic College of Medicine, Jacksonville, Florida Hyperglycemia and Diabetic Ketoacidosis; Sarcoidosis
Assistant Professor of Anesthesia and Pediatrics, Department of Anesthesiology, University of Cincinnati College of Medicine; Staff Anesthesiologist, Department of Anesthesiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Postoperative Apnea in Infants
Joy L. Hawkins, MD Professor of Anesthesiology and Director of Obstetric Anesthesia, University of Colorado School of Medicine, Denver, Colorado Nonobstetric Surgery during Pregnancy
Christopher M. B. Heard, MB,ChB, FRCA Research Assistant Professor, Department of Anesthesiology and Division of Pediatric Critical Care, State University of New York at Buffalo School of Medicine; Assistant Attending, Children’s Hospital of Buffalo, Buffalo, New York Magnetic Resonance Imaging; Alleged Malpractice; The HostileCombative Patient
Stephen O. Heard, MD Interim Chair, Professor of Anesthesiology and Surgery, University of Massachusetts Medical School, Worcester, Massachusetts Perioperative Care of Immunocompromised Patients
James R. Hebl, MD Assistant Professor, Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota Anticoagulants and Peripheral Nerve Block
Robert F. Helfand, MD Associate Professor, Cleveland Clinic Lerner College of Medicine; Staff Anesthesiologist; Vice Chairman, Department of General Anesthesiology; Section Head of Orthopedic Anesthesia, Glickman Urological Center, Cleveland Clinic Foundation, Cleveland, Ohio Thromboembolic Complications
Rosemary Hickey, MD Professor and Program Director, Department of Anesthesiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Intracranial Hypertension
Kate Huncke, MD Clinical Associate Professor, Department of Anesthesiology, New York University School of Medicine, New York, New York Radiation Oncology
Samuel A. Irefin, MD Associate Professor of Anesthesiology, Cleveland Clinic Lerner College of Medicine; Staff Anesthesiologist, Department of Anesthesiology and Critical Care Medicine, Cleveland Clinic Foundation, Cleveland, Ohio Complications of Thyroid Surgery
William Jacobs, MD Associate Professor, Departments of Psychiatry and Anesthesiology, University of Florida College of Medicine, Gainesville, Florida Chemical Dependency: Opioids; Chemical Dependency: Nonopioids
Eric Jacobsohn, MB,ChB, MHPE, FRCPC Associate Professor of Anesthesiology, Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri Complications after Pneumonectomy
J. Michael Jaeger, MD, PhD Associate Professor of Anesthesiology and Neurological Surgery; Director, Thoracic Anesthesia, Department of Anesthesiology, University of Virginia Health Sciences Center, Charlottesville, Virginia Class IV Antiarrhythmic Drugs: Calcium Channel Blockers
George A. Higgins, BSN, MS, CRNA Adjunct Faculty, Department of Nursing, University of Southern California; Senior Nurse Anesthetist, Department of Anesthesiology, Department of Veterans Affairs Medical Center, Los Angeles, California Embolization Procedures
Scott Holliday, MD Resident, Department of Anesthesiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Foreign Body Aspiration
William Hope, MD, PhD Assistant Professor, Department of Anesthesiology, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital East, Milwaukee, Wisconsin Laryngeal and Tracheal Injury
Michael F. M. James, MB,ChB, PhD, FRCA, FCA(SA) Professor and Head, Department of Anesthesia, University of Cape Town; Professor and Chief Anaesthetist, Department of Anaesthesia, Groote Schuur Hospital, Cape Town, Western Cape, South Africa Complications of Adrenal Surgery
Gregory M. Janelle, MD Assistant Professor, Chief of Cardiovascular Anesthesia, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida Phosphodiesterase Inhibitors
David R. Jobes, MD Terese T. Horlocker, MD Professor, Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota Spinal Hematoma; Persistent Paresthesia
Professor of Anesthesia, Department of Anesthesia and Critical Care Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Complications of Massive Transfusion
FM-X2215
8/19/06
3:25 PM
Page xv
Contributors
Nicola Jones, MA, MB,BS, DTM&H, MRCP, MRCPath, PhD Consultant in Microbiology and Infectious Diseases, Departments of Microbiology and Infectious Diseases, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom HIV Infection and AIDS
Shailendra Joshi, MD Assistant Professor of Anesthesiology, Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, New York Arteriovenous Malformation: Normal Perfusion Pressure Breakthrough
Zeev N. Kain, MD Professor of Anesthesiology, Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut Perioperative Psychological Trauma
Wendy B. Kang, MD Associate Professor and Chair, Residency Education Committee, Department of Anesthesiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Retrobulbar Block
Shubjeet Kaur, MD Clinical Vice Chair, Department of Anesthesiology, University of Massachussets Memorial Medical Center, Worcester, Massachusetts Perioperative Care of Immunocompromised Patients
Robert D. Kaye, MD Assistant Professor of Clinical Anesthesiology and Pediatrics, State University of New York at Buffalo School of Medicine; Attending Anesthesiologist, Children’s Hospital of Buffalo, Buffalo, New York Alleged Malpractice
xv
Jonathan T. Ketzler, MD Associate Professor of Anesthesiology; Associate Director, Trauma and Life Support Center, Department of Anesthesiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin Adrenal Insufficiency
Evan D. Kharasch, MD, PhD Assistant Dean for Clinical Research; Professor and Research Director, Department of Anesthesiology, University of Washington School of Medicine, Seattle, Washington Volatile Anesthetics: Organ Toxicity
M. Sean Kincaid, MD Resident, Department of Anesthesiology, University of Washington Medical Center, Seattle, Washington Head Injury
Kathryn P. King, MD Associate Clinical Professor, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina Methylmethacrylate
Kai T. Kiviluoma, MD, PhD Associate Professor, Department of Anaesthesiology, University of Oulu Faculty of Medicine; Head of the Department, Paediatric Anaesthesia, Oulu University Hospital, Oulu, Finland Disorders of Potassium Balance
Jerome M. Klafta, MD Associate Professor and Associate Chair for Education, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Mediastinal Masses
Pattricia S. Klarr, MD Paul E. Kazanjian, MD Clinical Assistant Professor, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Fires in the Operating Room; Pulmonary Artery Pressure Monitoring
Clinical Assistant Professor, Department of Anesthesiology, University of Michigan Medical School; Associate Clinical Director, Department of Anesthesiology, University of Michigan Medical Center, Ann Arbor, Michigan Laser Complications
Jeffrey S. Kelly, MD
Sandra L. Kopp, MD
Associate Professor of Anesthesiology, Section of Critical Care, Wake Forest University School of Medicine, Winston-Salem, North Carolina Complications from Toxic Ingestion
Kevin J. Kelly, MD Professor and Chair, Department of Pediatrics; Associate Dean, School of Medicine, Children’s Mercy Hospital and Clinics, University of Missouri, Kansas City, Missouri Latex Reactions in Health Care Personnel
Instructor, Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota Supraclavicular and Infraclavicular Block: Pneumothorax
Donald A. Kroll, MD, PhD Staff Anesthesiologist, Department of Surgery, Veterans Affairs Medical Center, Biloxi, Mississippi Quality Assurance; Cost Containment; Adverse Outcomes: Withheld Information or Misinformation
Robert E. Kettler, MD
Kenneth Kuchta, MD
Associate Professor, Department of Anesthesiology, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital East, Milwaukee, Wisconsin Patients with Seizure Disorders; Latex Reactions in Health Care Personnel
Assistant Clinical Professor, Department of Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California Misidentification of a Patient
FM-X2215
8/19/06
xvi
3:25 PM
Page xvi
Contributors
C. Dean Kurth, MD
Ray P. Liao, MD
Professor of Anesthesia and Pediatrics, University of Cincinnati College of Medicine, Anesthesiologist-in-Chief; Chair, Institute for Pediatric Research; Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Postoperative Apnea in Infants
Acting Assistant Professor, Department of Anesthesiology, University of Washington School of Medicine, Seattle, Washington Inotropic Drugs
Spencer S. Liu, MD Arthur M. Lam, MD, FRCPC Professor of Anesthesiology, Department of Anesthesiology, University of Washington School of Medicine; Head of Neuroanesthesia, Harborview Medical Center, Seattle, Washington Head Injury
Jeffrey L. Lane, MD Assistant Professor of Clinical Anesthesia and Director, Human Simulation Laboratory, Department of Anesthesia, Indiana University School of Medicine; Staff Anesthesiologist, Clarian Health Partners, Indianapolis, Indiana Postoperative Respiratory Insufficiency
Clinical Professor of Anesthesiology, Department of Anesthesiology, Virginia Mason Medical Center, Seattle, Washington Spinal Anesthesia: Post–Dural Puncture Headache
Emilio B. Lobato, MD Professor of Anesthesiology, Department of Anesthesiology, University of Florida College of Medicine; Chief, Cardiovascular Anesthesia, Department of Anesthesia Service, Malcom Randall Veterans Affairs Hospital, Gainesville, Florida Digitalis
Robert G. Loeb, MD Paul B. Langevin, MD Associate Professor, Department of Anesthesiology, Veterans Affairs–West Haven, West Haven, Connecticut Chemotherapeutic Agents
Associate Professor of Anesthesiology, University of Arizona College of Medicine, Tucson, Arizona Flowmeters
Celeste M. Lombardi, MD Melissa A. Laxton, MD Assistant Professor of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina Pituitary Tumors: Diabetes Insipidus
Fellow in Interventional Pain Medicine, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida Chronic Nonsteroidal Anti-inflammatory Drug Use
Prashant Lotlikar, MD Marcia M. Lee, MD, MBA Assistant Chief, Department of Anesthesiology, Kaiser Permanente–South Bay, Harbor City, California Awareness under Anesthesia
Clinical Assistant Professor, Department of Anesthesiology, University of Texas Health Science Center, Texas Heart Institute, Houston, Texas Troubleshooting Common Problems during Cardiopulmonary Bypass
Mijin Lee, MD Assistant Clinical Professor, Department of Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California Anesthesia for Electroconvulsive Therapy
Peter J. Lee, MD, MPH Formerly, Assistant Professor, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Central Venous Pressure Monitoring
Philip Levin, MD Associate Professor, Department of Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California Postoperative Delirium
Jerrold H. Levy, MD Professor and Department Chair/Research, Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia Perioperative Hypertension
Ian Lewis, MB,BS, MRCP, FRCA Associate Professor, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Surgical Diathermy and Electrocautery
Michelle L. Lotto, MD Assistant Professor of Anesthesiology, Department of General Anesthesiology and Critical Care Medicine, Cleveland Clinic Lerner College of Medicine; Associate Staff Anesthesiologist, Cleveland Clinic Foundation, Cleveland, Ohio Complications of Spinal Surgery
Katarzyna Luba, MD Assistant Professor of Clinical Anesthesiology, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Perioperative Management of Patients with Muscular Dystrophy
Stewart J. Lustik, MD Associate Professor of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, New York Proportioning Systems; Patient Warming Systems
Vinod Malhotra, MD Professor and Vice Chair for Clinical Affairs, Department of Anesthesiology, Weill Medical College of Cornell University, New York–Presbyterian Hospital, New York, New York Complications of Transurethral Surgery
FM-X2215
8/19/06
3:25 PM
Page xvii
Contributors
xvii
Christina M. Matadial, MD
Terri G. Monk, MD
Assistant Professor, Department of Anesthesiology, Leonard M. Miller School of Medicine at the University of Miami; Staff Physician, Department of Anesthesiology, Jackson Memorial Hospital, Miami, Florida Surgery in the Morbidly Obese
Professor, Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina Intraoperative Penile Erection; Complications of Radical Urologic Surgery
Lisa M. Montenegro, MD Viktoria D. Mayr, MD Resident in Anesthesiology and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Medical University Innsbruck, Innsbruck, Austria Vasopressors: Vasoconstrictor Drugs
Assistant Professor of Anesthesiology, University of Pennsylvania School of Medicine and Children’s Hospital of Philadelphia; Attending Anesthesiologist, Department of Anesthesiology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Complications of Massive Transfusion
Deborah A. McClain, MD Chief, Anesthesiology Section, Veterans Affairs Medical Center, Biloxi, Mississippi Delayed Emergence
Thomas McCutchen, MD Assistant Professor, Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina Epidural Anesthesia: Unintended Intrathecal Injection; Epidural Anesthesia: Unintended Subdural Injection
David L. McDonagh, MD Resident, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina Autonomic Dysreflexia
Susan B. McDonald, MD Staff Anesthesiologist, Department of Anesthesiology, Virginia Mason Medical Center, Seattle, Washington Side Effects of Neuraxial Opioids
Lynda J. Means, MD Professor of Anesthesia and Surgery, Department of Anesthesia, Indiana University School of Medicine, Indianapolis, Indiana Postobstruction Pulmonary Edema in Pediatric Patients
Mark Meyer, MD Assistant Professor of Clinical Anesthesia, Department of Anesthesia, University of Cincinnati College of Medicine; Assistant Professor, Clinical Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Perioperative Aspiration Pneumonitis
Mohammed Minhaj, MD Assistant Professor, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Adverse Neurologic Sequelae: Peripheral Nerve Injury
Vivek Moitra, MD Assistant Professor of Anesthesiology, Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, New York Carotid Endarterectomy
Timothy E. Morey, MD Associate Professor of Anesthesiology, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida Magnesium; Antibiotics
Lucille A. Mostello, MD Assistant Professor of Anesthesiology and Pediatrics, Department of Anesthesiology, George Washington University School of Medicine; Staff Anesthesiologist, Department of Anesthesiology, Children’s National Medical Center, Washington, DC Latex Allergy
Isobel Muhiudeen-Russell, MD Professor, Department of Anesthesia, University of California, San Francisco, San Francisco, California Postoperative Pulmonary Hypertension
J. Thomas Murphy, MD, FRCPC Associate Professor, Department of Anesthesiology, University of Kentucky College of Medicine, Lexington, Kentucky Disorders of Water Homeostasis: Hyponatremia and Hypernatremia
Catherine Friederich Murray Research Associate, Department of Anesthesiology, Mayo Clinic College of Medicine, Jacksonville, Florida Parkinson’s Disease; Alzheimer’s Disease
Michael J. Murray, MD, PhD Professor of Anesthesiology and Chair, Department of Anesthesiology, Mayo Clinic College of Medicine, Jacksonville, Florida Parkinson’s Disease; Alzheimer’s Disease
David Muzic, MD Fellow in Cardiac Anesthesia, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Adverse Neurologic Sequelae: Central Neurologic Impairment
Nader D. Nader, MD Constance L. Monitto, MD Assistant Professor of Anesthesiology, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medical Institute, Baltimore, Maryland Muscle Relaxants
Associate Professor of Anesthesiology, Surgery and Pathology, State University of New York at Buffalo School of Medicine, Buffalo, New York Uncontrolled Pain; Hemodynamic Instability; Cardioversion
FM-X2215
8/19/06
xviii
3:25 PM
Page xviii
Contributors
Carsten Nadjat-Haiem, MD
Hector F. Nicodemus, MD
Assistant Professor, Department of Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California Syringe Swaps
Pediatric Anesthesiologist, Department of Anesthesiology, Holy Cross Hospital, Silver Spring, Maryland Delayed Emergence in Pediatric Patients
Susan C. Nicolson, MD Mohamed Naguib, MB,Bch, MSc, FFARCSI, MD Professor, Department of Anesthesia, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa Myasthenic Disorders
Professor of Anesthesia, Department of Anesthesia, University of Pennsylvania School of Medicine; Division Director, Cardiothoracic Anesthesia, Department of Anesthesiology and Critical Care Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Upper Respiratory Tract Infection
Bhiken Naik, MD Fellow, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida Intrathecal Opiates; Ketamine; Steroids
David A. Nakata, MD Associate Clinical Professor and Vice Chair, Residency Development, Department of Anesthesia, Indiana University School of Medicine, Indianapolis, Indiana Postoperative Peripheral Neuropathy; Intractable Nausea and Vomiting
Charles A. Napolitano, MD, PhD Associate Professor; Director, Division of Cardiothoracic Anesthesia; Co-Director, Residency Program, Department of Anesthesiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas Class II Antiarrhythmic Drugs: β-Blockers—Heart Block or Bradycardia
Susan H. Noorily, MD Clinical Professor, Department of Anesthesiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Laryngoscopy and Microlaryngoscopy
Mark Nunnally, MD Assistant Professor, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Postoperative Acute Renal Failure; Metabolic Acidosis and Alkalosis
Christopher J. O’Connor, MD Associate Professor, Department of Anesthesiology, Rush University Medical Center, Chicago, Illinois Abdominal Aortic Aneurysm Repair
Michael F. O’Connor, MD Bradly J. Narr, MD Associate Professor and Chair, Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota Porphyrias
Associate Professor, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Thermally Injured Patients
Jerome F. O’Hara, Jr., MD Krishna M. Natrajan, MB,BS, FRCA Assistant Professor of Adult and Pediatric Cardiothoracic Anesthesiology, Department of Anesthesiology, University of Washington School of Medicine; Attending Anesthesiologist, Department of Anesthesiology, University of Washington Medical Center, Seattle, Washington Inotropic Drugs
Norah Naughton, MD Associate Professor of Anesthesiology and Associate Professor of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, Michigan Intracranial Pressure Monitoring
Patrick Neligan, MD Assistant Professor, Department of Anesthesia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania Metabolic Acidosis and Alkalosis
Philippa Newfield, MD Assistant Clinical Professor of Anesthesia and Neurosurgery, University of California, San Francisco, School of Medicine; Attending Anesthesiologist, Department of Anesthesiology, California Pacific Medical Center, San Francisco, California Intracranial Aneurysms: Rebleeding; Intracranial Aneurysms: Vasospasm and Other Issues
Associate Professor, College of Medicine, Case Western Reserve University; Vice Chairman, Department of General Anesthesiology; Section Head of Anesthesia, Glickman Urological Center, Urology Department, Cleveland Clinic Foundation, Cleveland, Ohio Complications of Lithotripsy ..
Maria A. K. Ohrn, MD Anesthesiology Associates of North Florida, PA, North Florida Regional Medical Center, Gainesville, Florida Nondepolarizing Neuromuscular Relaxants
Nollag O’Rourke, MD Fellow in Obstetric Anesthesia, Department of Anesthesia, Brigham and Women’s Hospital, Boston, Massachusetts Pulmonary Aspiration in the Parturient
Sheela S. Pai, MD Assistant Professor, Department of Anesthesiology, Baylor College of Medicine; Staff Anesthesiologist, Department of Anesthesiology and Critical Care, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas Mechanical Assist Devices
Craig M. Palmer, MD Professor of Clinical Anesthesiology; Director, Obstetric Anesthesia, University of Arizona College of Medicine, Tucson, Arizona Preterm Labor
FM-X2215
8/19/06
3:25 PM
Page xix
Contributors
xix
C. Lee Parmley, MD, JD
William Prince, MD
Professor of Anesthesiology, Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee Autonomic Hyperreflexia
Department of Anesthesiology, Kaiser Permanente Oakland Medical Center, Oakland, California Central Venous Pressure Monitoring
Lester T. Proctor, MD Komal Patel, MD Fellow in Cardiac Anesthesia, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Hypercoagulable States: Thrombosis and Embolism
D. Janet Pavlin, MD Professor, Department of Anesthesiology, University of Washington School of Medicine; Head of Teaching and Research in Ambulatory Anesthesia, Department of Anesthesia, University of Washington Medical Center, Seattle, Washington Postoperative Urinary Retention
Padmavathi Perala, MD Anesthesiologist, Department of Anesthesiology, Veterans Affairs Medical Center, Buffalo, New York Hemodynamic Instability
Patricia H. Petrozza, MD Professor of Anesthesiology, Associate Dean for Graduate Medical Education, Wake Forest University School of Medicine, Winston-Salem, North Carolina Pituitary Tumors: Diabetes Insipidus
Linda S. Polley, MD
Professor, Departments of Anesthesiology and Pediatrics, University of Wisconsin Medical School, Madison, Wisconsin Blood and Blood Products: Transfusion Reaction
Donald S. Prough, MD Professor and Chair, Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas Perioperative Fluid Management; Posterior Fossa Surgery
M. J. Pekka Raatikainen, MD Division of Cardiology, Oulu University Central Hospital, Oulu, Finland Adenosine; Class III Antiarrhythmic Drugs: Potassium Channel Blockers
Lee M. Radke, DDS Assistant Professor, Oral and Maxillofacial Surgery, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin Dental Injuries
Sivam Ramanathan, MD
Associate Professor, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Postpartum Hemorrhage
Professor of Anesthesiology, University of Pittsburgh School of Medicine, Magee-Womens Hospital, Pittsburgh, Pennsylvania Humidifiers; Peripartum Neurologic Complications
David Porembka, FCCM
James G. Ramsay, MD
Professor of Anesthesia, Surgery and Internal Medicine (Cardiology), Department of Anesthesiology; Associate Director of Surgical Intensive Care; Director of Perioperative Echocardiography, University of Cincinnati College of Medicine, Cincinnati, Ohio Postoperative Respiratory Failure
Professor of Anesthesiology, Program Director, Anesthesiology Critical Care Medicine, Department of Anesthesia, Emory University School of Medicine; Anesthesiology Service Chief, Department of Anesthesiology, Emory University Hospital, Atlanta, Georgia Central Venous Pressure Monitoring
Claudia Praetel, MD
Monica N. Riesner, MD
Research Fellow, Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, New York Nitrous Oxide: Neurotoxicity
Joseph Previte, MD Associate Professor of Pediatrics and Anesthesiology, Project Leader of Anesthesia Centricity IS, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Anesthetic Complications of Fetal Surgery: EXIT Procedures; Perioperative Aspiration Pneumonitis
Lecturer, Obstetric Anesthesia, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Postpartum Hemorrhage
Edward T. Riley, MD Associate Professor, Department of Anesthesia, Stanford University School of Medicine, Stanford, California Antihistamines: H1- and H2-Blockers
Pamela R. Roberts, MD, FCCM, FCCP Richard C. Prielipp, MD, FCCM JJ Buckley Professor and Chair, Department of Anesthesiology, University of Minnesota Medical School, Minneapolis, Minnesota Hypothyroidism: Myxedema Coma; Hyperthyroidism: Thyroid Storm
Professor and Division Chief, Critical Care Medicine, John A. Moffitt Endowed Chair, Department of Anesthesiology, University of Oklahama Health Science Center, Oklahoma City, Oklahoma Hypothyroidism: Myxedema Coma; Hyperthyroidism: Thyroid Storm
FM-X2215
8/19/06
xx
3:25 PM
Page xx
Contributors
Kerri M. Robertson, MD
Ramachandran Satya-Krishna, MD, FRCA
Associate Clinical Professor of Anesthesiology; Chief, General, Vascular, High-Risk Transplant and Surgical Critical Care Medicine Division; Chief, Transplant Services, Duke University School of Medicine, Department of Anesthesiology, Durham, North Carolina Postoperative Hepatic Dysfunction; Complications of Carcinoid Tumors; Complications of Deliberate Hypotension: Visual Loss
Lecturer, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan; Consultant, Department of Anaesthesia, John Radcliffe Hospital, Oxford, United Kingdom Anesthesia Circuit
Marnie Robinson, MD Assistant Professor of Anesthesiology and Pediatrics, Department of Anesthesiology, University of Cincinnati College of Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Anesthetic Complications of Fetal Surgery: EXIT Procedures
John B. Rose, MD Director, Pain Management Service, Department of Anesthesiology and Critical Care Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Delayed Emergence in Pediatric Patients
Mark I. Rossberg, MD Assistant Professor of Anesthesiology, Department of Anesthesia and Critical Care Medicine, Johns Hopkins Medical Institute, Baltimore, Maryland Postintubation Croup
Scott R. Schulman, MD Associate Professor of Anesthesiology and Pediatrics, Division of Pediatric Anesthesia and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina Malignant Hyperthermia
Annette Schure, MD Anesthesiologist and Pediatric Anesthesiologist, Department of Anesthesia, Tufts-New England Medical Center, Boston, Massachusetts Thoracic Aortic Aneurysm
Jeffrey J. Schwartz, MD Associate Professor, Department of Anesthesiology, Yale University School of Medicine; Attending Physician, Department of Anesthesiology, Yale-New Haven Hospital, New Haven, Connecticut Electrical Safety
Christian Seefelder, MD David M. Rothenberg, MD Professor of Anesthesiology; Associate Dean, Academic Affiliations; Co-Medical Director, Surgical Intensive Care Unit, Rush University Medical Center, Chicago, Illinois Acute Pancreatitis
Assistant in Anaesthesia, Harvard Medical School; Instructor in Anaesthesia, Department of Anaesthesiology, Perioperative and Pain Medicine, Children’s Hospital, Boston, Massachusetts Air Emboli
Daniel D. Rubens, MB,BS, FANZCA
Rajamani Sethuraman, MD, FRCA
Assistant Professor, Department of Anesthesia, University of Washington School of Medicine, Children’s Hospital and Regional Medical Center, Seattle, Washington Intraoperative Cardiac Arrest
Consultant Anaesthetist, Department of Anaesthesia, Princess Alexandra Hospital, Essex, United Kingdom Intravenous Drug Delivery Systems
Christoph N. Seubert, MD Senthilkumar Sadhasivam, MD Assistant Professor in Anesthesia and Pediatrics, Department of Anesthesia, University of Cincinnati College of Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Postoperative Nausea and Vomiting
Tetsuro Sakai, MD, PhD Resident, Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Complications in Orthopedic Outpatients Not Receiving Peripheral Nerve Blocks
Francis V. Salinas, MD Clinical Assistant Professor, Department of Anesthesiology, University of Washington School of Medicine; Staff Anesthesiologist, Department of Anesthesiology, Virginia Mason Medical Center, Seattle, Washington Local Anesthetic Systemic Toxicity
Theodore J. Sanford, Jr., MD Clinical Professor of Anesthesiology, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Difficult Airway: Opiate-Induced Muscle Rigidity
Assistant Professor, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida Barbiturates: Porphyrias
Jack S. Shanewise, MD Chief, Division of Cardiothoracic Anesthesiology, Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, New York Transesophageal Echocardiography
Kelly T. Shannon, MD Associate Professor of Anesthesiology, University of Pittsburgh School of Medicine; Associate Chief, Department of Anesthesiology, Magee-Womens Hospital, Pittsburgh, Pennsylvania Humidifiers
Gauhar Sharih, MD, FRCA Formerly, Visiting Instructor, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan; Specialist Registrar, Department of Anaesthetics, City Hospital, Birmingham, West Midlands, United Kingdom Inspiratory and Expiratory Gas Monitoring
FM-X2215
8/19/06
3:25 PM
Page xxi
Contributors
Aarti Sharma, MD, DA(UK)
Mark D. Stoneham, MD, FRCA
Assistant Professor of Anesthesiology, Department of Anesthesiology, Weill Medical College of Cornell University; Attending Anesthesiologist, Department of Anesthesiology, New York–Presbyterian Hospital, New York, New York Complications of Deliberate Hypotension: Visual Loss
Honorary Senior Clinical Lecturer, Nuffield Department of Anaesthesia, John Radcliffe Hospital, Oxford, United Kingdom Pulse Oximetry
Robert N. Sladen, MD Professor and Vice Chair, Department of Anesthesiology; Chief, Division of Critical Care, College of Physicians and Surgeons of Columbia University, New York, New York Postoperative Acute Renal Failure; Hypothermia
xxi
E. Price Stover, MD* Clinical Assistant Professor, Department of Anesthesia, Stanford University Medical Center, Stanford, California Nonbarbiturate Anesthetics
Laura Stover, MD, MASc, FRCP(C)
Professor of Anesthesia, Department of Anesthesiology, Toronto General Hospital, Toronto, Ontario, Canada One-Lung Ventilation
Acting Instructor, Department of Anesthesiology, University of Washington School of Medicine; Acting Instructor, Department of Cardiothoracic Anesthesiology, University of Washington Medical Center, Seattle, Washington; Assistant Professor of Anesthesiology, Hamilton Health Sciences, Hamilton, Ontario, Canada Drugs Affecting the Renin-Angiotensin System
Tod B. Sloan, MD
Vijayendra Sudheendra, MD
Professor of Anesthesiology, University of Colorado Health Sciences Center, Denver, Colorado Spinal Cord Injury
Clinical Instructor, Department of Surgery and Anesthesiology, Brown University School of Medicine; Staff Anesthesiologist, Miriam Hospital, Providence, Rhode Island; Chief of Anesthesia, East Bay Surgery Center, Swansea, Massachusetts Complications of Transurethral Surgery
Peter D. Slinger, MD
Jonathan H. Slonin, MD Chief Resident, Department of Anesthesiology, Leonard M. Miller School of Medicine at the University of Miami, Miami, Florida Surgery in the Morbidly Obese
Paul Smythe, MD Assistant Professor of Anesthesiology, University of Michigan Medical School; Adjunct Clinical Lecturer in Dentistry, Department of Oral and Maxillofacial Surgery/Hospital Dentistry, University of Michigan School of Dentistry, Ann Arbor, Michigan Intracranial Pressure Monitoring
Jennifer E. Souders, MD Clinical Associate Professor, Department of Anesthesiology, University of Washington School of Medicine, Seattle, Washington Venous Air Embolism
Scott R. Springman, MD Professor, Departments of Anesthesiology and Surgery, University of Wisconsin Medical School, Madison, Wisconsin Preanesthetic Evaluation: False-Positive Tests; Preanesthetic Evaluation: Inadequate or Missing Test Result
James M. Steven, MD Associate Professor of Anesthesia and Pediatrics, Department of Anesthesia, University of Pennsylvania School of Medicine; Chief Medical Officer, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Upper Respiratory Tract Infection
Robert K. Stoelting, MD Emeritus Professor and Chair, Department of Anesthesia, Indiana University School of Medicine, Indianapolis, Indiana Postoperative Peripheral Neuropathy; Intractable Nausea and Vomiting
Kevin J. Sullivan, MD Assistant Professor of Anesthesiology, Mayo Clinic College of Medicine; Clinical Assistant Professor of Pediatrics, University of Florida College of Medicine, Jacksonville; Staff Member, Department of Anesthesiology, Nemours Children’s Clinic; Staff Pediatric Anesthesiologist and Intensivist, Department of Anesthesia and Critical Care Medicine, Wolfson Children’s Hospital, Jacksonville, Florida Anticholinergics; Hypothermia in Pediatric Patients
Christer H. Svensén, MD Associate Professor, Department of Anesthesiology, University of Texas Medical Branch, Galveston, Texas Perioperative Fluid Management
James F. Szocik, MD Associate Professor, Department of Anesthesiology, University of Michigan Medical School; Chair, Technical Support Committee, Department of Anesthesiology, University of Michigan Medical Center, Ann Arbor, Michigan Pipeline Source Failure
Kenichi A. Tanaka, MD Assistant Professor, Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia Perioperative Hypertension
Mark D. Tasch, MD Associate Professor of Clinical Anesthesia, Department of Anesthesia, Indiana University School of Medicine, Indianapolis, Indiana Pulmonary Aspiration
*Deceased
FM-X2215
8/19/06
xxii
3:25 PM
Page xxii
Contributors
Peter Tassani-Prell, MD
Karen M. Van Tassel, MD
Professor of Cardiac Anesthesia, Department of Anesthesia, German Heart Center Munich, München, Germany Anticoagulation Initiation and Reversal for Cardiac Surgery; Bleeding after Cardiac Surgery
Chief Resident, Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina Malignant Hyperthermia
Lisa Thannikary, MD
Gurinder M. S. Vasdev, MB,BS
Adjunct Assistant Professor, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida Intrathecal Opiates; Ketamine; Steroids
Klaus D. Torp, MD Assistant Professor of Anesthesiology, Department of Anesthesiology, Mayo Clinic College of Medicine, Jacksonville, Florida Perioperative Management of Dialysis-Dependent Patients
Laurence C. Torsher, MD Assistant Professor of Anesthesiology, Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota Perioperative Care for Patients with Hepatic Insufficiency (Cirrhosis)
Mark F. Trankina, MD Staff Anesthesiologist, Carraway Methodist Medical Center and University of Alabama Hospital at Birmingham, Birmingham, Alabama Class I Antiarrhythmic Drugs: Ventricular Proarrhythmia
Kenneth W. Travis, MD Associate Professor Emeritus, Department of Anesthesiology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire Postobstruction Pulmonary Edema
Lawrence C. Tsen, MD Associate Professor of Anesthesia, Department of Anesthesia, Harvard Medical School; Director of Anesthesia, Center for Reproductive Medicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Boston, Massachusetts Antepartum Hemorrhage
Avery Tung, MD Associate Professor, Department of Anesthesia and Critical Care, University of Chicago Pritzker School of Medicine, Chicago, Illinois Major Organ System Dysfunction after Cardiopulmonary Bypass; Mechanical Assist Devices; Thermally Injured Patients
Manuel C. Vallejo, MD, DMD Associate Professor, Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Peripartum Neurologic Complications
Gail A. Van Norman, MD Clinical Associate Professor of Anesthesiology, Affiliate Associate Professor of Medical History and Ethics, University of Washington School of Medicine, Seattle, Washington; Physician, Department of Anesthesiology, St. Joseph Medical Center, Tacoma, Washington Patient Confidentiality; Do-Not-Resuscitate Orders in the Operating Room; The Jehovah’s Witness Patient
Assistant Professor of Anesthesiology, Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota Cardiopulmonary Bypass in Pregnancy
Melissa M. Vu, MD Instructor of Anesthesiology, Department of Anesthesiology, Mayo Clinic College of Medicine, Jacksonville, Florida Hyperthermia
Mehernoor F. Watcha, MD Associate Professor of Anesthesia, Department of Anesthesiology and Critical Care Medicine, University of Pennsylvania School of Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Postoperative Nausea and Vomiting
Eileen Watson, MD Clinical Assistant Professor, Department of Anesthesiology, State University of New York at Buffalo; Attending Anesthesiologist, Children’s Hospital of Buffalo, Buffalo, New York Hemodynamic Instability
B. Craig Weldon, MD Associate Professor, Department of Anesthesiology and Pediatrics, Duke University School of Medicine, Durham, North Carolina Cardiomyopathies; Emergence Agitation
Robert S. Weller, MD Associate Professor of Anesthesiology, Department of Anesthesiology, Wake Forest University School of Medicine; Staff Anesthesiologist, Department of Anesthesiology, North Carolina Baptist Hospitals, Inc., Winston-Salem, North Carolina Psoas Compartment Block: Potential Complications
Lynda Wells, MD Associate Professor of Anesthesiology, University of Virginia Health System, Charlottesville, Virginia Pediatric Neurosurgery
Volker Wenzel, MD, MSc Associate Professor of Anesthesiology and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Medical University of Innsbruck, Innsbruck, Austria Vasopressors: Vasoconstrictor Drugs
Harshdeep Wilkhu, MD Clinical Assistant Professor, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida Nonbarbiturate Anesthetics
FM-X2215
8/19/06
3:25 PM
Page xxiii
Contributors
Brian A. Williams, MD
Brian J. Woodcock, MD
Associate Professor, Department of Anesthesiology, University of Pittsburgh School of Medicine; Director of Outpatient Regional Anesthesia Service, Department of Anesthesiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Complications in Orthopedic Outpatients Not Receiving Peripheral Nerve Blocks
Assistant Professor of Anesthesiology, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan Mechanical Ventilators
Glyn D. Williams, MB,ChB, FFA Associate Professor, Department of Anesthesia, Stanford University School of Medicine, Lucile Packard Children’s Hospital, Palo Alto, California Catheter Ablation for Arrhythmias
xxiii
Christopher C. Young, MD, FCCM Assistant Clinical Professor of Surgery, Associate Clinical Professor of Anesthesiology, Chief of Critical Care Medicine Division, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina Hypothermia
William L. Young, MD
Assistant Professor, Departments of Anesthesiology and Pediatrics, University of Colorado School of Medicine, Denver, Colorado Antidepressants; Air Emboli
James P. Livingston Professor and Vice Chair, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco General Hospital, San Francisco, California Arteriovenous Malformation: Normal Perfusion Pressure Breakthrough
Eric P. Wittkugel, MD
Christine M. Zainer, MD
Associate Professor of Clinical Anesthesia and Critical Care; Staff Anesthesiologist; Director, Preoperative Services, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio Pediatric Laryngospasm
Assistant Professor of Anethesiology, Department of Anesthesiology, Medical College of Wisconsin, Froedtert Memorial Lutheran Hospital East, Milwaukee, Wisconsin Herbals and Alternative Medicine
Lisa Wise-Faberowski, MD
Mark A. Zakowski, MD David J. Wlody, MD Clinical Associate Professor of Anesthesiology and Vice Chair for Clinical Affairs, Department of Anesthesiology, State University of New York-Downstate Medical Center; Interim Chair, Department of Anesthesiology, Long Island College Hospital, Brooklyn, New York Postpartum Headache Other Than Post–Dural Puncture Headache
Gilbert Y. Wong, MD Assistant Professor of Anesthesiology and Consultant Physician, Division of Pain Medicine, Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, Minnesota Celiac Plexus Block: Side Effects and Complications
Chief, Section of Obstetric Anesthesia, Department of Anesthesiology, Cedars-Sinai Medical Center, Los Angeles, California Peripartum Neurologic Complications
Paul B. Zanaboni, MD, PhD Anesthesiologist, St. John’s Mercy Health Care, St. Louis, Missouri Bradyarrhythmias
R. Victor Zhang, MD, PhD Assistant Professor, Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida a2-Adrenoreceptor Agonists
FM-X2215
8/19/06
3:25 PM
Page xxv
Acknowledgments First, I wish to acknowledge the contributions to this work of my wife Barbara, my in-house administrative and editorial assistant. Thank you, Barbara! Your literary skills (you did major in English and minor in Philosophy) were much needed and greatly appreciated! I am deeply indebted to the Section Editors for this edition of Complications in Anesthesia, some of whom were Section Editors for the first edition as well. Organizing the topics for their sections or subsections, recruiting contributors, and seeing to it that the chapter manuscripts were submitted and pre-edited in a timely fashion were some of their tasks. Special appreciation goes to Natasha Andjelkovic (Executive Publisher), Jean Nevius (Senior Developmental Editor), and Amy Norwitz (Senior Project Manager). Once again, I salute Lewis Reines (former President of WB Saunders) and Leslie Day (former Medical Editor at WB Saunders), who in 1996-1997 convinced me of the need for this conceptually new work as a resource for busy practitioners in anesthesia and critical care. Finally, I express my sincere appreciation to John P. Kampine, MD, PhD, former Professor and Chair of the Department of Anesthesiology at the Medical College of Wisconsin, and to my colleagues in that department (some of whom have contributed to this work) for providing me the time and encouragement for yet again undertaking this work. John L. Atlee, MD
xxv
Ch001-X2215
8/12/06
3:05 PM
Page 3
PHARMACOLOGY
VASOACTIVE DRUGS
1
Vasodilator Drugs Jörg Dziersk Case Synopsis A 90-year-old man with severe aortic stenosis, stable angina, and pulmonary hypertension has surgery under general anesthesia for a femoral neck fracture. Owing to the associated cardiac morbidities, the anesthesiologist inserts a pulmonary artery catheter. Despite maintenance of normoxemia and mild hypocapnia, the patient’s pulmonary artery pressure rises from 60/25 to 70/35 mm Hg and is associated with signs of right ventricular strain. A nitroglycerin infusion is started at 0.2 μg/kg per minute. The pulmonary artery pressure returns to near baseline values, and the systemic blood pressure decreases from 125/90 to 75/30 mm Hg.
PROBLEM ANALYSIS Definition Left-sided heart disease (e.g., mitral valve disease, aortic stenosis, left ventricular failure) often causes significant pulmonary venous pressure elevation and leads to compensatory pulmonary artery (PA) hypertension. Chronic elevation of PA pressure promotes compensatory right ventricular (RV) hypertrophy and pulmonary vascular remodeling. This, in turn, results in increased pulmonary vascular resistance (PVR). For such patients, acute (or acute-on-chronic) increases in PA pressure are often poorly tolerated. The consequences are RV dilatation, significant tricuspid regurgitation, and reduced cardiac output secondary to reduced venous return and impaired left ventricular filling. Together, they may lead to a “downward spiral.” When RV systolic pressure exceeds aortic blood pressure, RV coronary perfusion is limited to diastole, which may further impair RV performance. Vasodilating drugs act by reducing the contraction of vascular smooth muscle cells through a reduction in cytoplasmic Ca2+ concentration [Ca2+]. Vascular smooth muscle relaxation may be mediated by the following: ●
●
●
● ●
●
Increased intracellular cyclic adenosine monophosphate (e.g., β2-adrenoceptor agonists, epoprostenol) Increased intracellular cyclic guanosine monophosphate (e.g., nitric oxide, nitroglycerin, sodium nitroprusside, brain natriuretic peptide) KATP channel-opening-related hyperpolarization (e.g., diazoxide) α1-Adrenoceptor antagonism (e.g., phentolamine) Ca2+ channel blockade (e.g., diltiazem, nicardipine, verapamil) Reduction of central sympathetic tone (e.g., clonidine)
Properties of an ideal vasodilator for perioperative use include (1) short onset time, (2) short to intermediate duration of action, (3) elimination independent of organ function (i.e., renal or hepatic), and (4) lack of serious side
effects or toxicity. At this time, there is no single drug that meets all these criteria. Clinical actions, mechanisms of action, and side effects of vasodilators currently available for intravenous or inhalational administration are listed in Table 1-1.
Recognition Systemic vasodilatation causes a decline in systemic blood pressure, the extent of which depends on circulating blood volume and venous return (cardiac preload), the adequacy of compensatory mechanisms (i.e., reflex increase in heart rate and contractility), and the cardiac ejection fraction (normal or reduced). The skin appears warm and may be flushed, with a shortened capillary refill time. Organ dysfunction may occur if systemic blood pressure is below the respective autoregulation threshold or if flow in a vascular territory is pressure dependent (e.g., in the presence of coronary artery disease, renal artery stenosis, head injury). Myocardial injury, acute renal failure, or neurologic deficits are typical examples of complications of systemic hypotension. Computation of systemic vascular resistance quantifies the average degree of vasodilatation (or vasoconstriction) in the whole body, but it requires a precise measurement of mean arterial pressure and central venous pressure, as well as a determination of cardiac output. A PA catheter equipped for thermodilution cardiac output is necessary. In the presence of PA hypertension, systemic vasodilatation may allow right-to-left shunting of blood through a patent foramen ovale, leading to a diminished arterial oxygen saturation. Reduced RV preload due to venous pooling and RV myocardial perfusion pressure may compromise RV performance and result in a low cardiac output state.
Risk Assessment Vasodilator therapy has an increased potential to cause complications in patients with the following conditions: ● ● ●
Hypovolemia Stenotic valvular lesions (especially severe aortic stenosis) Hypertrophic-obstructive cardiomyopathy 3
Ch001-X2215
8/12/06
4
3:05 PM
Section 1
Table 1–1
■
■
Page 4
Pharmacology
Vasodilators Available for Intravenous or Inhalational Administration
Drug Class and Drug*
Terminal Half-life
α1-Antagonists Labetalol
5-8 hr
Phentolamine
19 min (IV)
Urapidil†
2.7 hr
α2-Adrenoceptor Agonists Clonidine
8-16 hr
Donors Nitric oxide
6 sec
Nitroglycerin
2-8 min
Sodium nitroprusside
3-4 min
Blockers Diltiazem
3-6 hr
Nicardipine
8.6 hr (infusions ≥48 hr)
Verapamil
2-8 hr
Angiotensin-Converting 11 hr
Venous > arterial vasodilatation NO or S-nitrosothiol release by metabolism ⇒ activation of guanylyl cyclase Arterial ª venous vasodilatation NO release by red cell metabolism ⇒ activation of guanylyl cyclase
Bradycardia Drug fever Reflex tachycardia Hypoglycemia
Bradycardia Potentiates anesthetic/narcotic sedation Slow IV onset (30-60 min)
Arterial vasodilatation Vascular remodeling Inhibits generation of angiotensin II Stimulates kallikrein-kinin system
18 min
Cyanide toxicity, especially with higher doses and lengthy infusions Thiocyanate toxicity (lengthy infusions) Methemoglobinemia Reflex tachycardia
Vasodilatation unpredictable Little effect in PA HTN
Possibly severe (first dose) Acute renal failure ↑ K+, especially with renal failure No effect on PA HTN (given acutely) Slow IV onset (>15 min)
Severe systemic hypotension with IV dosing (common) Inhibition of platelet aggregation and adhesion Stimulates coughing (inhalational use)
5-10 min 3-5 min 13-30 min
Natriuretic Peptides
Inhibits platelet aggregation Pulmonary edema secondary to contaminants (NO2) and metabolites (peroxynitrite) Methemoglobinemia Tachyphylaxis Methemoglobinemia
Moderate negative inotrope AV conduction blockade Does not block L-type cardiac Ca2+ channels (little or no effect on contractility or AV conduction) Significant negative inotrope Depresses sinus node Blocks AV node conduction Longer half-life with chronic use
Activation of adenylyl cyclase ⇒↑cAMP
Prostaglandins with VSM Relaxing Effect
Brain natriuretic peptide
↓ Central sympathetic vasomotor tone Inhibits peripheral NE release
Block L-type Ca2+ channels Primary arterial dilators (no venodilatation at therapeutic doses)
Calcium Channel
Alprostadil (PGE1) Epoprostenol (PGI2) Iloprost
Arterial > venous vasodilatation Competitive adrenoceptor blockade (α1:β = 1:7) Competitive α1- = α2-adrenoceptor blockade Direct action on VSM Competitive α1-adrenoceptor blockade Competitive α2-adrenoceptor block
Side Effects and Problems
Activation of guanylyl cyclase ⇒↑cGMP
Nitric Oxide and
Enzyme Inhibitors Enalaprilat
Principal Action and Mechanism of Action
Arterial and venous vasodilatation Stimulation of natriuretic peptide receptor A ⇒ activation of guanylyl cyclase domain ⇒ ↑cGMP Inhibits renin-aldosterone axis
Miscellaneous Agents Adenosine
<10 sec
Stimulation of adenosine receptors ⇒ Direct vasodilatation (A2a, A2b, A3) Reduces central sympathetic vasomotor tone (A2a) Inhibits peripheral NE release (A1)
Bradycardia Bronchoconstriction Decreased glomerular filtration rate
Table continued on following page
Ch001-X2215
8/12/06
3:05 PM
Page 5
Chapter 1
■
Vasodilator Drugs
5
Vasodilators Available for Intravenous or Inhalational Administration—cont’d
Drug Class and Drug*
Terminal Half-life
Diazoxide
20-45 hr
Fenoldopam
5-10 min
Hydralazine
2-4 min
Principal Action and Mechanism of Action
Side Effects and Problems
Opens KATP channels ⇒ hyperpolarization and arteriolar vasodilatation Dopamine (DA1) agonist ⇒ arteriolar vasodilatation Arterial vasodilatation only
Sodium and water retention Hyperglycemia Reflex tachycardia Hypokalemia Nausea Slow IV onset (5-15 min) Reflex tachycardia (quite common) Sodium and water retention Lupus-like syndrome (slow acetylators)
*Drugs with vasodilator activity used principally for their sympathomimetic effects (e.g., β2-adrenoceptor agonists, phosphodiesterase-3 inhibitors) are not included. † Urapidil is widely used in Europe but is currently not available in the United States. AV, atrioventricular; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; HTN, hypertension; IV, intravenous; NE, norepinephrine; NO, nitric oxide; NO2, nitrogen dioxide; PA, pulmonary artery; PG, prostaglandin; VSM, vascular smooth muscle.
● ●
●
Intracardiac shunts Altered organ blood flow autoregulation (e.g., systemic hypertension, head injury) Perfusion territories with pressure-dependent blood flow (e.g., coronary artery disease, renal artery stenosis, aortic coarctation)
Besides their potential to cause inappropriate systemic hypotension, many vasodilators have other undesirable physiologic effects or toxicities (summarized in Table 1-1).
Implications Systemically administered vasodilators inhibit hypoxic pulmonary vasoconstriction. They may cause or aggravate hypoxemia during one-lung ventilation or in the presence of lung pathology (e.g., atelectasis, lung contusion, pneumonia), leading to increased ventilation-perfusion mismatch or intrapulmonary shunting. Pulmonary hypertension is associated with increased perioperative morbidity and mortality in cardiac surgery. The most recent ACC/AHA guidelines on Perioperative Evaluation for Noncardiac Surgery (2002) state: “although most experts agree that pulmonary hypertension poses an increased risk for noncardiac surgery, no organized study of the problem has been performed.”
MANAGEMENT Avoidance of vasodilator drug overdose is based on titration to effect with an intravenous infusion or repeated small bolus doses, depending on pharmacokinetics. Vasodilatorinduced hypotension can be treated by the following means: ●
● ●
●
Dose adjustment or (temporary) discontinuation of the responsible vasodilator Intravascular volume loading Head-down positioning or leg elevation (circumstances permitting) Judicious application of a (short-acting) vasoconstrictor
Management of PA hypertension begins with the elimination or modulation of factors known to increase PVR: ● ●
Hypoxemia Acidemia
● ●
High sympathetic tone High intrathoracic pressure
There is evidence that PVR begins to increase significantly when arterial PO2 falls below 60 mm Hg. Conversely, the existence of pulmonary vasodilatation with hyperoxia is controversial. However, there may be circumstances when the application of a high fraction of inspired oxygen (even 1.0) is indicated, if only to increase the margin of safety against hypoxemia. Pulmonary vasoconstriction occurs with an arterial pH of less than 7.35, irrespective of the cause of acidemia (respiratory versus metabolic). Moderate hyperventilation to an arterial PCO2 of 30 to 35 mm Hg and aggressive correction of any metabolic acidosis with sodium bicarbonate or tris(hydroxymethy) aminomethane (THAM) are advised. Extreme alkalosis (pH >7.5) may produce further pulmonary vasorelaxation but adversely affects oxygen delivery and enzyme function. High endogenous catecholamine levels cause pulmonary vasoconstriction through the stimulation of α1adrenoceptors. These high levels can be avoided or treated by providing adequate anesthetic depth and postoperative analgesia. Finally, it should be remembered that lung inflation above functional residual capacity causes a progressive increase in PVR. Ventilator settings should be adjusted, based on the patient’s pulmonary function, to provide adequate oxygenation and carbon dioxide elimination while keeping mean intrathoracic pressure to a minimum. Pharmacologic pulmonary vasodilatation without concomitant systemic vasodilatation, as was required in the case described here, can be attained in two ways: 1. Inhalation of a short-acting vasodilator, such as nitric oxide (NO) or prostacyclin (epoprostenol) 2. Coadministration of an intravenous pulmonary vasodilator (e.g., nitroglycerin, nitroprusside, epoprostenol) and a pulmonary vasculature-sparing vasoconstrictor (e.g., vasopressin or its synthetic analogue terlipressin). NO activates soluble guanylyl cyclase to increase cyclic guanosine monophosphate levels in vascular smooth muscle. It is inactivated by the heme moiety of hemoglobin and superoxide anions and has a blood half-life of approximately 6 seconds. Therefore, inhaled NO affects predominantly
PHARMACOLOGY
Table 1–1
■
Ch001-X2215
6
8/12/06
3:05 PM
Section 1
■
Page 6
Pharmacology
the tone of pulmonary vessels in ventilated lung areas but has negligible effects on systemic vascular resistance. Broader application is currently limited by its very high cost and the special equipment required for its administration. Prostacyclin (PGI2, epoprostenol) and its synthetic analogue iloprost are the most potent pulmonary vasodilators known. Their main application is continuous infusion in cases of severe pulmonary hypertension. Their vasodilator action is mediated by cyclic adenosine monophosphate. Intravenous administration frequently causes prohibitive systemic hypotension, but when administered via inhalation, the effectiveness is comparable to that of inhaled NO. Arginine vasopressin is a vasoactive nonapeptide produced in the hypothalamus. It is an agonist at three specific receptor types. Stimulation of the V1a receptor results in contraction of systemic vascular smooth muscle by means of an intracellular activation pathway shared with angiotensin II. Successful use of arginine vasopressin in vasodilatory shock after cardiopulmonary bypass and in hyperdynamic septic shock has been reported. The advanced cardiovascular life support guidelines of 2000 recommend vasopressin as an alternative to epinephrine in patients with refractory ventricular fibrillation. In contradistinction to the pulmonary vascular effects of other vasoconstrictors (e.g., α1adrenoceptor agonists, angiotensin II), vasopressin has been shown to cause pulmonary and cerebral artery vasodilatation, possibly through receptor-mediated local NO release. It may be the vasopressor drug of choice in patients with significantly elevated PVR or RV failure.
PREVENTION Preventing the complications of vasodilator use is based on an understanding of the patient’s pathophysiology and the pharmacology of available drugs. Vasodilators are used to advantage based on their specific profiles, always keeping in mind any undesired or dangerous side effects. For instance, in a patient with aortic stenosis and coronary artery disease, both systemic hypotension and tachycardia must be avoided. In the case described in this chapter, nitroglycerin would be a reasonable choice for treatment of
pulmonary hypertension, because it produces less relaxation of systemic resistance vessels than do other pulmonary vasodilators and does not cause a reflex tachycardia. Use of vasodilators in the perioperative period should take into account the common occurrence of hypovolemia due to preoperative fluid restriction, intraoperative fluid shifts or blood loss, and globally or regionally reduced sympathetic tone in anesthetized patients. Careful dose titration of vasodilators is advisable and is facilitated by using drugs with short half-lives. Vasodilator therapy for pulmonary hypertension coincides with the appropriate manipulation of physiologic factors known to affect PVR. Inhalational administration of NO or epoprostenol, if feasible, may help avoid unwanted systemic venodilatation or arterial vasodilatation effects. Finally, always keep in mind that adrenoceptor antagonists and vasodilators attenuate sympathetic responses, possibly masking the clinical signs of inadequate depth of anesthesia. The use of a depth-of-anesthesia monitor is encouraged, especially when neuromuscular blockers are used.
Further Reading Balser JR, Butterworth J: Cardiovascular drugs. In Hensley FA Jr, Martin DE, Gravlee GP (eds): A Practical Approach to Cardiac Anesthesia, 3rd ed. Philadelphia, JB Lippincott–Williams & Wilkins, 2003. Barnes PJ, Liu SF: Regulation of pulmonary vascular tone. Pharmacol Rev 47:87-131, 1995. Eagle KA, Berger PB, Calkins H, et al: ACC/AHA Guideline Update on Perioperative Cardiovascular Evaluation for Noncardiac Surgery, 2002. American College of Cardiology Web site available at http://www.acc.org/ clinical/ guidelines/perio/dirIndex.htm Frishman WH, Sonnenblick EH, Sica DH (eds): Cardiovascular Pharmacotherapeutics, 2nd ed. New York, McGraw-Hill, 2003. Katzung BG (ed): Basic & Clinical Pharmacology, 9th ed. New York, Lange Medical Books/McGraw-Hill, 2004. Malouf JF, Enriquez-Sarano M, Pellikka PA, et al: Severe pulmonary hypertension in patients with severe aortic valve stenosis: Clinical profile and prognostic implications. J Am Coll Cardiol 40:789-795, 2002. Olschewski H, Rose F, Schermuly R, et al: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 102:139-153, 2004. Reich DL, Bodian CA, Krol M, et al: Intraoperative hemodynamic predictors of mortality, stroke, and myocardial infarction after coronary artery bypass surgery. Anesth Analg 89:814-822, 1999.
Ch002-X2215
8/12/06
3:27 PM
Page 7
REGIONAL ANESTHESIA & PAIN PHARMACOLOGY MANAGMENT
Vasopressors: Vasoconstrictor Drugs
2
Viktoria D. Mayr, Volker Wenzel, and Martin W. Dünser Case Synopsis A 73-year-old woman with a history of chronic arterial hypertension and coronary heart disease undergoes surgery for an infected hip prosthesis. Etomidate, fentanyl, and rocuronium are used to induce anesthesia. After induction, the patient’s arterial blood pressure (BP) suddenly drops to 60/40/30 mm Hg (systolic/mean/diastolic). Infusion of 1 L normal saline and two 5-mg intravenous bolus injections of ephedrine have no significant effect on BP. Continuous infusion of norepinephrine restores BP to a more normal range (105/74/58 mm Hg); however, simultaneously, the patient develops tachycardia with ventricular ectopic beats. After norepinephrine is increased to 0.35 μg/kg per minute, atrial fibrillation with a rapid ventricular response develops and results in a sustained reduction in arterial BP.
PROBLEM ANALYSIS Definition The first priority of perioperative cardiovascular care is to maintain adequate perfusion of vital organs. In addition to sufficient cardiac output, mean arterial BP must be maintained to secure organ perfusion pressure. Accordingly, arterial hypotension is either a mean arterial pressure (MAP) less than 60 mm Hg or a drop in MAP of more than 30% from preoperative values. Below a MAP of about 60 mm Hg, vascular autoregulation1 declines in the brain, kidneys, and parts of the gastrointestinal tract. For the heart, autoregulation is lost below a diastolic BP of 50 to 55 mm Hg, presuming a normal left ventricular end-diastolic pressure. With loss of autoregulation, vital organ perfusion becomes compromised. Fluids, inotropes, and vasopressors are used to treat hypotension in perioperative and critical care settings. After restoration of normovolemia and adequate cardiac output with intravenous fluids and inotropes, ongoing hypotension may require the use of vasopressors. Commonly used vasopressors in the perioperative setting are dopamine, norepinephrine, epinephrine, phenylephrine, ephedrine, and vasopressin (Table 2-1). All these drugs exert their effects by stimulating α-adrenergic and β-adrenergic receptors. These receptors are found not only in vascular and cardiac smooth muscle but also in the liver, platelets, leukocytes, bronchiolar smooth muscle, fat, and muscle.
1 The autoregulatory (AR) curve is shifted upward and to the right in chronic hypertension. In normotensives, flow is constant over the MAP range of 60 to 160 mm Hg. With chronic hypertension, the AR range is 80 to 180 mm Hg or higher. Below or above this, flow is directly proportional to MAP: flow increases for MAP values above the upper AR setpoint, and it decreases for values below the lower setpoint. For the heart, the AR curve is a diastolic BP of 50 to 150 mm Hg, presuming a normal left ventricular end-diastolic pressure (0 to 3 mm Hg). If the left ventricular enddiastolic pressure increases, the AR curve shifts upward and to the right.
Systemic inflammation or sepsis leads to high cytokine concentrations, with overproduction of nitric oxide. In turn, both membranous and cytosolic adrenergic receptor complexes are quantitatively and qualitatively down-regulated. These pathophysiologic adaptive mechanisms lead to reduced effects of endogenous or exogenous catecholamines, often necessitating the infusion of even higher catecholamine doses to ensure adequate vital organ perfusion. However, such high-dose catecholamine infusions may adversely affect the risk-benefit ratio of adrenergic vasopressor therapy beyond clinically acceptable ranges.
Recognition Institution of vasopressor therapy may have a number of untoward effects on major organ systems. Among the more common side effects of catecholamines are α1- and primarily β-adrenergic-mediated ventricular ectopy and tachyarrhythmia.2 High-dose vasopressor therapy with primary α-adrenergic agonists may increase pulmonary artery pressure. Aside from these effects, some catecholamine derivatives have specific side effects that may have an adverse impact on patient outcomes. For example, dopamine is known to reduce mucosal perfusion in the gastrointestinal tract. Although mesenteric blood flow significantly increases during therapy with dopamine, mucosal oxygenation deteriorates. This paradoxical effect is likely due to an intervillus shunt (i.e., shift of intestinal wall blood flow to the submucosa). Dopamine also influences the production and release of several hormones. Lengthy infusions may lead to reduced serum concentrations of prolactin, human growth hormone, and thyroid hormones.
2 A synergistic interaction between α1- and β-adrenoceptors has been implicated in the genesis of catecholamine-anesthetic ventricular arrhythmias: a1A-mediated slowing of Purkinje fiber conduction, with enhanced conduction at the Purkinje fiber–ventricular muscle fiber junction.
7
Ch002-X2215
8/12/06
8
3:27 PM
Section 1
Table 2–1
■
■
Page 8
Pharmacology
Effects of Vasopressor Drugs
Drug
Negative Effects
Positive Effects
Dopamine
Tachycardia Tachyarrhythmia Pulmonary artery vasoconstriction ↓ PaO2 (↑ O2 demand) ↑ Systemic vascular resistance Tachycardia Tachyarrhythmias ↑ O2 consumption Tachycardia Tachyarrhythmias ↑ O2 consumption Hyperglycemia ↑ Systemic vascular resistance ↑ O2 consumption
↑ Myocardial contractility ↑ Glomerular filtration rate
Norepinephrine
Epinephrine
Phenylephrine
Ephedrine
Tachycardia Indirectly mediated effects†
Vasopressin
Ischemic skin lesions Gut ischemia
↑ Myocardial contractility
↑ Cardiac index ↑ Stroke volume ↑ O2 delivery ↑ Cardiac index* ↑ Stroke volume* ↑ Cardiac output* ↑ O2 delivery ↑ Heart rate ↑ Cardiac output ↑ Mean arterial pressure ↑ O2 delivery ↑ Mean arterial pressure Heart rate‡ ↑ Mean pulmonary artery pressure ↑ Catecholamine requirements
*Venous constriction in venous capacitance bed augments venous return and cardiac preload, thereby increasing cardiac output. † Effects largely mediated by endogenous catecholamine release. ‡ No effect, or decrease due to baroreceptor stimulation caused by increased blood pressure.
Apart from reduced gastrointestinal blood flow, phenylephrine may reduce cardiac output. Although this is not a consistent finding, it may be explained by a baroreceptormediated reduced heart rate and possibly reduced contractility. Aside from substantial tachycardia and proarrhythmia potential, both epinephrine and norepinephrine may have significant metabolic side effects, including sustained hyperglycemia due to β-adrenergic stimulation of hepatic gluconeogenesis and down-regulation of peripheral insulin receptors. Further, epinephrine may lead to significant hyperlactatemia via the stimulation of muscular β receptors. Consequently, excessive stimulation of glycoclysis leads to the overproduction of lactate. Epinephrine is also known to cause a significant reduction in the hepatosplanchnic oxygen supply. Catecholamines stimulate α receptors to activate platelets and induce a hypercoagulable state. Such hypercoagulability may be aggravated by α-adrenergic-mediated vasoconstriction. Consequent thrombosis or vasoconstriction could further impair vital organ perfusion. Also, adrenergic receptor stimulation exerts several immune-modulating effects. Whereas α receptors mediate immune-suppressive effects by increasing tumor necrosis factor α, stimulation of β receptors improves immune function by releasing interleukin-10 to reduce dendritic cell migration. This influences antigen expression and contact hypersensitivity responses. Thus, a number of complications involving multiple organ systems may occur when administering catecholamines to support BP.
Risk Assessment The occurrence of adverse effects during vasopressor therapy with catecholamines depends not only on the doses used but
also on individual patient characteristics. Patients with coronary heart disease or congestive heart failure are more prone to develop tachyarrhythmias, myocardial ischemia, or myocardial infarction during therapy with catecholamine vasopressors. Owing to a reduced arrhythmogenic threshold in the elderly, catecholamine-induced tachyarrhythmias occur at much lower doses in older patients than in younger ones. Moreover, the α-receptor-mediated increase in pulmonary vascular resistance may significantly impair right heart function in patients suffering from chronic pulmonary hypertension or right ventricular failure. If fluids and inotropic therapy fail to restore normovolemia and sufficient cardiac output, complications caused by catecholamine vasopressor therapy may occur sooner and with greater severity than would otherwise be the case. In this circumstance, catecholamine vasopressors may produce tissue hypoxia by aggravating peripheral vasoconstriction and significantly interfering with vital organ perfusion. Thus, ensuring adequate cardiac output with fluids and inotropic support is the mainstay of cardiovascular therapy, before initiating any vasopressor treatment.
Implications Adverse effects of high-dose catecholamine therapy substantially alter the risk-benefit ratio of any vasopressor therapy. Further, they increase the risk for adverse perioperative outcomes. Especially in elderly patients and those with cardiac dysfunction, catecholamine-induced tachycardia may significantly increase myocardial oxygen demand, thereby causing ischemia or myocardial infarction. Vasopressor-induced increased myocardial oxygen consumption not only compromises oxygen availability but also significantly reduces cardiac output and systemic oxygen delivery.
Ch002-X2215
8/12/06
3:27 PM
Page 9
Chapter 2
Vasopressors: Vasoconstrictor Drugs
9
of new tachyarrhythmias (8.3%) compared with high-dose norepinephrine alone (54.3%). Although arginine vasopressin has no antiarrhythmic activity by itself, adding it to high-dose norepinephrine in patients with advanced vasodilatory shock after cardiopulmonary bypass can significantly reduce norepinephrine needs and facilitate spontaneous conversion of about 50% of new-onset tachyarrhythmias independent of antiarrhythmic therapy. In contrast to high-dose norepinephrine, the significantly lower heart rates after arginine vasopressin therapy in patients with advanced vasodilatory shock can substantially reduce myocardial oxygen demand. There is now evidence of improved myocardial performance with norepinephrine–arginine vasopressin, likely owing to the reduced need for norepinephrine. Adverse effects of arginine vasopressin include possible deterioration of hepatic function and reduced platelet counts; however, reduced platelet counts do not appear to lead to increased clinical bleeding. Effects of arginine vasopressin on gastrointestinal blood flow have been inadequately studied. Although some authorities fear gastrointestinal hypoperfusion, there is evidence that arginine vasopressin may actually improve gastrointestinal perfusion when given continuously at doses of 4 units/hour in patients with advanced vasodilatory shock. At present, because there are no data supporting a beneficial effect on patient outcomes with the administration of supplementary arginine vasopressin in cases of advanced vasodilatory shock, its use with catecholamine vasopressors to reduce the latter’s toxicity can be advised only as a last resort.
MANAGEMENT If vasopressors are not necessary, do not use them. However, do assure normovolemia and adequate inotropic therapy. If cardiac output is still inadequate, administer catecholamine vasopressors in the lowest possible doses. In patients with significant cardiovascular dysfunction, even this may not be possible. If this is the case, symptomatic therapy, such as that for new-onset tachyarrhythmias, is the only therapy for catecholamine-induced complications. Striking recent evidence suggests that supraphysiologic doses of hydrocortisone (200 to 300 mg/day) not only significantly improve cardiovascular function and reduce catecholamine requirements but also reduce mortality in patients with septic shock. Possible mechanisms include relief of relative adrenal insufficiency as well as unspecific, permissive effects leading to up-regulation of adrenergic receptors. Also, hydrocortisone may favorably alter several pathophysiologically relevant inflammatory pathways that contribute to cardiovascular failure. Adverse hydrocortisone effects appear to occur independent of the dosage used and include hypernatremia and hyperglycemia. It is unknown whether hydrocortisone-mediated immune modulation or aggravation of catabolic metabolism is clinically relevant. Arginine vasopressin is used as a supplementary vasopressor in the treatment of advanced vasodilatory shock. Several studies show that continuous arginine vasopressin (4 units/hour) significantly improves hemodynamic variables and reduces catecholamine vasopressor requirements. In these cases, combined arginine vasopressin–norepinephrine infusion leads to a significant reduction in the incidence
PREVENTION Assurance of adequate volume and inotropic therapy to guarantee sufficient cardiac output are the most important preventive measures to avoid catecholamine vasopressormediated complications. Infusion of high dosages of hydrocortisone may reduce the need for high-dose norepinephrine therapy and thus reduce catecholamine-associated complications. Also, recent evidence suggests that a supplementary continuous infusion of arginine vasopressin (4 units/hour) might contribute to improved hemodynamic stability, fewer norepinephrine-related complications, and higher survival rates, but only when started before norepinephrine doses exceed 0.6 μg/kg per minute.
Further Reading Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862-871, 2002. Dellinger RP: Cardiovascular management of septic shock. Crit Care Med 31:946-955, 2003. Dunser MW, Mayr AJ, Ulmer H, et al: Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 107:2313-2319, 2003. Heyndrickx GR, Boettcher DH, Vatner SF: Effects of angiotensin, vasopressin, and methoxamine on cardiac function and blood flow distribution in conscious dogs. Am J Physiol 231:1579-1587, 1976. James JH, Luchette FA, McCarter FD, Fischer JE: Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet 354:505-508, 1999.
PHARMACOLOGY
Catecholamine-induced tachyarrhythmias may further aggravate myocardial ischemia. In particular, the development of atrial fibrillation with a rapid ventricular response—the most common tachyarrhythmia with catecholamine therapy— exacerbates cardiovascular dysfunction due to a loss of atrial transport function and reduced ventricular filling. This can cause a substantial reduction in cardiac output, with a subsequent backward increase in pulmonary vascular resistance, leading to right ventricular failure and further deterioration of cardiovascular function. Reduced hepatic, splanchnic, or intestinal mucosal oxygen delivery with prolonged epinephrine or dopamine infusions can increase organ damage, facilitate endotoxin production, and exacerbate systemic inflammation and multiple organ dysfunction. Arterial lactate concentrations correlate with patient outcome, because hyperlactatemia may increase perioperative mortality irrespective of metabolic acidosis. Moreover, elevated serum glucose concentrations significantly contribute to adverse patient outcomes, especially among the critically ill. Theoretically, catecholamine-induced hypercoagulability may facilitate thrombus formation at the microcirculatory level, thus precipitating multiorgan system damage; however, there is no clinical evidence of this. Such hypercoagulability may also facilitate the evolution of perioperative myocardial infarction. Further, it is unknown whether adrenergic vasopressor-mediated immune modulation influences immune responses in the perioperative setting.
■
Ch002-X2215
10
8/12/06
3:27 PM
Section 1
■
Page 10
Pharmacology
Lorton D, Lubahn C, Bellinger DL: Potential use of drugs that target neuralimmune pathways in the treatment of rheumatoid arthritis and other autoimmune diseases. Curr Drug Targets Inflamm Allergy 2:1-30, 2003. Luckner G, Dunser MW, Jochberger S, et al: Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33:2659-2666, 2005. Maestroni GJ, Mazzola P: Langerhans cells beta 2-adrenoceptors: Role in migration, cytokine production, Th priming and contact hypersensitivity. J Neuroimmunol 144:91-99, 2003. Marik PE, Varon J: The hemodynamic derangements in sepsis: Implications for treatment strategies. Chest 114:854-860, 1998. Meier-Hellmann A, Reinhart K, Bredle DL, et al: Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 25:399-404, 1997. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care
Medicine, Society of Critical Care Medicine. Crit Care Med 27: 639-660, 1999. Rudis MI, Basha MA, Zarowitz BJ: Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 24:525-537, 1996. Schutz W, Anhaupl T, Gauss A: Principles of catecholamine therapy. 1. Characterization of clinically relevant sympathomimetics. Anasthesiol Intensivmed Notfallmed Schmerzther 35:67-81, 2000. Trager K, DeBacker D, Radermacher P: Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 9:271-278, 2003. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patient. N Engl J Med 345:1359-1367, 2001. Zhang H, De Jongh R, DeBacker D, et al: Effects of alpha- and beta-adrenergic stimulation on hepatosplanchnic perfusion and oxygen extraction in endotoxic shock. Crit Care Med 29:581-588, 2001.
Ch003-X2215
8/19/06
2:20 PM
Page 11
Krishna M. Natrajan and Ray P. Liao
PHARMACOLOGY
3
Inotropic Drugs Case Synopsis A 72-year-old man with mitral regurgitation has mitral valve replacement. His preoperative transesophageal echocardiogram (TEE) reveals reduced left ventricular function and moderate pulmonary hypertension. Just before separation from cardiopulmonary bypass (CPB), a 50 μg/kg bolus of milrinone is given, followed by an infusion at 0.5 μg/kg per minute, along with epinephrine at 0.03 μg/kg per minute. The TEE reveals good left ventricular function with adequate filling after release of the aortic cross-clamp, but the patient cannot be weaned from CPB owing to low mean arterial pressure. Pulmonary artery catheter data show a cardiac index of 2.8 L/min/m2 and systemic vascular resistance of 550 dyne . sec . cm–5. The addition of vasopressin (4 units/hour) enables weaning from CPB, after which the heart rate is 94 beats per minute and the mean arterial pressure is 72 mm Hg.
PROBLEM ANALYSIS Definition Inotropic drugs (Table 3-1) are classified as (1) naturally occurring catecholamines (e.g., dopamine, epinephrine, norepinephrine), (2) synthetic catecholamines (e.g., dobutamine, isoproterenol), or (3) phosphodiesterase-3 inhibitors (e.g., amrinone, milrinone). They are commonly administered solely or used in combination to treat low-output syndromes that are frequently encountered in congestive heart failure and myocardial infarction and following openheart surgery. The primary effect of inotropic drugs is to increase contractility, which ultimately increases cardiac output and promotes tissue perfusion.
Recognition The case synopsis illustrates the need to tailor appropriate therapy. Depressed left ventricular function with elevated pulmonary artery pressure suggests the need for inotropic
Table 3–1
■
Inotropic Drugs
Digitalis Digoxin Digitoxin Ouabain Catecholamines Natural Epinephrine Norepinephrine Dopamine Synthetic Dobutamine Dopexamine Isoproterenol Synthetic noncatecholamines Indirect acting Ephedrine
Mephentermine Amphetamines Metaraminol Direct acting Phenylephrine Methoxamine Phosphodiesterase-3 inhibitors Amrinone Milrinone Enoximone Miscellaneous Calcium Glucagon Thyroid hormone
support, but with a drug that does not increase pulmonary vascular resistance (PVR). Milrinone is one option because it increases cardiac output and lowers PVR. However, it also significantly lowers systemic vascular resistance (SVR), which can jeopardize perfusion of the heart and other vital organs. Reduced SVR with milrinone may require therapy with a vasopressor, such as norepinephrine, epinephrine, phenylephrine, or vasopressin. Notably, vasopressin increases SVR without increasing pulmonary artery pressure.
Risk Assessment The primary goal of inotropic drugs is to improve myocardial contractility and increase cardiac output, vital organ perfusion, and tissue oxygen delivery (Table 3-2). However, these drugs have other effects that can be useful or problematic, depending on the circumstances. Their effects on SVR are important and can be used to divide the drugs into two groups: vasoconstrictors (epinephrine, norepinephrine, dopamine) and vasodilators (dobutamine, isoproterenol, milrinone). Epinephrine and norepinephrine are naturally occurring catecholamines used in cardiac emergencies. The inotropic and vasoconstrictive responses are mediated by the activation of adrenergic receptors. The effects of these drugs can be titrated to the desired level owing to their linear dose response, rapid (almost immediate) onset of action, and fast elimination. Dopamine is another inotrope with vasoconstrictive properties. Its positive inotropic effect is mediated by the release of norepinephrine from nerve terminals. Dopamine’s pharmacodynamic effect is dose dependent, and the hemodynamic profile with low, medium, and high doses can vary greatly among individuals, with higher doses commonly producing an increase in SVR. Dopamine has the theoretical advantage of selective renal and mesenteric vascular dilatation, thus enhancing renal blood flow and natriuresis while preventing mesenteric ischemia in low cardiac output states. However, the clinical value of this effect remains uncertain. Isoproterenol and its chemical derivative dobutamine are vasodilators. They act directly on β-adrenergic receptors 11
Ch003-X2215
8/19/06
12
Table 3–2
2:20 PM
Section 1
■
■
Page 12
Pharmacology
Hemodynamic Profile of Inotropic Drugs
Drug
CO
HR
MAP
VR
SVR
PVR
MCO
Epinephrine Norepinephrine Dopamine Dobutamine Isoproterenol Milrinone
↑↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑
↑↑↑ ↑↑ ↑↑ ↑↑ ↑↑↑ ←→
↑ ↑↑ ↑ ↓ ↓↓ ↓↓
↑ ↑↑↑ ↑ ↓ ↓ ↓↓
↑↑↑ ↑↑↑ ↑↑ ↓ ↓↓↓ ↓↓↓
↑ ↑↑ ↑↑ ↓↓ ↓↓ ↓↓↓
↑↑↑ ↑↑↑ ↑↑ ↑↑ ↑↑↑ ←→
CO, cardiac output; HR, heart rate; MAP, mean arterial pressure; MCO, myocardial oxygen consumption; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance; VR, venous return (preload). ↑, increase; ↓, decrease; ←→, unchanged.
to cause a positive inotropic response while decreasing SVR. Hypotension resulting from their use may require treatment with vasoconstrictors. Milrinone is a phosphodiesterase-3 inhibitor and prevents cyclic adenosine monophosphate (cAMP) degradation. It increases myocardial contractility in a linear doseresponse relationship without increasing myocardial oxygen consumption. The onset of action is slower than that of catecholamines, and its elimination half-life is longer, causing a prolonged duration of effect. Rapid administration produces vascular smooth muscle relaxation to reduce SVR and venous return. This can lead to hypotension, especially in hypovolemic patients. Concomitant use of volume loading and vasoconstrictors (e.g., phenylephrine, epinephrine, norepinephrine, vasopressin) attenuates milrinone’s potential for vasodilatation and hypotension. These inotropes are routinely used to treat the low cardiac output states often seen after CPB. The unique hemodynamic profile of each agent needs to be considered when deciding which inotrope, alone or in combination, will best facilitate a particular patient’s separation from CPB.
Implications Low cardiac output and hypotension following separation from CPB can reduce tissue perfusion and lead to vital organ dysfunction. The use of hemodynamic parameters and TEE identifies its cause. Treatment must be prompt and may require the administration of combined inotropes. The use of inotropes with vasodilator properties may necessitate the addition of a vasoconstrictor. Of the available vasoconstricting agents, vasopressin has the advantage of not increasing PVR. Arrhythmias resulting from inotropes can occur and should be monitored closely.
CPB is often complicated by post-CPB low cardiac output states that require inotropic support. Combined epinephrine and milrinone, which have different actions, increase cardiac contractility better than either agent alone. Epinephrine increases the formation of cAMP by activating adrenergic receptors, while milrinone reduces the rate of cAMP degradation by inhibiting the phosphodiesterase-3 enzyme. The cardiovascular actions and other effects of each of these drugs must be taken into consideration. At low doses, epinephrine has predominant β-adrenergic actions: positive inotropy and chronotropy. Milrinone is also a positive inotrope, and a systemic and pulmonary arterial vasodilator as well. A reduction in PVR may benefit patients with pulmonary artery hypertension. However, reduced SVR and systemic hypotension may require substantial volume loading and use of a vasoconstrictor, such as vasopressin, which has minimal effects on the pulmonary and splanchnic vasculature. Also, a reduction in either PVR or SVR may lead to a reflex increase in heart rate, mediated by pulmonary mechanoreceptors or aortic barorecptors, respectively. Phosphodiesterase-3 inhibitors (e.g., amrinone) have been associated with thrombocytopenia, possibly due to a metabolite-mediated toxic effect on platelets. However, milrinone appears to have a better safety profile. Further, like all positive inotropic agents, milrinone and epinephrine have the potential to initiate or aggravate troublesome arrhythmias. Causative or provocative factors, such as a concurrent physiologic imbalance and (perhaps) even the inotrope itself, must be quickly identified and corrected before significant hemodynamic compromise occurs.
PREVENTION ● ●
MANAGEMENT ●
●
●
●
TEE to assess left ventricular filling and function and maintain adequate preload and afterload Careful titration of inotropes to achieve adequate cardiac output and arterial pressure Vasoconstrictors as needed for low perfusion pressure due to vasodilator effects of inotropes Prompt correction of acid-base and electrolyte abnormalities
●
Ensure adequate preload and afterload Normalize metabolic parameters Titrate inotropic drugs precisely
TEE to assess left ventricular filling and function, preload, and afterload is often useful when weaning patients from CPB. Volume depletion should be corrected by the judicious use of fluids or blood products. It is also important to correct metabolic abnormalities, especially acidosis and hypokalemia. Inotropic support is commonly necessary for separation from CPB. The choice of inotropic agent or agents depends on surgical and patient factors. Precise titration of
Ch003-X2215
8/19/06
2:20 PM
Page 13
Chapter 3
Further Reading Lehtonen LA, Antila S, Pentikainen PJ: Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 43: 187-203, 2004.
Inotropic Drugs
13
Levy JH, Bailey JM, Deeb GM: Intravenous milrinone in cardiac surgery. Ann Thorac Surg 73:325-330, 2002. Stoelting RK: Sympathomimetics: Pharmacology and Physiology in Anesthetic Practice, 3rd ed. Philadelphia, JB Lippincott, 1999, pp 259-277. Tisdale JE, Patel R, Webb CR, et al: Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 38: 167-180, 1995.
PHARMACOLOGY
inotropic drugs is needed, especially when several drugs are used in combination.
■
Ch004-X2215
8/12/06
3:28 PM
Page 14
Chronotropic Drugs Cyrus DeSouza
4
Case Synopsis Five years after heart transplantation, a 44-year-old man has laparoscopic cholecystectomy. After induction of anesthesia, the electrocardiogram (ECG) rhythm strip shows absent P waves and a wide QRS rhythm at a rate of 38 beats per minute (Fig. 4-1). Neither intravenous (IV) atropine (1.0 mg) nor ephedrine (10 mg) affects the rhythm or increases its rate. IV bolus epinephrine (200 μg) is given, followed by an IV infusion at 0.25 μg/kg per minute. The heart rate increases to 130 beats per minute, accompanied by frequent ventricular ectopic beats.
PROBLEM ANALYSIS Definition Epinephrine and other positive chronotropes, especially when given in large doses, can have deleterious effects in patients with cardiovascular disease. These effects include the following: ● ● ●
Untoward tachycardia and hypertension Generation of new or worse atrial or ventricular arrhythmias Increased myocardial oxygen consumption and ischemia due to increased heart rate and contractility and left ventricular wall stress
As the case synopsis illustrates, the effects in cardiac transplant patients are even more unpredictable or may be nonexistent owing to cardiac denervation. Consequently, only drugs that act directly on cardiac receptors should be used. Drugs such as atropine and ephedrine may be ineffective or unpredictable because they act indirectly to increase heart rate. Moreover, coronary atherosclerosis can occur in transplant recipients, with an incidence of up to 50% at 5 years. Without cardiac afferent innervation, ischemia in heart transplant recipients may be silent.
Recognition Bradycardia with absent P waves on the ECG can have many causes, including the following: ●
● ● ●
Sinoatrial (SA) exit block, sinus arrest, or sick sinus syndrome Atrioventricular (AV) junctional rhythm Idioventricular rhythm Slow atrial fibrillation or flutter
Also, P waves may be “buried” within the QRS complex with AV dissociation, such as in advanced second degree or third degree (complete) AV heart block. With third degree SA exit block, P waves are absent or have an altered morphology if a subsidiary atrial pacemaker has usurped atrial control. If so, they will be bifid, inverted, or flattened in leads with SA node origin (upright) P waves. On the surface ECG, third degree SA exit block is indistinguishable from sinus arrest. A subsidiary atrial, junctional, or ventricular pacemaker usually usurps ventricular control. Third degree SA exit block is distinguished from third degree AV block, which has the following features on ECG: ● ●
●
P waves present but with no relation to QRS complexes QRS complexes wide (ventricular origin or with ventricular aberration) or of normal width (AV junctional origin above bifurcation of bundle of His [common]) Slow ventricular escape rate (≈30 to 45 beats per minute)
Intraoperative bradycardia that is severe or that compromises the patient’s cardiac output or blood pressure must be treated aggressively. Assessment for reversible causes is important (Fig. 4-2) and must occur simultaneously with treatment. Temporary pacing and drug therapy are the two main options. Two different classes of drugs are commonly used to increase the heart rate: anticholinergics (e.g., atropine, glycopyrrolate) and adrenergic receptor agonists (e.g., ephedrine, epinephrine, isoproterenol, dopamine). Direct adrenergic agonists are more reliable than ephedrine. Isoproterenol is a nonselective β agonist with chronotropic, inotropic, and vasodilatory effects. It is usually recommended to treat bradycardia after heart transplantation, but care must be exercised in the presence of coronary artery disease. Isoproterenol increases myocardial osygen consumption and may reduce coronary perfusion pressure, worsening ischemia. Thus, isoproterenol is no longer part of
Figure 4–1 ■ Bradycardia and absent P waves with ventricular escape rhythm. (From Conover MB: Understanding Electrocardiography, 8th ed. St. Louis, Mosby, 2003.)
14
Ch004-X2215
8/12/06
3:28 PM
Page 15
Chapter 4
■
Chronotropic Drugs
15 PHARMACOLOGY
Figure 4–2 ■ Algorithm for the management of intraoperative bradycardia. AV, atrioventricular. (Modified from Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advanced cardiovascular life support. Section 7: Algorithm approach to ACLS emergencies. 7C: A guide to the international ACLS algorithms. Circulation 102 [8 Suppl]: I142-I157, 2000.)
the advanced cardiovascular life support algorithms for the emergency treatment of bradycardia. The side effects of atropine are as follows: ● ● ● ●
Excessive tachycardia; arrhythmias Pupillary dilatation, blurred vision, dry mouth Difficulty in micturition; decreased intestinal peristalsis Central anticholinergic crisis (e.g., ataxia, restlessness, delirium, coma) (This cannot occur with glycopyrrolate because it does not cross the blood-brain barrier.)
Atropine is ineffective in heart transplant patients owing to the lack of vagal innervation. In fact, in some cases, it may provoke bradyarrhythmias. Ephedrine acts predominantly by a presynaptic mechanism (i.e., indirect release of catecholamines) and may be unpredictable or ineffective owing to cardiac sympathetic denervation in heart transplant recipients. However, it offers some protection against many reflex-mediated causes of bradycardia and produces a high resting heart rate. Bradyarrhythmias occurring late
after heart transplantation, without an obvious reversible cause, may be a sign of ischemia or chronic rejection.
Risk Assessment ●
●
●
Heart transplant patients have denervated hearts and are prone to accelerated coronary vasculopathy. Effects of chronotropic drugs are unpredictable or nonexistent owing to cardiac denervation in heart transient recipients. Epinephrine can exacerbate ischemia by causing tachycardia, hypertension, increased contractility, and arrhythmias in patients with intact hearts, whether diseased or not.
Epinephrine is given as an IV bolus or infusion in emergencies. Typical starting infusion rates are 0.03 to 0.2 μg/kg per minute, with titration to the desired effect. The goal should be to restore the heart rate to greater than 60 beats per minute while avoiding excess tachycardia.
Ch004-X2215
8/12/06
16
3:28 PM
Section 1
■
Page 16
Pharmacology
However, temporary pacing is often the preferred treatment for nontransient, severe bradycardia and can be rapidly instituted via the noninvasive transcutaneous or transesophageal (atrial pacing only; requires intact AV conduction) route. Pacing is more predictable (i.e., precision titration of rate, can be turned “on” or “off ” as needed) than treatment with positive chronotropic drugs, which have the following disadvantages: ● ●
● ●
May cause excess tachycardia or arrhythmias May cause myocardial ischemia or decompensation (i.e., heart failure) May take time or fail to produce the desired effect May produce adverse drug effects that are compounded by the drugs used to treat them
Implications Tachycardia associated with severe ventricular ectopy must be treated urgently, because it may degenerate into ventricular tachycardia-fibrillation. Also, the potential for myocardial ischemia exists if myocardial oxygen consumption exceeds demand.
MANAGEMENT ●
● ●
Cease the epinephrine infusion and allow its plasma concentration to decrease. Prepare for temporary pacing if the bradycardia recurs. Assess for reversible causes of intraoperative bradycardia (see Fig. 4-2).
Low-dose epinephrine infusions may restore the heart rate without adverse effects. If drug therapy is ineffective, is contraindicated, or causes complications, pacing should be instituted. Temporary transcutaneous pacing is a class I therapy for the emergency treatment of severe bradycardia. If available, transesophageal atrial pacing is useful (with intact AV conduction). Arrangements should be made for the insertion of a temporary pacing pulmonary artery catheter or transvenous pacing catheter.
PREVENTION ●
●
Suspect coronary artery disease in heart transplant recipients more than 2 years post transplant. Recognize the implications of cardiac denervation for treating bradycardia with drugs.
●
●
●
Anticipate and avoid common reversible causes of intraoperative bradycardia. Avoid high doses of chronotropic drugs by carefully titrating smaller doses to effect. Use temporary pacing for severe bradycardia or when drugs fail.
Careful preoperative evaluation is important to identify patients at increased risk for bradycardia. Pretreatment with a chronotrope and avoidance of known causes of bradycardia may prevent tachycardia or arrhythmias from occurring. In some cases, pacing therapy is required preoperatively, depending on the underlying rhythm (e.g., advanced second degree or complete AV heart block). There are special considerations for heart transplant recipients who develop intraoperative bradycardia.
Further Reading Atlee JL, Pattison CZ, Mathews EL, et al: Transesophageal atrial pacing for intraoperative sinus bradycardia or AV junctional rhythm: Feasibility as prophylaxis in 200 anesthetized adults and hemodynamic effects of treatment. J Cardiothorac Vasc Anesth 7:436-441, 1993. Bernheim A, Fatio R, Kiowski W, et al: Atropine often results in complete atrioventricular block or sinus arrest after cardiac transplantation: An unpredictable and dose-independent phenomenon. Transplantation 77:1181-1185, 2004. Brawn JH, Taylor P: Muscarinic receptor agonists and antagonists. In Hardman JG, Limbird LE (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. New York, McGrawHill, 2001, pp 155-174. Conover MB: Understanding Electrocardiography, 7th ed. St. Louis, Mosby, 1996. Gao SZ, Schroeder JS, Alderman EL, et al: Prevalence of accelerated coronary artery disease in heart transplant survivors: Comparison of cyclosporine and azathioprine regimens. Circulation 80:100-105, 1989. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advanced cardiovascular life support. Section 5: Pharmacology. I: Agents for arrhythmias. Circulation 102 (8 Suppl): I112-I128, 2000. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advanced cardiovascular life support. Section 7: Algorithm approach to ACLS emergencies. 7C: A guide to the international ACLS algorithms. Circulation 102(8 Suppl):I142-I157, 2000. Hoffman BB: Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In Hardman JG, Limbird LE (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. New York, McGraw-Hill, 2001, pp 215-268. Quinlan JJ, Firestone S, Firestone LL: Anesthesia for heart, lung, and heartlung transplantation. In Kaplan JA, Reich DL, Konstadt SN (eds): Cardiac Anesthesia, 4th ed. Philadelphia, WB Saunders, 1999. Weinfeld MS, Kartashov A, Piana R, et al: Bradycardia: A late complication following cardiac transplantation. Am J Cardiol 78:969-971, 1996.
Ch005-X2215
8/12/06
3:17 PM
Page 17
PHARMACOLOGY
5
Drugs Affecting the Renin-Angiotensin System Laura Stover Case Synopsis A 95-kg, 70-year-old man is scheduled to have left internal carotid endarterectomy. He takes nicardipine (50 mg/day) and irbesartan (150 mg/day), an angiotensin II receptor antagonist, for hypertension. He took his usual doses of both medications on the morning of surgery. Preoperative tests included a transthoracic echocardiogram that showed normal left ventricular systolic function and septal hypertrophy. Blood pressure and heart rate immediately before induction of anesthesia were 150/70 mm Hg and 56 beats per minute, respectively. After receiving 900 mL of crystalloid, he was induced slowly with sufentanil (45 μg), propofol (140 mg), and vecuronium (7 mg), with subsequent endotracheal intubation and anesthetic maintenance with oxygen and nitrous oxide (50:50) and a propofol infusion. Three minutes after induction, his blood pressure fell to 92/44 mm Hg. Despite repeated intravenous boluses of ephedrine (20 mg total), his blood pressure was 47/30 mm Hg 5 minutes after induction.
PROBLEM ANALYSIS Definition Renin-angiotensin system (RAS) antagonists include both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists. These drugs are used with increasing frequency to treat hypertension and heart failure in selected patients. ACE inhibitors and angiotensin II receptor antagonists cause a blockage of the RAS that can adversely affect hemodynamics during anesthesia and surgery. Although anesthesia is not invariably associated with hemodynamic instability in RAS-blocked patients, unexpected episodes of refractory hypotension have been reported. Also, RAS antagonists, specifically ACE inhibitors, have been associated with potentially life-threatening angioedema of the head and neck. The RAS plays an essential role in the regulation of vascular tone and extracellular fluid volume. As shown in Figure 5-1, sympathetic stimulation via β1-adrenergic receptors, renal artery hypotension, and decreased sodium delivery to the distal tubules stimulate the release of renin by the kidney. Renin is a proteolytic enzyme that cleaves to the circulating substrate angiotensinogen to form angiotensin I, which has little intrinsic pharmacologic activity. Angiotensin I is converted immediately to angiotensin II via a reaction catalyzed by ACE, which is present in vascular endothelium and lung tissue. In the short term (e.g., intraoperatively), angiotensin II contributes to vascular homeostasis by increasing vascular (especially arteriolar) tone. It acts directly on angiotensin II receptors and indirectly by enhancing sympathetic adrenergic function to increase vascular tone, which is necessary to maintain adequate perfusion pressure in patients with hypovolemia or reduced cardiac output. In the longer term (e.g., hours to days), angiotensin II contributes to vascular
homeostasis by its effect on extracellular fluid volume. It causes the adrenal cortex to release aldosterone, a hormone that acts on the kidneys to increase sodium and fluid retention. Angiotensin II also stimulates the release of vasopressin (i.e., antidiuretic hormone) from the posterior pituitary, which causes the kidneys to increase fluid retention. Blocking angiotensin II–mediated increased vascular tone and relative reductions in intravascular volume in patients receiving RAS antagonists chronically may cause refractory hypotension following the induction of anesthesia. Angioedema of the oropharynx or larynx has been recognized as an unusual complication of ACE inhibitor therapy. ACE-induced angioedema usually manifests spontaneously within hours to days of the initiation of treatment and has been described in association with anesthesia and Sympathetic stimulation Hypotension Decreased sodium delivery Angiotensinogen
Kidneys
Renin
Angiotensin I
Cardiac and vascular hypertrophy
ACE
Adrenal cortex
Angiotensin II
Pituitary
Aldosterone
ADH Thirst Systemic vasoconstriction
Renal sodium and fluid retention
Increased blood volume
Figure 5–1 ■ The renin-angiotensin system. ACE, angiotensin-converting enzyme; ADH, antidiuretic hormone.
17
Ch005-X2215
18
8/12/06
3:17 PM
Section 1
■
Page 18
Pharmacology
endotracheal intubation. Edema of the tongue is commonly the presenting symptom, with involvement of the face, lips, floor of the mouth, pharynx, glottis, or larynx frequently observed. The precise mechanism of angioedema formation is uncertain. Because it is likely mediated by the kallikreinbradykinin system, it is probably a biochemical rather than an immunologic phenomenon. Bradykinin is a potent vasodilator that increases vascular permeability and produces tissue edema. Kinase II (which is identical to ACE) is the major tissue enzyme responsible for the breakdown of bradykinin. ACE inhibitors inhibit kinase II to prevent bradykinin breakdown. Angioedema associated with ACE inhibitor therapy may therefore be a result of inhibition of bradykinin inactivation by kinase II.
Recognition HYPOTENSION Recognition of RAS antagonist therapy as a contributor to hypotension relies on the exclusion of other intraoperative events that may produce hypotension. A heightened index of suspicion in patients chronically treated with these drugs, especially those with a history of severe hypotension or left ventricular diastolic dysfunction, is justified. The temporal relationship between cardiovascular instability and induction of anesthesia in patients chronically treated with RAS antagonists, along with the failure of ephedrine in usual doses (10 to 20 mg IV in adult patients) to resolve the hypotension, makes RAS antagonism a likely cause of hypotension. ANGIOEDEMA Recognition of ACE inhibition as the cause of angioedema relies on the exclusion of other perioperative events associated with swelling of the head and neck (e.g., allergy, anaphylaxis), as well as the knowledge that angioedema can occur (though infrequently) with ACE inhibitors. When it does occur, angioedema is usually temporally related to the initiation of ACE inhibitor therapy.
Risk Assessment HYPOTENSION A number of patient factors modify the risk of severe hypotension with the induction of anesthesia in those treated with RAS antagonists. Patients treated with other antihypertensive agents in combination with a RAS antagonist are more likely to have refractory hypotension on induction. Likewise, the combination of RAS antagonists and other vasodilator drugs (e.g., amiodarone) increases the risk for hypotension. Patients with “complete” RAS blockade, which is associated with high doses and recent administration, are more likely to be unstable on induction. Patients with a history of severe hypertension, especially those with left ventricular diastolic dysfunction (which amplifies the dependence of blood pressure on intravascular volume in patients receiving ACE inhibitors), are also at increased risk for refractory hypotension. Short-term preoperative RAS inhibition (1 to 2 days) in normotensive or mildly hypertensive subjects
is less likely to result in refractory hypotension on induction. Patients who continue therapy until the day of surgery are also at increased risk. One review found that the incidence of hypotension on induction of anesthesia in patients with a history of severe hypertension was 75% to 100% when ACE inhibitors were continued until the day of surgery. ANGIOEDEMA Angioedema involving the oropharynx or larynx is an unusual complication of ACE inhibitor therapy, occurring on average in 0.1% of patients taking captopril, lisinopril, or enalapril; the incidence in patients taking enalapril may be slightly higher (0.2%) than in those taking the other two drugs. Patients are at highest risk within the first week of starting an ACE inhibitor; a retrospective study of 36,000 patients receiving enalapril showed that 60% to 70% of cases of angioedema occurred within this period. However, angioedema has occurred suddenly after months to years of therapy, and about 20% of known cases of angioedema occurring in this context may involve severe symptoms (e.g., dyspnea, stridor, laryngospasm). Unfortunately, there are no characteristics to predict which patients will progress to lifethreatening airway compromise.
Implications Concerning the risk for refractory hypotension on induction of anesthesia in patients taking RAS antagonists, there is no consensus on continuing or discontinuing the drug in the immediate preoperative period. For this class of drugs, the elimination half-life does not necessarily predict the duration of action, making recommendations with respect to perioperative dosing difficult.
MANAGEMENT Hypotension If RAS blockade contributes significantly to refractory hypotension after induction of anesthesia, therapy relies on the prompt restoration of adequate systemic vascular resistance and venous tone1 with phenylephrine or vasopressin, as well as increased intravenous fluid administration. Remedial actions for managing hypotension related to RAS antagonists include discontinuing or reducing the dose of other agents that might contribute to hypotension. Advanced cardiovascular life support protocols should be invoked in the event of cardiovascular collapse.
Angioedema Most occurrences of ACE inhibitor–induced angioedema are mild and resolve spontaneously or with discontinuation of the drug. However, swelling may progress rapidly to include the posterior pharynx or larynx, causing partial or complete 1 Venoconstriction (venous capacitance bed) indirectly increases venous return and preload.
Ch005-X2215
8/12/06
3:17 PM
Page 19
Chapter 5
Drugs Affecting the Renin-Angiotensin System
19
time to allow the return of RAS activity. However, any risk reduction might be at the expense of optimal therapy for hypertension or heart failure. Identifying patients at the greatest risk for severe hypotension (those with severe hypertension or those receiving high doses of RAS antagonists, RAS antagonists in combination with other antihypertensives, or RAS antagonists chronically), along with intravenous fluid loading before the induction of anesthesia, may reduce the risk for refractory hypotension. Such pretreatment combined with the early use of vasopressors for hypotension believed to be caused by RAS blockade will shorten the duration of hypotension. Consistent with the foregoing, frequent blood pressure measurement immediately after induction (direct arterial pressure monitoring may be necessary) contributes to the earlier detection of severe hypotension.
Further Reading PREVENTION As noted earlier, there is no consensus regarding the management of patients receiving RAS antagonist therapy in the immediate preoperative period. Discontinuation of RAS antagonists during this period reduces the risk for hypotension with anesthesia induction, provided there is sufficient
Colson P, Ryckwaert F, Coriat P: Renin angiotensin antagonists and anesthesia. Anesth Analg 89:1143-1155, 1999. Dean DE, Schultz DL, Powers RH: Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 46: 1239-1243, 2001. Kharash ED: Angiotensin-converting enzyme inhibitor–induced angioedema associated with endotracheal intubation. Anesth Analg 74:602-604, 1992.
PHARMACOLOGY
upper airway obstruction. The symptoms may progress despite aggressive therapy and may recur hours after apparent resolution. Angioedema caused by ACE inhibitors can be fatal. Management ranges from simply stopping the ACE inhibitor to endotracheal intubation or tracheostomy. Mild cases confined to the anterior tongue or lips generally resolve with discontinuation of the drug and administration of intravenous diphenhydramine and corticosteroids. More severe cases involving the pharynx and associated with dysphagia may require subcutaneous epinephrine, tracheal intubation, or both. As with any evolving process involving the airway, the potential for life-threatening airway obstruction dictates close observation and prompt intervention. Following resolution of the acute process, a note should be made in the patient’s medical record of this potentially lifethreatening adverse reaction to ACE inhibitor therapy, and the patient should receive appropriate counseling.
■
Ch006-X2215
8/12/06
3:29 PM
Page 20
CARDIAC DRUGS
Phosphodiesterase Inhibitors
6
Gregory M. Janelle Case Synopsis A 56-year-old man presents for emergent repair of an open olecranon fracture sustained in a motorcycle accident. There are no other signs of trauma. His past medical history is significant for hypertension, dyslipidemia, gastroesophageal reflux disease, and a 40-pack-year history of tobacco use. His father died from a myocardial infarction at age 60. He has no allergies and denies alcohol or other illicit drug use. Medications prior to admission include atorvastatin, ramipril, and esomeprazole. Baseline vital signs include blood pressure, 148/74 mm Hg; heart rate, 86 beats per minute; and respiration, 18 breaths per minute and nonlabored. An electrocardiogram (ECG) in the emergency room shows normal sinus rhythm with no evidence of ischemic changes. The patient refuses regional anesthesia. Preoperative medications include midazolam 2 mg and sodium bicitrate 30 mL. After uneventful induction of general anesthesia (thiopental, fentanyl, and succinylcholine), anesthesia is continued with isoflurane. After surgical stimulation, the patient has hypertension (180/100 mm Hg) and tachycardia (115 beats per minute). Concomitantly, there is 2-mm downsloping ST depression in lead V5 of a calibrated, monitored ECG. The end-tidal isoflurane concentration is increased from 0.8% to 1.2%, and intravenous esmolol (20 mg) and sublingual nitroglycerin spray (0.4 mg × 2) are also given. Within minutes, the patient’s blood pressure drops to 60/40 mm Hg and his heart rate increases to 90 beats per minute. While treating this, the anesthesiologist has the circulating nurse call the patient’s wife to inquire about unreported drug use. He learns that the patient was taking sildenafil for erectile dysfunction along with his other medications.
PROBLEM ANALYSIS Definition Intraoperative myocardial ischemia is potentially life threatening, especially if it is not recognized and promptly treated. It demands utmost vigilance on the part of the anesthesiologist. Intraoperative ischemia is defined as ST deviation, relative to the preoperative, reference ECG, of 0.2 mV or greater in one lead or 0.1 mV or greater in two contiguous leads and lasting at least 10 minutes. Once ischemia is diagnosed, the anesthesiologist must identify and aggressively treat the cause. Based on this definition of intraoperative myocardial ischemia, the patient described in the case synopsis had at least demand ischemia and likely significant underlying coronary artery disease (CAD) as well. The case synopsis also illustrates that aggressive treatment of hypertension, tachycardia, and myocardial ischemia by increasing the end-tidal concentration of isoflurane, along with esmolol and sublingual nitroglycerin, can lead to profound hypotension in patients also taking phosphodiesterase-5 (PDE-5) inhibitors. This hypotension may further aggravate myocardial ischemia by reducing coronary perfusion pressure. In this case, the anesthesiologist was not expecting 20
the sudden, profound hypotension that resulted from his treatment, which was quite reasonable given the ECG evidence, the circulatory changes, and the patient’s past medical history. Unfortunately, the patient had failed to report his use of sildenafil. Only further (indirect) inquiry by an astute and knowledgeable anesthesiologist led to the discovery of the likely proximate cause of the patient’s hypotension. Sildenafil citrate is a highly selective PDE-5 inhibitor that interacts with organic nitrates such as nitroglycerin to potentiate vascular smooth muscle relaxation, with the potential to cause profound blood pressure reduction. For this reason, organic nitrates are contraindicated if sildenafil has been taken in the preceding 24 hours.
Recognition PDE-5 breaks down cyclic guanosine monophosphate (cGMP). Therefore, PDE-5 inhibitors such as sildenafil are expected to increase available cGMP. The formation of cGMP is stimulated by guanylate cyclase, which in turn is stimulated by nitric oxide (NO). Nitroglycerin is a potent NO donor, although its effects are more prominent in the venous capacitance bed, except in very high doses. Nonetheless, nitroglycerin does dilate epicardial coronary
Ch006-X2215
8/12/06
3:29 PM
Page 21
Chapter 6
Risk Assessment Although the intraoperative hypotension experienced by the patient described in the case synopsis was probably due to an adverse interaction between nitroglycerin and the PDE-5 inhibitor sildenafil, intraoperative hypotension has many other causes unrelated to this interaction (Table 6-1) that are discussed elsewhere in this book. In addition, for this patient, increasing the end-tidal isoflurane concentration and giving intravenous esmolol compounded his hypotension. Refractory hypotension is also associated with angiotensin-converting enzyme (ACE) inhibitors and selective antagonists of angiotensin II receptors, such as olmesartan (see Chapter 5). Patients with preoperative sympathetic blockade or volume depletion due to fasting, blood loss, or diuretic therapy have a reduced venous capacitance. This reduces venous return and cardiac output and often compounds hypotension with the induction of anesthesia. For patients on ACE inhibitors, angiotensin II (a potent vasoconstrictor) does not counter such hypotension.
Table 6–1
■
Causes of Intraoperative Hypotension Unrelated to Phosphodiesterase-5 and Nitroglycerin Interactions
Anesthetics (IV and volatile agents) Central neuraxial anesthesia (spinal, epidural) Myocardial ischemia and reperfusion injury Heart failure (systolic or diastolic) Cardiac rhythm disturbances Chronic adrenocortical insufficiency Overly aggressive use of diuretics Recent hemo- or peritoneal dialysis Volume depletion related to third-space loss Inadequate fluid resuscitation Severe hemorrhage; hemorrhagic shock Hemothorax; hemopericardium Reduced venous return secondary to caval compression Restrictive pericarditis; pericardial effusion Tumors compressing or restricting heart Tumors compressing or restricting great vessels Severe bronchospasm; pneumothorax Increased intrathoracic pressure Excessive tidal volumes or airway pressures Sepsis and septic shock Anaphylactic and anaphylactoid reactions Carcinoid syndrome Monitoring artifacts Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Phosphodiesterase Inhibitors
21
However, the timing of this patient’s hypotension makes it less likely that ramipril (an ACE inhibitor) was the primary agent that precipitated the profound decrease in blood pressure. The patient also had multiple risk factors for CAD: ● ● ● ● ●
Hypertension Age older than 50 years Dyslipidemia Tobacco abuse Strongly positive family history
Further, erectile dysfunction disproportionately affects patients with cardiovascular disease. Thus, one must consider that these patients may be receiving sildenafil or similar potent PDE inhibitors. As the case synopsis illustrates, patients may fail to report the use of these drugs. Finally, this patient had objective evidence of CAD: ECG changes consistent with ischemia associated with tachycardia and hypertension with surgical stimulation.
Implications The clinical effects of sildenafil and other PDE-5 inhibitors (e.g., tidalafil, vardenafil) are mediated by a local increase in available cGMP. This, in turn, leads directly to smooth muscle relaxation in the arteries, arterioles, and sinusoids of the corpus cavernosum. The net result with sildenafil alone is vasodilatation and enhanced erectile function. The reduction in systolic and diastolic blood pressure is modest (≈8 and 5.5 mm Hg, respectively). When given to healthy volunteers, sildenafil had no apparent orthostatic effects. Sildenafil has also been investigated as a potential treatment for pulmonary hypertension. In patients with severe congestive heart failure, sildenafil reduces mean pulmonary artery pressure and arteriolar resistance by 20% and 45%, respectively. However, the drug has no significant effect on the cardiac index, ejection fraction, or pulmonary capillary wedge pressure. The safety of sildenafil in patients with documented CAD has been the subject of numerous reports. In one recent controlled trial, patients with CAD receiving sildenafil reported improved erections and sexual performance but experienced more side effects (e.g., transient headache, hypertension, flushing, dyspepsia) compared with placebo. However, there were no serious drug-related cardiovascular effects. An American College of Cardiology–American Heart Association consensus statement asserts that the available evidence supports the general safety of sildenafil in patients with CAD. Patients should not receive PDE-5 inhibitors and nitrates concomitantly. In fact, the current sildenafil product label states that the use of nitrates with sildenafil is strictly contraindicated. The simultaneous administration of nitric oxide donors (e.g., nitroglycerin) results in a marked accumulation of cGMP. This occurs because nitrates increase the production of cGMP, whereas sildenafil prevents its breakdown. The net result is a pronounced reduction in blood pressure with symptomatic hypotension. Other drugs that attenuate or block compensatory hemodynamic responses, including β- or α-adrenergic blockers, ACE inhibitors, and angiotensin II receptor antagonists, can also dramatically
PHARMACOLOGY
arteries; also important to the anti-ischemic action of nitroglycerin are reduced venous return and decreased cardiac preload, which lessen myocardial wall stress and reduce oxygen consumption. Sildenafil is prescribed for erectile dysfunction because sexual stimulation normally results in the release of NO from nerves and endothelial cells in the corpus cavernosum and systemic blood vessels, and NO stimulates guanylate cyclase to promote the formation of cGMP. Both aging and peripheral vascular disease interfere with this process; hence, the rationale for prescribing sildenafil or other PGE-5 inhibitors.
■
Ch006-X2215
8/12/06
22
3:29 PM
Section 1
■
Page 22
Pharmacology
exaggerate the adverse drug interaction between organic nitrates and PDE-5 inhibitors, especially when there is preexisting cardiovascular compromise. Twenty-one PDE genes have been cloned and belong to 11 PDE families based on their homology sequence and biochemical and pharmacologic properties. Table 6-2 depicts both experimental and clinical PDE inhibitors and their relative selectivity as inhibitors of PDE-1 through -11. Among these families, the PDE-3 inhibitors (e.g., enoximone, amrinone, milrinone, imazodan) are the most extensively studied group. By blocking the breakdown of cyclic adenosine monophosphate (cAMP), PDE-3 inhibitors reduce systemic and pulmonary arterial pressures. They also increase cardiac cAMP and Ca2+-induced Ca2+ release to increase myocardial contractility and the cardiac index, but without increasing myocardial oxygen consumption. Thus, PDE-3 inhibitors are considered positive inotropes and vasodilator agents. They have been used successfully in patients with advanced heart failure (both acutely and chronically) and as a bridge to cardiac transplantation. Thrombocytopenia limits the long-term use of amrinone, and the chronic use of milrinone has been associated with increased mortality in patients with New York Heart Association class III and IV heart failure. This mortality increase may be due to QTc prolongation with intravenous milrinone. The addition of a β-adrenergic blocking agent to low-dose milrinone therapy has been shown to reduce QTc prolongation and is associated with an improvement in patients’ functional status; however, sudden death was a relatively uncommon occurrence. Also, milrinone has been used to treat cerebral vasospasm associated with subarachnoid hemorrhage.
Table 6–2
■
Experimental and Clinical Inhibitors of Phosphodiesterase and Their Relative Selectivity
Phosphodiesterase Inhibitor
Phosphodiesterase Selectivity (IC50)
IBMAX Papaverine EHNA Rolipram Dipyridamole
Nonselective (2-50 μM) Nonselective (5-25 μM) PDE-2 (1.0 μM) PDE-4 (2.0 μM) PDE-5 (0.9 μM) PDE-6 (0.38 μM) PDE-7 (9.0 μM) PDE-8 (4.5 μM) PDE-10 (1.1 μM) PDE-1 and -5 (0.1 μM) PDE-7 (35 μM) PDE-9 (1.15 μM) PDE-10 (1.0 μM) PDE-3 (1.0 μM) PDE-5 (3.9 nM) PDE-5 (0.76 μM) PDE-6 (0.15 μM) Nonselective (45-150 nM)
SCH51866
Enoximone Sildenafil Zaprinast Pentoxifylline
EHNA, erythro-9-[3-(2-hydroxynonyl)]adenine; IBMAX, 3-isobutyl-1-methylxanthine; IC50, concentration of PDE inhibitor with 50% activity against PDE; PDE, phosphodiesterase; SCH, succinylcholine. Adapted from Hetman JM, Robas N, Baxendale R, et al: Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci U S A 97:12891-12895, 2000.
Inhibition of PDE-3 and PDE-4 may have therapeutic utility in reactive airway disease and for ameliorating pulmonary hypertension. PDE-4 inhibitors, such as compound A, cilomilast, and rolipram, also have anti-inflammatory and uterorelaxant effects. Finally, several commonly used drugs (e.g., papaverine, dipyridamole, pentoxifylline) appear to have significant nonselective PDE-inhibiting properties. Clinical effects of inhibition of the various PDE subtypes require further elucidation.
MANAGEMENT The management of perioperative myocardial ischemia and infarction is discussed in Chapter 76. Treatment for perioperative hypotension includes correction of the underlying pathophysiology and the administration of vasopressors if needed. For the patient described in the case synopsis, knowledge of all his preoperative medications would have permitted the recognition of potential drug-drug interactions (i.e., sildenafil-nitroglycerin) and prevented his profound hypotension. Therapy to counter nitroglycerin’s potentiation of sildenafil’s vasodilatory effect includes restoring intravascular volume by fluid resuscitation and increasing blood pressure with a vasoconstrictor such as phenylephrine, vasopressin, norepinephrine, epinephrine, or ephedrine. All are systemic arterial and venous vasoconstrictors, but phenylephrine and vasopressin have no β-adrenergic effects and would be the most judicious primary therapy in light of the patient’s predisposition for developing demand myocardial ischemia. Further, and importantly, by constricting the venous capacitance bed, α1 agonists such as phenylephrine and vasopressin increase venous return to augment preload and cardiac output. Refractory hypotension may necessitate the use of an intraaortic balloon counterpulsation device (see Chapter 98). Finally, administration of subsequent nitroglycerin doses is absolutely contraindicated.
PREVENTION Awareness is the key factor in preventing potentially lifethreatening drug-drug interactions. Unfortunately, erectile dysfunction still represents a social stigma in many cultures, which may prevent patients from reporting the problem and its treatment to their physicians and sexual partners. Sildenafil use increased by approximately 84% between 1998 and 2002. It was estimated that more than 14 million patients in the United States were taking sildenafil by 2001. With the advent of novel formulations of PDE-5 inhibitors and the reported growth in use among females and males between 18 and 45 years of age, it is likely that this number will well exceed 20 million patients by 2006. Although sildenafil is safe when taken by healthy patients, it should be administered with extreme caution in patients with cardiovascular disease. It is absolutely contraindicated in patients taking organic nitrates and those with hemodynamically significant aortic stenosis or hypertrophic obstructive cardiomyopathy. The cytochrome P-450 2C9 and 3A4
Ch006-X2215
8/12/06
3:29 PM
Page 23
Chapter 6
Further Reading Cheitlin MD, Hutter AM Jr, Brindis RG, et al: Use of sildenafil (Viagra) in patients with cardiovascular disease: ACC/AHA expert consensus document. Circulation 99:168-177, 1999. Hermann HC, Chang G, Klugherz BD, et al: Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 342:1622-1626, 2000.
Phosphodiesterase Inhibitors
23
Hetman JM, Robas N, Baxendale R, et al: Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci U S A 97:12891-12895, 2000. Jaski BE, Fifer MA, Wright RF, et al: Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure: Dose-response relationships and comparison to nitroprusside. J Clin Invest 75:643-649, 1985. Kulkarni SK, Patil CS: Phosphodiesterase 5 enzyme and its inhibitors: Update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol 26:789-799, 2004. Landesberg G, Mosseri M, Wolf Y, et al: Perioperative myocardial ischemia and infarction: Identification by continuous 12-lead electrocardiogram with online ST-segment monitoring. Anesthesiology 96:264-270, 2002. Viagra (sildenafil citrate): US prescribing information. In Physicians’ Desk Reference, 57th ed. Montvale, NJ, Medical Economics, 2003, pp 2653-2656. Zusman RM, Morales A, Glasser DB, et al: Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 83(Suppl):35C-44C, 1999.
PHARMACOLOGY
pathways are the primary pathways for the metabolism of sildenafil. Thus, potent inhibitors of the these cytochromes (e.g., cimetidine, erythromycin, digoxin, some statins) may increase sildenafil’s plasma concentration. In such patients, and in those with severely compromised renal or hepatic function, reduced starting doses of sildenafil have been advocated to reduce the incidence of significant untoward effects.
■
Ch007-X2215
8/12/06
3:30 PM
Page 24
7
Digitalis Emilio B. Lobato Case Synopsis A 70-year-old man is scheduled for a subtotal colectomy under general anesthesia. He has a history of anterior myocardial infarction and intermittent atrial fibrillation and is receiving digoxin. His preoperative serum digoxin and potassium concentrations are 1.5 ng/dL and 3.9 mEq/L, respectively. Preparation for surgery includes colonic enemas (given until clear). His digoxin is withheld. Soon after the patient is placed on mechanical ventilation, he develops atrioventricular junctional tachycardia (AVJT) at 95 to 100 beats per minute (Fig. 7-1). Pulse oximetry reveals an arterial blood oxygen saturation of 100%. The end-tidal carbon dioxide partial pressure is 22 mm Hg, and the serum potassium concentration is 3.0 mEq/L. Digitalis toxicity is the suspected cause of the AVJT. Intravenous potassium chloride is given, and ventilation is reduced. Eventually, AVJT gives way to sinus rhythm, and the surgical procedure continues uneventfully.
PROBLEM ANALYSIS
●
●
Definition The use of digitalis to treat congestive heart failure (CHF) has been eclipsed by the current widespread use of angiotensinconverting enzyme (ACE) inhibitors and β-blockers to treat this condition. Prospective, randomized clinical trials have shown conclusively that both ACE inhibitors and β-blockers reduce mortality, whereas digoxin does not. However, one meta-analysis of available clinical trials (2001) showed that digoxin had beneficial effects, even in patients treated with ACE inhibitors; these findings may extend to β-blockers, but specific data were lacking. The results of this meta-analysis strengthen the concept that digoxin still has beneficial clinical effects in symptomatic patients with CHF, including the ability to reduce hospitalizations. Further, most patients in these reviewed trials were also receiving diuretics. Thus, clinicians still offer digoxin to symptomatic patients or those at appreciable risk for hospitalization for CHF, with a reasonable expectation of some benefit. Digitalis increases myocardial contractility in patients with heart failure and reduces the ventricular rate in those with atrial fibrillation. Cardiac complications can result from therapeutic or toxic effects of digitalis, primarily due to inhibition of membrane Na+,K+-ATPase. Extracardiac complications usually involve the central nervous system and gastrointestinal tract. Monitoring serum concentrations of digoxin (normally, 0.9 to 2.0 ng/dL) may help prevent toxic effects; however, there is considerable overlap between digoxin’s toxic and therapeutic effects, especially with hypokalemia or increased sensitivity to its effects (e.g., patients with severe cardiac disease or hypothyroidism). To avoid sampling errors due to slow digoxin equilibration, blood must be drawn at least 4 hours after intravenous dosing or 12 hours after oral dosing. Elevated serum digoxin concentrations may be due to the following: ● ●
Overdose or increased bioavailability (e.g., digitalis gel caps) Reduced volume of distribution (especially in elderly patients)
24
Reduced excretion (e.g., renal failure, patients receiving quinidine) Displacement from binding sites (e.g., with calcium channel blockers)
Recognition Digitalis toxicity may be immediately apparent or difficult to recognize, especially if cardiac manifestations are due to underlying heart disease. The presenting signs and symptoms depend on whether the digitalis toxicity is acute or chronic. If acute, gastrointestinal symptoms may be prominent. If chronic, patients may present with nonspecific symptoms (e.g., weakness and malaise). However, the sole evidence of chronic toxicity may be new arrhythmias. CARDIAC MANIFESTATIONS Cardiac manifestations of digitalis toxicity (primarily arrhythmias) include the following: ● ● ● ● ● ● ●
Sinus bradycardia Ventricular premature beats Nonparoxysmal AVJT Wenckebach atrioventricular (AV) block Atrial tachycardia with varying AV block Bidirectional ventricular tachycardia Ventricular fibrillation
When interpreting electrocardiogram (ECG) findings in patients receiving digitalis, one must distinguish between
Figure 7–1 ■ Nonparoxysmal atrioventricular junctional tachycardia at 100 beats per minute. Negative P waves after each QRS complex indicate retrograde atrial capture.
Ch007-X2215
8/12/06
3:30 PM
Page 25
Chapter 7
●
● ●
●
T-wave changes (often the earliest sign), ranging from flattening to inversion or peaking of the terminal portion of the T wave Shortening of the Q-T interval ST-T segment flattening or depression, resulting in the classic concave (“scooped”) appearance (often more pronounced in ECG leads with tall R waves) Increased U-wave amplitude
Also, a slowed but irregular ventricular rate in atrial fibrillation implies a therapeutic digitalis effect. Regularization of the ventricular rate suggests toxicity and is usually due to the development of AV junctional rhythm (rate ≤70 beats per minute) or AVJT (rate >70 beats per minute). Cardiac complications can also result from the therapeutic effects of digitalis and include the following: ●
●
●
Increased risk for ventricular tachycardia and ventricular fibrillation in patients with Wolff-Parkinson-White syndrome and atrial fibrillation. Digitalis shortens refractoriness and speeds conduction in accessory AV conducting pathways. This may lead to preferential accessory pathway conduction and a greatly increased ventricular rate with atrial fibrillation (see Chapter 80). The latter can exceed 300 beats per minute and is limited solely by accessory pathway refractoriness. If this rate is sustained, there is a strong potential for early degeneration into ventricular tachycardia or ventricular fibrillation. Increased ventricular outflow tract obstruction in patients with asymmetrical ventricular septal hypertrophy, due to the positive inotropic effects of digitalis. Aggravation of myocardial ischemia in patients with coronary artery disease; this is “demand” ischemia due to digitalis-increased myocardial oxygen consumption.
Digitalis is ill-advised in any of these circumstances. The associated risks outweigh any potential benefits. ECG signs of toxicity occur in 5% to 20% of patients receiving digitalis. Almost any arrhythmia can result from the direct toxic or neurally mediated electrophysiologic effects of digitalis on cardiac muscle or the specialized conducting tissues (Table 7-1). The most common arrhythmia
Table 7–1
■
Digitalis
in patients with sinus rhythm is the appearance of ventricular extrasystoles. With atrial fibrillation, regularization of the ventricular rate occurs due to the development of AV junctional rhythm or AVJT; this may be the first manifestation of digitalis toxicity. In fact, the development of accelerated AV junctional rhythm or idioventricular rhythm in patients with AV heart block is highly suggestive of digitalis toxicity. Two other arrhythmias are characteristically identified with digitalis toxicity: 1. Paroxysmal atrial tachycardia with AV heart block. This is due to increased atrial conduction time and reduced refractoriness, along with AV node conduction block. 2. Bidirectional ventricular tachycardia. In this case, QRS complexes alternate between two distinctly different morphologies. In some leads, distinct R and S waves alternate between each other. Table 7-2 lists arrhythmias associated with digitalis toxicity in decreasing order of frequency. Worsening of preexisting CHF is often the first symptom of digitalis-induced arrhythmias and should alert the clinician to possible toxicity. EXTRACARDIAC MANIFESTATIONS Extracardiac manifestations of digitalis toxicity include the following: ●
●
●
Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and increased salivation, from stimulation of central vagal nuclei Central nervous system manifestations (more common in the elderly), including blurred vision, abnormal color perception (e.g., green halos), hallucinations, and frank delirium Acute life-threatening hyperkalemia, occurring with severe digitalis overdose and caused by paralysis of the Na+-K+ pump and outward intracellular K+ leak
Risk Assessment Knowledge of factors that may alter digitalis pharmacokinetics or myocardial sensitivity and thus predispose patients to digitalis toxicity is of paramount importance (Table 7-3). Elderly patients are at greater risk than younger ones, and
Electrophysiologic Effects of Therapeutic and Toxic Digitalis
Tissue
Therapeutic Effects
Clinical Manifestations
Toxic Effects
Clinical Manifestations
Sinus node
Slows sinus rate
Sinus bradycardia
Sinus pause; SA conduction block
Atrium
None
None
AV node/AVJ
↓ Conduction time
Purkinje fibers
↓ Refractoriness; ↑ repolarization ↓ Refractoriness
↓ Ventricular rate; ↑ P-R interval None; ST-T segment depression ↓ Q-T interval
Sinus pause or arrest; SA conduction block ↑ Conduction; ↓ refractoriness AV heart block; ↑ AVJ automaticity ↑ Automaticity; DADtriggered activity ↑ Automaticity; DADtriggered activity
Ventricle
25
↑ Atrial rate (atrial flutter/fibrillation) Mobitz type I-II second or third degree heart block; AVJR or AVJT VPB; VT VPB; VT
AV, atrioventricular; AVJ, atrioventricular junction; AVJR, atrioventricular junctional rhythm; AVJT, atrioventricular junctional tachycardia; DAD, delayed after depolarization; SA, sinoatrial; VPB, ventricular premature beats; VT, ventricular tachycardia.
PHARMACOLOGY
normal and toxic effects. Normal ECG changes with therapeutic levels of digitalis include the following:
■
Ch007-X2215
8/12/06
26
3:30 PM
Section 1
Table 7–2
■
■
Page 26
Pharmacology
Digitalis-Caused Arrhythmias in Decreasing Order of Frequency
Premature ventricular beats Accelerated AV junctional rhythm or tachycardia Wenckebach (Mobitz type I) AV block Sinus bradycardia or arrest Atrial tachycardia with variable AV block* Bidirectional ventricular tachycardia* Atrial flutter Ventricular fibrillation *Almost always due to the toxic effects of digitalis. AV, atrioventricular.
reduced body mass lowers the volume of distribution for digitalis. Other drugs administered concomitantly may interact with digoxin and affect serum concentrations. Also, a progressive decline in renal function and reduced serum albumin may elevate serum digoxin concentrations, as does reduced creatinine clearance if no adjustment in dosage is made. Importantly, dialysis is not effective for clearing digoxin. In hypothyroidism, the activity of membrane Na+,K+ATPase is reduced, which means that lower digoxin doses are needed to achieve a therapeutic effect, and toxicity can occur with usual doses. Hypoxemia enhances digitalis’s acceleration of lower pacemaker activity and may trigger arrhythmias from delayed afterpotentials. In patients receiving digitalis, ectopic beats or tachycardia can be exacerbated by the concomitant use of β-adrenergic agonists and diuretics. Hypokalemia potentiates the effects of digitalis owing to impaired Na+-K+ pump function. Low serum K+ concentrations increase the binding of digitalis to myocardium. Hypomagnesemia reduces the activity of membrane Na+,K+ATPase and may increase kaliuresis and cause hypokalemia. Hypercalcemia increases digitalis activity by increasing intracellular Ca2+. In addition, many drugs and other factors interact with digoxin to alter its pharmacokinetics, displace it from tissue binding sites, or reduce its clearance to increase serum drug concentrations (see Table 7-3).
Table 7–3
■
Factors that Predispose to Digitalis Toxicity
Older age Electrolyte imbalance (hypokalemia, hypomagnesemia, hypercalcemia) Renal insufficiency Severity of heart disease Hypoxemia Hypothyroidism Drug interactions Angiotensin-converting enzyme inhibitors Benzodiazepines Quinidine or quinine Calcium channel blockers Erythromycin Cyclosporine Amiodarone
Implications Digitalis toxicity constitutes a serious condition that merits hospitalization. Hemodynamic deterioration with associated arrhythmias in patients with significantly impaired cardiac function may cause acute hemodynamic decompensation. In addition to hemodynamic compromise, some arrhythmias themselves are life threatening. Therefore, early recognition of the toxic effects of digitalis is imperative. Some extracardiac manifestations may be debilitating and may, in fact, precipitate arrhythmias. In surgical candidates, all but the most urgent procedures should be postponed until the digitalis toxicity has been resolved.
MANAGEMENT The treatment of digitalis toxicity depends on the severity of the clinical manifestations (Table 7-4). However, all patients suspected of digitalis intoxication should have an assessment of serum electrolytes, potassium, magnesium, and calcium, as well as a determination of serum digoxin concentration. For patients with mild symptoms, temporary discontinuation of the drug, cardiac monitoring, and supportive measures are sufficient. For patients with severe or lifethreatening arrhythmias (complete heart block, ventricular tachyarrhythmias), in addition to discontinuing digitalis, the administration of potassium chloride (in the absence of hyperkalemia) and magnesium sulfate should be considered. For heart block, 1 mg of atropine is usually effective in counteracting the vagal effects of digoxin. For ventricular arrhythmias, in addition to monitoring serum levels, lidocaine is the drug of choice, with a loading dose of 1 to 2 mg/kg, followed by an infusion of 1 to 2 mg/minute. Phenytoin was used in the past but, owing to its myocardial depressant properties and its tendency to produce hypotension when given intravenously, has largely been replaced by digoxin-specific antibodies (Digibind). There is no evidence to support the use of amiodarone to treat ventricular tachycardia or to prevent recurrences of ventricular fibrillation in patients with digitalis toxicity. At least in theory, the complementary electrophysiologic actions of amiodarone and digitalis to promote sinus bradycardia and increase sinoatrial and AV node conduction times and refractoriness might promote or precipitate asystole. More important is that amiodarone is known to
Table 7–4
■
Management of Digitalis Toxicity
Withhold further digitalis Assess electrolytes (K+, Ca2+, Mg2+) Administer potassium chloride in the absence of hyperkalemia Administer magnesium sulfate Treat bradyarrhythmias Atropine Temporary or (possibly) permanent artificial pacing Treat ventricular arrhythmias Lidocaine Phenytoin (diphenylhydantoin) Digoxin-specific antibodies (Digibind)
Ch007-X2215
8/12/06
3:30 PM
Page 27
Chapter 7
PREVENTION Knowledge of the multiple factors that affect digoxin pharmacokinetics and pharmacodynamics is important to avoid
Digitalis
27
its toxic effects. Regular determination of serum digoxin concentrations and dose adjustments in patients with conditions that increase the risk of digitalis toxicity are important measures, especially in the elderly.
Further Reading Antman EM, Wenger TL, Butler VP Jr, et al: Treatment of 150 cases of life-threatening digitalis intoxication with specific Fab antibody fragments: Final report of a multicenter study. Circulation 81:1744-1750, 1990. Fenster PE, White NW Jr, Hanson CD: Pharmacokinetic evaluation of the digoxin-amiodarone interaction. J Am Coll Cardiol 5:108-112, 1985. Hauptman PJ, Kelly RA: Digitalis. Circulation 99:1265-1270, 1999. Hood WB Jr, Dans AL, Guyatt GH, et al: Digitalis for treatment of congestive heart failure in patients in sinus rhythm. Update of Cochrane Database Syst Rev 3:CD002901, 2001; PMID: 11687032. Kelly RA, Smith TW: Recognition and management of digitalis toxicity. Am J Cardiol 69:108G-119G, 1992. Ma G, Brady WJ, Pollack M, et al: Electrocardiographic manifestations: Digitalis toxicity. J Emerg Med 20:145-152, 2000. Ooi H, Colucci WS: Pharmacological treatment of heart failure. In Hardman JG, Limbird LE (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. New York, McGrawHill, 2001, pp 901-932. Spratt KA, Doherty JE: Principles and practice of digitalis. In Messerli FH (ed): Cardiovascular Drug Therapy, 2nd ed. Philadelphia, WB Saunders, 1996, pp 1136-1146.
PHARMACOLOGY
increase serum digoxin levels. Systemic clearance of digoxin is significantly prolonged owing to reduced renal and nonrenal clearance, which lengthens its half-life of elimination by approximately 20%. However, amiodarone does not appear to affect the volume of distribution for digoxin. Electrical countershock (direct-current cardioversion) is contraindicated because it can exacerbate the severity of arrhythmias. Administration of digoxin-specific antibodies (Digibind) is the treatment of choice for life-threatening arrhythmias and for digoxin-induced refractory hyperkalemia. The use of an antibody rapidly reduces the percentage of unbound digoxin in the serum from 75% to less than 5%. The antibody-digoxin complex then undergoes renal excretion. Side effects are infrequent but include allergic reactions and rebound toxic digoxin effects in patients treated with inadequate doses of Digibind. Importantly, conventional serum assays for digoxin cannot distinguish between free and bound digoxin; thus, serum digoxin concentrations appear markedly elevated following Digibind treatment. The results of treatment are monitored by manifestations of clinical improvement; however, free digoxin determinations can be obtained in patients who show a poor response to treatment.
■
Ch008-X2215
8/12/06
3:18 PM
Page 28
8
Anticholinergics Kevin J. Sullivan Case Synopsis A 1-year-old child weighing 10 kg is in the pediatric intensive care unit with respiratory failure and a difficult airway. Prior attempts at laryngoscopy and endotracheal intubation have been unsuccessful, and mask ventilation is difficult. The infant, who becomes hypoxic and bradycardic during resuscitation efforts, is unintentionally given 4 mg of intravenous atropine, instead of the 0.2 mg that was ordered. Endotracheal intubation is performed to reverse the respiratory failure and hypoxia. Shortly thereafter, the patient is noted to be tachycardic (225 beats per minute), with warm, red, dry skin and fever (39°C). He appears disoriented, agitated, and inconsolable.
PROBLEM ANALYSIS Definition Because infants and young children have a relatively enhanced vagal tone compared with adults, vagotonic physiologic perturbations, such as airway instrumentation, can result in bradycardia. Thus, in pediatric anesthesia and critical care settings, bradycardia can be seen during laryngoscopy and induction of anesthesia with volatile inhalational agents (most commonly halothane), as well as with hypoxemia and elevated intracranial pressure. Bradycardia and the consequent reduced cardiac output can be prevented by premedication with oral, intravenous, or intramuscular anticholinergic drugs. In the case synopsis, an inadvertently high dose of atropine (about 20-fold too high) was given to increase the patient’s heart rate during bradycardia. Anticholinergic (antimuscarinic) toxicity is commonly seen in infants and young children after the accidental ingestion of belladonna alkaloids and their synthetic congeners, antiparkinson medications, histamine receptor antagonists, tricyclic antidepressants, and phenothiazines. For persons of all ages, the ingestion of plants that contain large quantities of belladonna alkaloids can cause anticholinergic toxicity. Such plants include deadly nightshade (Atropa belladonna), jimsonweed (Datura stramonium), and angel’s trumpet (Brugmansia candida). Anticholinergics used in anesthesia include atropine, glycopyrrolate, and scopolamine. They compete with neurally released acetylcholine to attach to muscarinic cholinergic receptors and block the effects of acetylcholine, and they antagonize muscarinic agonist actions at noninnervated muscarinic cholinergic receptors. Further, presynaptic muscarinic receptors on adrenergic nerve terminals inhibit norepinephrine release. Thus, muscarinic antagonists (anticholinergics) can enhance sympathetic activity. Except for the fact that quaternary ammonium compounds (glycopyrrolate) do not readily cross the blood-brain barrier to exert central nervous system (CNS) actions, there is little difference in the qualitative actions of atropine, glycopyrrolate, and scopolamine. However, some quantitative differences in effect may be seen. For example, both atropine and scopolamine have a shorter duration of action than glycopyrrolate. Further, the 28
antisialagogue effects of glycopyrrolate and scopolamine are greater than those of atropine. In addition, heart rate is most increased by atropine, then by glycopyrrolate, and least by scopolamine. Finally, although both atropine and scopolamine are tertiary amines that readily cross the blood-brain barrier, they differ in CNS effects: atropine causes CNS stimulation, whereas scopolamine produces sedation and amnesia. Human tissues vary with respect to both the density and the type of muscarinic receptors present. Five subtypes of muscarinic receptors have been identified (M1, M2, M3, M4, M5), each with a different location and function. For example, M1 receptors are found in the cerebral cortex, sympathetic ganglia and postganglionic neurons, and some presynaptic sites. M2 receptors are present in myocardium, smooth muscle cells, and some presynaptic sites. M3 receptors are found in exocrine glands, and M4 receptors in heart. M5 receptors are found mostly in brain. All muscarinic receptor subtypes interact with heterotrimeric, guanine nucleotide-binding regulatory proteins (G proteins) linked to cellular effectors. Although selectivity is not absolute, stimulation of M1 or M3 receptors causes hydrolysis of polyphosphoinositides and mobilization of intracellular Ca2+, which is due to interaction with a G protein (Gq) that activates phospholipase C. The latter causes a variety of Ca2+-mediated events, either directly or via phosphorylation of target proteins. In contrast, M2 and M4 muscarinic receptors inhibit adenylyl cyclase and regulate specific ion channels (e.g., enhancement of K+ conductance in cardiac atrial tissue) through subunits released from pertussis toxinsensitive G proteins (G1 and G0). These are distinct from the G proteins used by the M1 and M3 receptors. Finally, M5 receptors may inhibit M-type (KCNQ2/KCNQ3) K+ channels via the activation of a common G protein.
Recognition Table 8-1 lists the effects of anticholinergics in various organ systems. Appreciation of the range of organ systems affected by anticholinergic drugs is required to maximize their benefits while minimizing side effects. Drugs in common use (atropine, scopolamine, glycopyrrolate) are nonselective muscarinic receptor antagonists. They have similar side effects, but to a varying extent. As stated earlier, atropine and
Ch008-X2215
8/12/06
3:18 PM
Page 29
Chapter 8
■
Clinical Effects of Anticholinergic Drugs
Cardiovascular effects (observed at moderate doses) Increased rate of sinoatrial (SA) node discharge Decreased rate of SA node discharge (low doses of atropine) Enhanced atrioventricular node conduction Little or no effect on ventricular function Little effect on peripheral vasculature Cutaneous vasodilatation in high doses Respiratory effects (observed at low doses) Drying of respiratory secretions Relaxation of bronchial smooth muscle Increased anatomic dead space Central nervous system effects (observed at larger doses) Wide range of symptoms, from sedation and depression to agitation and delirium Gastrointestinal effects (observed at larger doses) Decreased salivation Reduced gastric secretions and motility Decreased lower esophageal sphincter tone Ophthalmic effects (observed at moderate doses) Mydriasis Cycloplegia Genitourinary effects (observed at larger doses) Decreased ureter and bladder tone Urinary retention Thermoregulation effects (observed at small doses) Inhibition of sweat gland secretions (function most sensitive to anticholinergics) Elevated temperature
scopolamine cross the blood-brain barrier, whereas glycopyrrolate does not. Scopolamine is more sedating than atropine but causes less of a heart rate increase; similar to atropine, it is a moderately potent antisialagogue. Glycopyrrolate is the most potent antisialagogue, causes moderate tachycardia, and is nonsedating. The pharmacologic effects of anticholinergics used in anesthesia are summarized in Table 8-2. Another anticholinergic agent, ipratropium (Atrovent), is used primarily in pulmonary care. This drug was introduced
Table 8–2
■
Pharmacologic Effects of Anticholinergics Used in Anesthesia
Atropine Causes greater vagolysis than glycopyrrolate Increases heart rate and enhances atrioventricular node conduction Paradoxical slowing of heart rate at low doses Little sedation Moderately potent antisialagogue Glycopyrrolate Moderate vagolytic effect on heart, but less than that of atropine No sedation (charged quaternary amine; does not cross blood-brain barrier) Highly potent antisialagogue Scopolamine Marked sedation-amnesia (tertiary amine structure; lipid soluble; crosses blood-brain barrier) Most likely to cause central anticholinergic syndrome (easily reversed with physostigmine) Moderately potent antisialagogue
Anticholinergics
29
in the 1980s and reestablished anticholinergics as a therapy for bronchospastic disorders. Although ipratropium is structurally similar to atropine and has similar actions if given parenterally, it is a quaternary ammonium compound. Ipratropium is poorly absorbed when inhaled and has few extrapulmonary effects, even with very large inhaled doses. When inhaled, 90% of ipratropium is swallowed, and only 1% of the total dose is absorbed systemically. When given to normal volunteers, the drug provides almost complete protection against bronchospasm induced by a variety of provocative agents. However, in asthmatics, the results can vary. Whereas the bronchospastic effects of some agents (e.g., methacholine, sulfur dioxide) are completely blocked, there is little blocking of leukotriene-induced bronchoconstriction. Also, unlike atropine, ipratropium has no negative effect on ciliary clearance. In general, this drug and other anticholinergics are more effective in chronic obstructive pulmonary disease, especially when cholinergic tone is high. The development of new drugs that affect specific muscarinic receptor subtypes will provide more effective therapy with fewer adverse or troublesome side effects than the drugs used today. The child in the case synopsis displayed many of the signs and symptoms of anticholinergic toxicity, which can be divided into two types: CNS and peripheral antimuscarinic. CNS toxicity can manifest as agitation, delirium, seizures, or coma. Systemic anticholinergic effects are most prominent in tissues or organs with dense parasympathetic innervation and include tachycardia; dry mucous membranes; urinary retention; dry, flushed skin; dilated pupils with cycloplegia; fever; and ileus. The child in the case illustrated the typical findings accompanying anticholinergic overdose in pediatric patients. Although the cause of his condition was known, the differential diagnosis includes other potentially lifethreatening conditions (Table 8-3). Physical examination and the natural history of the disease process should allow the clinician to differentiate among these conditions. Physical and laboratory findings of anticholinergic toxicity that help exclude other conditions are summarized in Table 8-4. Although the conditions in the differential diagnosis share overlapping features with anticholinergic toxicity, the combination of abolition of pupillary responses and sweating is very specific for anticholinergic toxicity. Many clinicians confuse anticholinergic toxicity with the diametrically opposed toxidrome associated with anticholinesterase poisoning, which results in excessive cholinergic tone. Physician familiarity with toxic syndromes due to anticholinesterase poisoning has increased dramatically with the proliferation of chemical weapons of mass destruction. In contrast to the symptoms and signs of anticholinergic
Table 8–3
■
Differential Diagnosis of Anticholinergic Toxicity
Hypoxemia and/or hypercarbia Sepsis Malignant hyperthermia Thyroid storm (crisis) Pheochromocytoma Carcinoid syndrome
PHARMACOLOGY
Table 8–1
■
Ch008-X2215
8/12/06
30
Table 8–4
3:18 PM
Section 1
■
■
Page 30
Pharmacology
Distinguishing Features of Anticholinergic Toxicity*
Relatively normal arterial O2 and CO2 tensions (rules out hypoxemia and hypercarbia) Cycloplegia (pupillary light reflexes remain intact for most other conditions) Mydriasis (pupils may also be dilated in MH due to elevated circulating catecholamines) Anhidrosis; warm, red skin (sweating is preserved in other disorders within the differential diagnosis; see Table 8-3) Lack of muscle rigidity (commonly seen with MH) No ventricular arrhythmias (not characteristic of carcinoid syndrome, but common with MH, pheochromocytoma, and thyrotoxicosis) Minimal to modest increase in end-tidal CO2 due to hyperthermia (usually far greater with MH or thyrotoxicosis) Mild (or no) hypertension (as in MH), or paroxysmal, severe hypertension (thyroid storm, pheochromocytoma, or carcinoid tumor†), especially with gland or tumor manipulation Mild to no metabolic acidosis (far more severe in MH) *In anesthetized patients, the modulatory effects of anesthesia must be considered. † Serotonin released by carcinoid tumors has little if any direct effect on the heart. However, positive chronotropic and inotropic effects, and possibly arrhythmias, may occur with the release of norepinephrine. Effects of serotonin on the peripheral vasculature include both vasoconstriction and vasodilatation. MH, malignant hyperthermia.
overdose, poisoning with carbamate insecticides or organophosphates leads to CNS excitation and excessive nicotinic and muscarinic receptor activation. CNS signs include ataxia, restlessness, agitation, convulsions, and coma. Muscarinic signs include excessive salivation, perspiration, vomiting, diarrhea, abdominal cramps, tenesmus, bradycardia or heart block, pupillary constriction, lacrimation, wheezing, hypotension, blurred vision, and urinary and fecal incontinence. Nicotinic signs include muscle twitching, fasciculations, cramping, paralysis, respiratory compromise, and subsequent cardiac arrest.
Risk Assessment Patients with heart disease are at far greater risk for anticholinergic complications. In this respect, atropine and glycopyrrolate produce more vagolysis than scopolamine does, causing a much greater increase in the sinus rate and speed of atrioventricular (AV) node conduction. An increased heart rate is more dangerous in patients with coronary artery disease and valvular or subvalvular restrictive cardiac lesions (e.g., aortic and mitral valve stenosis, idiopathic hypertrophic subaortic stenosis). Further, in patients with functional accessory AV pathways and a history of AV reciprocating tachycardia or atrial flutter or fibrillation (e.g., WolffParkinson-White syndrome), atropine or glycopyrrolate (especially in a relative overdose) may precipitate dangerously fast tachyarrhythmias (see Chapter 80). Also, because both drugs facilitate AV node conduction, they are contraindicated in patients with supraventricular tachyarrhythmias, especially atrial flutter or fibrillation.
Implications Anticholinergics exert their effects in many organ systems (see Table 8-1). Therapeutic effects in one organ system may be accompanied by undesirable side effects in others. Careful selection of the anticholinergic agent and its dose allows the clinician to target the appropriate organ system and simultaneously minimize undesirable side effects in other organ systems (see Table 8-2). Although atropine is considered relatively safe and benign in adults, an atropine overdose is very dangerous in pediatric
patients, especially infants. Deaths due to anticholinergic poisoning have been reported with doses as low as 2 mg of atropine in infants. Anticholinergics have complex gastrointestinal actions. Salivary gland secretions are reduced and are the most sensitive to cholinergic block. Gastric secretions are also reduced, but this requires larger doses. Both gastrointestinal motility and lower esophageal sphincter tone are reduced. However, it is important to remember that anticholinergic premedication does not confer protection against aspiration of gastric contents and chemical or bacterial pneumonitis. Also, the function of a number of other organs can be impaired by anticholinergic therapy. In the eye, anticholinergic drugs can precipitate narrow-angle glaucoma. Individuals with a shallow anterior chamber can suffer acute increased intraocular pressure due to impaired drainage via the canal of Schlemm. Postsurgical patients, especially elderly men with prostatic hypertrophy, are at risk for severe urinary retention after taking anticholinergics. Further, confusion, agitation, and delirium are CNS side effects of anticholinergics that cross the blood-brain barrier (scopolamine, atropine). Patients at greatest risk for mental status changes are those at the extremes of age, those with preexisting abnormalities of mental status, and those taking drugs with significant anticholinergic properties (e.g., antiparkinson drugs, phenothiazines, tricyclic antidepressants, butyrophenones, antihistamines, cycloplegics, antispasmodics). Impaired thermoregulation due to the inability to sweat can result in hyperpyrexia. Children and infants are especially vulnerable owing to their high metabolic rate and immature thermoregulatory mechanisms. It is clear that hyperpyrexia involves an impaired ability to dissipate heat through sweating. Whether there is a central effect on thermal regulation remains unclear. Finally, atropine and glycopyrrolate are commonly given with or prior to anticholinesterase drugs to reverse nondepolarizing neuromuscular blockade. Because of similarities in onset of drug action, atropine is commonly administered with edrophonium, which has a very rapid onset. Similarly, glycopyrrolate is often administered with neostigmine because both have a slower onset and a longer duration of action. By selecting an anticholinergic that matches the anticholinesterase drug’s onset and duration of action, heart
Ch008-X2215
8/12/06
3:18 PM
Page 31
Chapter 8
MANAGEMENT Most complications related to anticholinergic drugs are self-limited and can be effectively treated with supportive care. For example, urinary retention in elderly men may require short-term or intermittent bladder catheterization. However, some complications, such as fast sinus or nonparoxysmal atrial tachycardias in patients with myocardial ischemia or infarction, aortic or mitral valve stenosis, or idiopathic hypertrophic subaortic stenosis, require prompt treatment. Therapeutic options include β-blockers and calcium channel antagonists. If paroxysmal supraventricular tachycardia is likely, adenosine is useful. However, the current advanced cardiovascular life support guidelines advise early cardioversion for most hemodynamically disadvantageous tachyarrhythmias, rather than a trial of drugs (see Chapter 79). Likewise, severe hyperthermia should be treated aggressively with cooling blankets and, if needed, immersion in ice water and irrigation of body cavities with cold saline. With careful consideration of the underlying medical history and the pharmacodynamics of the various anticholinergics, it is possible to maximize the benefits of this class of medications while minimizing undesirable side effects of therapy.
PREVENTION Prevention of the side effects of anticholinergic drugs begins with an appreciation of the fact that they affect different
Anticholinergics
31
organ systems with different intensities (see Tables 8-1 and 8-2) but do so in a predictable, dose-related fashion. To avoid complications, it is most important to recognize that certain subsets of patients are at greater risk for morbidity related to the use of anticholinergic drugs. Therefore, it is crucial to evaluate the specific vulnerabilities of the patient, delineate the goals of anticholinergic therapy, and select a drug with a pharmacodynamic profile that most closely suits the goals of therapy.
Further Reading Brown JH, Taylor P: Muscarinic receptor agonists and antagonists. In Hardman JG, Limbird LE (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. New York, McGrawHill, 2001, pp 155-173. Das G: Therapeutic review: Cardiac effects of atropine in man: An update. Int J Clin Pharmacol 27:473-477, 1989. Feldman MD: The syndrome of anticholinergic intoxication. Am Fam Physician 34:113-116, 1986. Friesen RH, Lichtor JL: Cardiovascular depression during halothane anesthesia in infants: A study of three induction techniques. Anesth Analg 61:42-45, 1982. Goyal RK: Muscarinic receptor subtypes: Physiology and clinical implications. N Engl J Med 321:1022, 1989. Gross NJ: Ipratropium bromide. N Engl J Med 319:486-494, 1988. Guo J, Schofield GG: Activation of muscarinic M5 receptors inhibits recombinant KCNQ2/KCNQ3 K+ channels expressed in HEK293T cells. Eur J Pharmacol 462:25-32, 2003. Mirakhur RK: Antagonism of the muscarinic effects of edrophonium with atropine or glycopyrrolate. Br J Anaesth 57:1213-1216, 1985. Moss J, Glick D: The autonomic nervous system. In Miller RD (ed): Miller’s Anesthesia, 6th ed. Philadelphia, Churchill Livingstone, 2005, pp 617-677. Patton WDM: The principles of drug action. Proc R Soc Med 53:815-820, 1965. Polak RL: Effects of hyoscine on the output of acetylcholine into preferred cerebral ventricles on cats. J Physiol 181:317-323, 1965.
PHARMACOLOGY
rates that are too fast or too slow can be avoided. It also appears that lower doses of anticholinergics are required to antagonize the weaker and shorter-lived muscarinic effects of edrophonium compared with those of neostigmine.
■
Ch009-X2215
8/12/06
3:18 PM
Page 32
9
Adenosine M. J. Pekka Raatikainen and John L. Atlee Case Synopsis A 63-year-old man with a history of transient ischemic attacks is admitted to the hospital for elective surgery. His medications include aspirin 250 mg/day orally and dipyridamole 75 mg orally three times a day. During the operation under regional anesthesia, a regular supraventricular tachycardia (SVT) is observed. The tachycardia terminates after intravenous bolus adenosine (12 mg) and is followed by a long sinus pause and angina-like pain (Fig. 9-1).
PROBLEM ANALYSIS Definition The first step is to determine whether the signs or symptoms are due to tachycardia. If they are, the existing advanced cardiovascular life support guidelines advise immediate cardioversion rather than a trial of antiarrhythmic drugs. If cardioversion is not indicated (e.g., ectopic atrial tachycardia), the guidelines stress making a specific diagnosis and identifying patients with impaired cardiac function (ejection fraction <40%). Importantly, the 2000 guidelines downplay the use of adenosine to differentiate wide QRS tachycardia due to ventricular aberration versus ectopy. This unnecessarily exposes patients to adenosine’s unpleasant side effects, possibly worsens arrhythmias, and may destabilize heart rate and pressure. However, given the history of the patient described in the case synopsis, the circumstances, and the apparent suddenness of onset, it was reasonable to administer adenosine to terminate this regular, narrow QRS complex tachycardia, especially because it was associated with apparent ST segment
depression in the lead depicted. The advantage of adenosine (versus intravenous calcium channel antagonists, such as verapamil or diltiazem, or β-blockers) for the chemical conversion of sudden-onset, narrow QRS tachycardia is related to its rapid action and ultrashort half-life. Although adenosine rarely causes severe side effects, minor adverse effects such as facial flushing and chest discomfort are frequently observed. In the majority of patients, these are well tolerated and resolve rapidly without intervention. However, the concomitant administration of drugs that inhibit the elimination of adenosine from blood, and the presence of some clinical conditions (e.g., asthma), may render some patients more susceptible to the development of severe adverse effects with adenosine.
Recognition Endogenous adenosine is involved in numerous physiologic and pathophysiologic processes in mammalian organs and tissues. Most, if not all, of these actions are mediated by specific cell surface receptors (A1-, A2A-, A2B-, and A3-adenosine receptors). Because of the ubiquitous nature and distribution of these receptors, administration of adenosine to terminate SVT may cause adverse effects unrelated to the heart. Following are the most common patient complaints after the administration of adenosine: ● ●
A
B
Rhythm strip during the tachycardia
20 sec after 12 mg adenosine bolus
●
5.5 s
Figure 9–1 ■ A, Intraoperative rhythm strip from the patient described in the case synopsis (paper speed, 25 mm/second). It shows a regular, narrow QRS tachycardia (180 beats per minute). B, Rhythm strip 20 seconds after the administration of intravenous bolus adenosine (12 mg). Sinus arrest lasting 5.5 seconds occurs after termination of the tachycardia. The patient was receiving dipyridamole, which is a potent nucleoside transport blocker and likely potentiated adenosine’s effects. In later ambulatory electrocardiographic recordings and electrophysiologic testing, there was no evidence of sinoatrial node dysfunction.
32
Facial flushing Dyspnea Chest discomfort
Less common side effects are nausea, lightheadedness, headache, dizziness, and palpitations. These adverse side effects often occur concomitantly with tachycardia termination and persist for 2 to 3 minutes. Many, but not all, of these effects are attributable to vasodilatation with activation of the A2adenosine receptors. For example, facial flushing is caused by cutaneous vasodilatation. Direct stimulation of carotid chemoreceptors and cardiac pain receptors may explain respiratory stimulation and the sensation of dyspnea and chest discomfort (angina-like pain), respectively. Adenosine may also cause bronchoconstriction, especially in asthmatics. Like all antiarrhythmics, adenosine may be proarrhythmic, provoking new or worse arrhythmias. Given the potent depressant effects of adenosine in the sinoatrial (SA) and atrioventricular (AV) nodes, it is not surprising that adenosine
Ch009-X2215
8/12/06
3:18 PM
Page 33
Chapter 9
● ● ● ● ● ● ● ●
Sinus bradycardia; transient sinus arrest Transient AV block Supraventricular premature beats Atrial flutter Atrial fibrillation Ventricular premature beats Nonsustained VT Torsades de pointes–type polymorphic VT
The potent negative chronotropic (slowed sinus rate) and dromotropic (slowed AV node conduction) effects of adenosine explain its ability to cause pronounced bradycardia or sinus arrest or AV heart block. The induction of atrial flutter or fibrillation by adenosine appears to be due to shortening of atrial repolarization and refractoriness. Although the drug effectively terminates most paroxysmal SVT, some reports have demonstrated its proarrhythmic potential, including the induction of VT. However, the mechanisms of adenosine-induced ventricular premature beats and nonsustained or even sustained VT are less clear. Adenosine has no known direct effect on ventricular myocytes. Thus, it seems unlikely that adenosine exerts a direct proarrhythmic effect, at least in normal ventricles. Further, ventricular premature beats are not specific for adenosine but may also be seen after termination of SVT by calcium channel blockers (e.g., verapamil, diltiazem) or AV node ablation. Some reports suggest that termination of SVT by adenosine may occasionally lead to the development of torsades de pointes polymorphic VT. Adenosine markedly slows the sinus and ventricular rates and, when given intravenously, leads to increased sympathetic discharge. In fact, adenosine has been used to reproduce clinical torsades de pointes in patients with congenital long Q-T interval syndrome during electrophysiologic testing. Thus, one might speculate that an adenosineslowed ventricular rate and an increased sympathetic discharge interact adversely to facilitate early afterdepolarizations, the proximate cause of ventricular tachyarrhythmias in experimental models. One group attempted to define the proarrhythmic effects of adenosine used to terminate 187 episodes of SVT in 127 patients admitted to the emergency room over a 5-year period. In two thirds of cases, adenosine induced ventricular ectopy after successful termination of SVT, including premature ventricular beats and nonsustained VT, both of which were transient and self-terminating. Based on morphologic criteria, more than half the arrhythmias appeared to originate in the inferior left ventricular septum, which may be more susceptible to adenosine’s proarrhythmic effects. Although this high incidence of ventricular arrhythmias was surprising, no further intervention was required. These proarrhythmic
Adenosine
33
effects may be due to abnormal electrophysiologic mechanisms facilitated by adenosine-increased sympathetic discharge. To recognize transient or sustained ventricular proarrhythmias after the administration of adenosine for the treatment of paroxysmal SVT, one should monitor the electrocardiogram (ECG) continuously for at least 2 minutes following each intravenous adenosine bolus.
Risk Assessment The reported incidence of adverse extracardiac symptoms after an intravenous bolus injection of adenosine ranges from less than 30% to more than 70%. Proarrhythmic effects are less common; for example, the incidence of atrial fibrillation is 1% to 5%, and the incidence of ventricular premature beats is approximately 10% to 30%. Only occasionally do case reports describe more severe proarrhythmic actions. However, it is known that interactions with drugs inhibiting adenosine metabolism and some clinical conditions may sensitize patients to the effects of adenosine and thus render them susceptible to more severe adverse effects. For example, in patients receiving dipyridamole, the cellular uptake of adenosine is blocked, and the half-life of the nucleoside is markedly prolonged. Consequently, these patients are much more vulnerable to the development of prolonged bradycardia, AV node conduction disturbances, and extracardiac adverse effects. Likewise, patients with preexisting AV node conduction disturbances, sick sinus syndrome, myocardial ischemia, and cardiac allografts are more sensitized to the cardiac effects of adenosine, and asthmatic patients are more susceptible to adenosine-induced bronchoconstriction. In view of the finding that abrupt slowing of the heart rate may cause torsades de pointes VT, adenosine, like any other agent that promotes the development of sudden bradycardia, may be arrhythmogenic in patients with long QT syndrome. Factors and clinical conditions that predispose patients to the adverse effects of adenosine include the following: ●
●
● ● ● ●
Medications that inhibit the elimination of adenosine from blood (e.g., dipyridamole) Myocardial ischemia (especially inferior myocardial infarction or ischemia) Heart transplantation Preexisting AV node conduction disturbances Preexisting SA node disease Acquired or congenital long QT syndrome
Nevertheless, compared with calcium channel antagonists, β-blockers, and other antiarrhythmic agents, adenosine has many important advantages related to its rapid onset of action and less severe and shorter-lived adverse effects. Initial experience also indicates that adenosine can be relatively safely administered to patients in whom the use of calcium channel antagonists may be hazardous (e.g., those with heart failure, ischemic heart disease, WolffParkinson-White syndrome, or wide-complex tachycardia or those taking β-blockers). In addition, adenosine may still have utility for differentiating wide QRS complex SVT from VT and for identifying the arrhythmogenic mechanism of a variety of tachycardias, especially in the cardiac catheterization laboratory during electrophysiologic testing (Fig. 9-2). However, as stated earlier, for arrhythmias involving
PHARMACOLOGY
often causes transient sinus bradycardia and AV block. In fact, adenosine’s efficacy in terminating AV nodal reentrant tachycardia and AV reciprocating tachycardia depends on the production of transient AV block. In addition to commonly associated bradyarrhythmias, clinicians report that adenosine occasionally induces atrial fibrillation, ventricular premature beats, brief episodes of nonsustained ventricular tachycardia (VT), and torsades de pointes VT (a polymorphic VT in association with Q-T interval prolongation; see Chapter 81). The following proarrhythmias have been observed after the intravenous administration of adenosine:
■
Ch009-X2215
8/12/06
34
3:18 PM
Section 1
■
Page 34
Pharmacology
Tachycardia Adenosine Termination • • • •
Transient suppression
AVNRT, AVRT cAMP-dependent VT SNRT Atrial tachycardia
• Sinus tachycardia • Atrial tachycardia
No effect • • • •
Reentrant and automatic VT Atrial flutter Atrial fibrillation Atrial tachycardia
Figure 9–2 ■ Possible effects of adenosine on cardiac arrhythmias. Because important diagnostic information can be obtained during the drug’s peak effect, the cardiac rhythm should be monitored by electrocardiogram for at least 2 minutes after each adenosine bolus. Rapid intravenous bolus adenosine (6 mg, followed by 12 mg if necessary) terminates more than 90% of supraventricular tachycardias that involve the atrioventricular (AV) node, including AV nodal reentrant tachycardia (AVNRT) and AV reentrant tachycardia (AVRT) involving the AV node and accessory AV conduction pathways. Some catecholamine-dependent (e.g., cyclic adenosine monophosphate [cAMP]) ventricular tachycardia (VT) and sinoatrial node reentrant tachycardia (SNRT) are also terminated by adenosine. Depending on the tachycardia mechanism and the location of the arrhythmogenic focus, the effect of adenosine on atrial tachycardias can vary considerably. Although adenosine may terminate some atrial tachyarrhythmias, it can also precipitate atrial fibrillation or flutter.
severe hemodynamic compromise, immediate cardioversion is recommended rather than a trial of antiarrhythmic drugs.
Implications Among the drugs used for the acute treatment of paroxysmal SVT, adenosine appears to be the least likely to cause significant adverse hemodynamic effects. It can also be used safely throughout the perioperative period. However, caution is necessary when administrating adenosine to patients receiving dipyridamole or other agents that inhibit the elimination of adenosine. Likewise, patients with myocardial ischemia, SA or AV node dysfunction, and cardiac allografts seem to be sensitized to both the therapeutic and the adverse effects of adenosine.
restore sinus rhythm in patients with ischemia-induced AV node block during the early phase of inferior myocardial infarction. They can also relieve angina-like pain in patients treated with adenosine. The principles for the management of proarrhythmias associated with adenosine administration are outlined in Figure 9-3. With hemodynamically unstable AV heart block or bradyarrhythmias, cardiopulmonary resuscitation must be started without delay. Likewise, patients with adenosineinduced tachyarrhythmias and hemodynamic compromise require emergency direct-current cardioversion. Otherwise, an adenosine receptor antagonist (e.g., theophylline, aminophylline) is the initial drug of choice. The recommended dose of theophylline is 150 to 250 mg as a slow intravenous bolus injection (approximately 100 mg/minute). If bradycardia or AV block does not respond to theophylline, adrenergic drugs, atropine, or cardiac pacing may be effective. If antiarrhythmic drugs are used to treat adenosine-induced tachyarrhythmias, they should be selected according to the type or mechanism of tachycardia. However, cardioversion is generally preferred to drugs.
PREVENTION There are only a few absolute contraindications for the use of adenosine. Adenosine should not be administered to patients with second or third degree AV block or sick sinus syndrome unless the patient has a pacemaker. In addition, patients with asthma or severe obstructive pulmonary disease probably should not be given adenosine. When administering adenosine therapeutically, physicians should be aware of important drug interactions. Drugs that inhibit the metabolism of adenosine, either by blocking the nucleoside transporter or by directly inhibiting adenosine-metabolizing enzymes (adenosine kinase and adenosine deaminase), significantly prolong the half-life of the adenosine and dramatically potentiate its effects. For example, the concurrent use of dipyridamole potentiates the effects of adenosine by a factor of four. Accordingly, clinicians
Adenosine-induced proarrhythmia
Bradyarrhythmia
MANAGEMENT Because of adenosine’s extremely short half-life, any adverse effects caused by its intravenous bolus injection are usually transient and require observation only. Again, to recognize transient or sustained ventricular proarrhythmias after the administration of adenosine for paroxysmal SVT, the ECG must be monitored continuously for at least 2 minutes after each injection. The nonselective A1- and A2-adenosine receptor antagonists aminophylline and theophylline are highly effective in reversing any unfavorable side effects of adenosine injection or infusion. In addition, these agents have been used to
Tachyarrhythmia
Hemodynamically stable?
Hemodynamically stable?
NO YES
NO YES
Theophylline
Theophylline CPR Theophylline Adrenergic drugs Cardiac pacing Atropine
Sinus rhythm?
Immediate DC shock; CPR
Sinus rhythm? NO YES
NO YES Successful
Antiarrhythmic drugs DC shock
Successful
Monitor for further arrhythmias Figure 9–3 ■ Algorithm for the management of proarrhythmias associated with the administration of adenosine. CPR, cardiopulmonary resuscitation; DC, direct current.
Ch009-X2215
8/12/06
3:18 PM
Page 35
Chapter 9
●
●
● ●
●
●
Identify and correct factors that may predispose patients to proarrhythmia and other adverse effects. Reduce the dosage in patients receiving dipyridamole or other agents that inhibit the elimination of adenosine. Reduce the dose when using central vascular access. Always use incremental adenosine dosing, starting with a low initial dose. An unnecessarily large initial dose will not improve adenosine’s efficacy in terminating SVT but will certainly increase the risk for adverse effects. Warn patients about adenosine’s common side effects and reassure them that these effects will resolve within 2 minutes. Monitor the ECG continuously for several minutes after each intravenous bolus of adenosine. This facilitates early diagnosis and treatment of proarrhythmia and may provide valuable diagnostic information.
In summary, an understanding of the pharmacologic basis of adenosine’s actions (pharmacokinetics and drug
Adenosine
35
interactions), combined with meticulous attention to minimizing the factors predisposing to adverse effects, is crucial to this drug’s safe and effective use.
Further Reading Bertolet BD, McMurtrie EB, Hill JA: Theophylline for the treatment of atrioventricular block after myocardial infarction. Ann Intern Med 123:509-511, 1995. Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al: ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary. J Am Coll Cardiol 42:1493-1531, 2003. Camm AJ, Garratt CJ: Adenosine and supraventricular tachycardia. N Engl J Med 325:1621-1629, 1991. Celiker A, Tokel K, Cil E, et al: Adenosine induced torsades de pointes in a child with congenital long QT syndrome. Pacing Clin Electrophysiol 17:1814-1817, 1994. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advanced cardiovascular life support. Section 5: Pharmacology. I: Agents for arrhythmias. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 102(8 Suppl):I112-I128, 2000. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advanced cardiovascular life support. 7D: The tachycardia algorithms. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 102(8 Suppl):I158-I165, 2000. Harrington GR, Froelich EG: Adenosine-induced torsades de pointes. Chest 103:1299-1301, 1993. Pelleg A, Pennock RS, Kutalek SP: Proarrhythmic effects of adenosine: One decade of clinical data. Am J Ther 9:141-147, 2002. Raatikainen MJP, Dennis DM, Belardinelli L: Cardiac electrophysiology of adenosine: Cellular basis and clinical implications. In Pelleg A, Belardinelli L (eds): Effects of Extracellular Adenosine and ATP on Cardiomyocytes. Austin, Tex, RG Landes, 1998, pp 87-132. Sylven C: Mechanisms of pain in angina pectoris: Critical review of the adenosine hypothesis. Cardiovasc Drug Ther 7:745-759, 1993. Tan HL, Spekhorst HH, Peters RJ, et al: Adenosine induced ventricular arrhythmias in the emergency room. Pacing Clin Electrophysiol 24:450-455, 2001. Wesley RC Jr, Turnquest P: Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome. Am Heart J 123:794-796, 1992.
PHARMACOLOGY
recommend that the initial dose of adenosine in patients receiving dipyridamole should not exceed 1 mg, compared with the typical initial dose of 6 mg rapidly administered via a peripheral vein. It is also advisable to use lower-than-usual doses if adenosine is given via a central vein or to patients with myocardial ischemia or to cardiac transplant recipients. In contrast, larger doses (≥12 mg) may be needed to terminate SVT in patients receiving adenosine receptor antagonists such as aminophylline or theophylline. The response to adenosine may be attenuated in patients who consume food or drink containing methylxanthines (e.g., coffee, cola, chocolate). Although no severe interactions with anesthetic drugs have been reported, it may be important to recognize that benzodiazepines block nucleoside transport in the brain, albeit to a lesser extent than dipyridamole. Adenosine may also lower anesthetic requirements (reduced minimum alveolar concentration) and potentiate nondepolarizing neuromuscular blockade. The following actions may help prevent adverse effects associated with the use of adenosine:
■
Ch010-X2215
8/12/06
3:19 PM
Page 36
Class I Antiarrhythmic Drugs: Ventricular Proarrhythmia
10
Mark F. Trankina Case Synopsis A 56-year-old man with stable angina and paroxysmal atrial fibrillation is scheduled for ambulatory inguinal hernia repair. He takes sublingual nitroglycerin as needed, quinidine (400 mg four times a day), and metoprolol (50 mg/day). His preoperative electrocardiogram (ECG) shows normal sinus rhythm at 60 beats per minute, with a corrected Q-T interval of 490 msec and possible left atrial enlargement. He refuses regional anesthesia. He is induced with fentanyl (150 μg), thiopental (350 mg), and succinylcholine (100 mg). His airway is secured without difficulty. However, the pulse oximeter malfunctions within minutes of induction. A sporadic carotid pulse is felt, and the ECG shows twisting of QRS complexes around the isoelectric baseline (Fig. 10-1).
PROBLEM ANALYSIS Definition The Cardiac Arrhythmia Suppression Trial (CAST) in 1989 and CAST II in 1992 tested the idea that chronic suppression of lesser ventricular arrhythmias (e.g., ventricular premature beats and nonsustained ventricular tachycardia) by class I antiarrhythmics would reduce mortality in survivors of myocardial infarction. Such arrhythmias were believed to be the inciting events for lethal (malignant) ventricular arrhythmias such as sustained ventricular tachycardia (VT) or ventricular fibrillation. Although encainide and flecainide reduced the incidence of lesser ventricular arrhythmias, they also conferred excess mortality (7.7% in the treatment group versus 3.0% in placebo groups). This excess mortality was attributed to proarrhythmia. Further, deaths in the treatment group were equally distributed throughout the treatment period, suggesting that the proarrhythmic response could occur any time after the start of drug therapy. Proarrhythmia is defined as the provocation of new or worse arrhythmias by antiarrhythmic drugs. The incidence can be as high as 9% to 10% with some class IA, IB, IC, or III drugs and is lowest (2% to 3%) with amiodarone (a class III antiarrhythmic that also has class I, II, and IV actions). Ventricular proarrhythmia manifests as (1) incessant monomorphic VT or polymorphic VT without Q-T interval prolongation or (2) polymorphic VT with Q-T interval prolongation, or torsades de pointes (TDP). Because the patient in the case synopsis had Q-T prolongation, his arrhythmia was TDP (see Fig. 10-1). Early afterdepolarizations (EADs) are believed to be the inciting mechanism for TDP. EADs are oscillations in the transmembrane potential of ventricular myocytes that occur during the repolarization phase. EADs are caused by the blockage of outward potassium (K+) 36
repolarization currents; however, this blockage also leads to Q-T interval prolongation and increased ventricular refractoriness. This is conducive to reentry of excitation, the likely sustaining mechanism for TDP. However, because the increase in refractoriness is uneven (greater in some ventricular fibers than in others), VT induced by EADs has a multiform rather than a uniform morphology. Ischemia-related regional differences in cardiac conduction delay and refractoriness promote ventricular reentry. Ischemia also leads to heterogeneity in antiarrhythmic drug concentrations in myocardium, which augments ischemic cellular electrophysiologic changes. However, the reentry circuits are larger (i.e., macroreentry versus microreentry), and the associated VT is often monomorphic as opposed to polymorphic. When polymorphic VT occurs in patients without Q-T interval prolongation, it is simply polymorphic VT; in association with Q-T interval prolongation, it is TDP. Both have the same ECG appearance (see Fig. 10-1). Mechanisms for the development of clinical arrhythmias include automaticity, which refers to spontaneous cardiac impulse formation without the need for prior stimulation; it can be normal or abnormal. Normal automaticity occurs in the sinoatrial node (the primary pacemaker) or in latent pacemakers (e.g., subsidiary atrial or Purkinje fibers). Abnormal automaticity can occur in any myocardial fiber type, although it usually occurs in fibers that do not normally exhibit automaticity, such as atrial and working ventricular muscle fibers. Such fibers manifest automaticity only if their cell membrane potentials become depressed by the effects of disease, drugs, or imbalance (i.e., the loss of cell membrane potential). At these low cell membrane potentials, ionic currents responsible for automaticity become activated. Arrhythmias ascribed to enhanced normal automaticity are atrioventricular (AV) junctional and ventricular escape rhythms with advanced second degree or complete (third degree) AV heart block or increased AV node refractoriness.
Ch010-X2215
8/12/06
3:19 PM
Page 37
Chapter 10
■
Class I Antiarrhythmic Drugs: Ventricular Proarrhythmia
37 PHARMACOLOGY
Figure 10–1
■
Torsades de pointes after induction of general anesthesia. Note “twisting” of the QRS complexes around the isoelectric baseline.
Those ascribed to abnormal automaticity include automatic atrial and AV junctional tachycardia, as well as accelerated idioventricular rhythm or tachycardia following cardiopulmonary bypass or in patients with acute coronary syndromes. Triggered activity is initiated by depolarizing oscillations in the cell transmembrane potential (afterdepolarizations) that occur before EADs or after full cell repolarization (delayed afterdepolarizations). Thus, triggered activity is the result of a preceding impulse or series of impulses, without which electrical quiescence occurs. Not all afterdepolarizations reach the threshold potential for a regenerative action potential. However, if they do, they can trigger further afterdepolarizations and thus become self-perpetuating. Arrhythmias caused by digitalis toxicity are triggered by delayed afterdepolarizations. Some ectopic atrial tachycardia may also be triggered. As already noted, there is strong evidence that EADs and EAD-triggered activity are the cause of polymorphic VT associated with congenital or acquired long QT syndromes (e.g., TDP). Some causes of EADs are listed in Table 10-1. In addition, there has been a great deal of controversy over the Food and Drug Administration’s “black box” warning about the clinical significance of Q-T prolongation due to droperidol, a drug that has been used safely for decades by anesthesiologists and other health care providers. A more comprehensive listing of drugs associated with TDP (and thus likely causes of EADs) can be found in Chapter 81 or on the Web site http.//www.torsades.org.
Table 10–1
■
Causes of Early Afterdepolarizations and Triggered Activity
α-Adrenergic stimulation Imbalance Hypoxia Hypercarbia Acidosis Hypokalemia Anitarrhythmic drugs Quinidine Ibutilide Sotalol Local anesthetics Bupivacaine Etidocaine Miscellaneous Cesium
Recognition The Vaughan-Williams antiarrhythmic drug classification divides drugs into four classes based on their principal mode of action: class I, sodium channel blockers; class II, β-adrenergic blockers; class III, potassium channel blockers; and class IV, calcium channel blockers. Class I antiarrhythmic drugs are further subdivided into classes IA, IB, and IC. Signs of toxicity caused by class I antiarrhythmics include the following: ●
●
● ●
●
Lengthened Q-T interval (class IA) or widened QRS complexes (class IC) manifesting as proarrhythmia Long Q-T interval (corrected Q-T interval of 440 to 450 msec) History of dizziness or syncope preoperatively Change in dosing or the recent initiation of antiarrhythmic therapy Occurrence of TDP (see Fig. 10-1)
Class IA Antiarrhythmic Drugs. All class I antiarrhythmics are sodium channel blockers, and some also affect the currents involved in action potential repolarization. Class IA drugs (e.g., quinidine, procainamide, disopyramide) reduce action potential upstroke velocity and prolong its duration. The kinetics of these drugs’ onset and offset of effect are of intermediate rapidity (<5 seconds). Class IB Antiarrhythmic Drugs. Class IB drugs (e.g., mexiletine, phenytoin, lidocaine) do not reduce upstroke velocity, but they do shorten action potential duration. They have fast onset and offset kinetics (<500 msec). Class IC Antiarrhythmic Drugs. Class IC drugs (e.g., flecainide, propafenone, moricizine) reduce upstroke velocity (primarily by slowing conduction) and also prolong refractoriness somewhat. They have slow onset and offset kinetics (10 to 20 seconds). The Vaughan-Williams classification is still widely used, but it has many limitations because of the complexity of drug actions. The “Sicilian gambit’’ (see Further Reading) provides a more realistic view. Some drugs exert greater effects at slow rates than at fast rates (reverse use dependence); this is particularly true of drugs that lengthen repolarization (class IA). Thus, the Q-T interval becomes prolonged at slow rates rather than at fast rates, which is exactly the opposite of what an ideal antiarrhythmic drug should do. Prolongation of refractoriness should be increased at fast rates to interrupt or prevent a reentrant tachycardia and minimal at slow rates to avoid precipitating TDP.
Ch010-X2215
38
8/12/06
3:19 PM
Section 1
■
Page 38
Pharmacology
Finally, it is important to remember that anesthesiologists must evaluate the patient with a rhythm disturbance, not the rhythm disturbance itself. Some arrhythmias are hazardous to the patient regardless of the clinical setting, whereas others are hazardous because of the clinical setting (e.g., anesthesia and surgery, acute coronary syndromes, post cardiopulmonary bypass).
Risk Assessment Conditions associated with Q-T interval prolongation and thus predisposition to TDP are listed in Table 10-2. A variety of commonly prescribed drugs belonging to many different therapeutic classes, including antiarrhythmics, antibiotics, antihistamines, and prokinetic drugs, can adversely prolong cardiac repolarization. However, arrhythmias related to drug-induced Q-T prolongation do not occur in every patient treated with such drugs; they occur only in susceptible patients. It has been postulated that these individuals may be silent carriers of genes responsible for congenital long QT syndromes. Up to 70% of these patients have normal Q-Tc intervals until exposed to a Q-T interval–prolonging drug. The primary objective of pharmacologic therapy for a patient with a cardiac arrhythmia is to achieve an effective and well-tolerated plasma drug concentration as quickly as possible and to maintain that concentration for as long as required without producing adverse effects. In many circumstances (but not with all drugs), the plasma concentration after equilibration correlates with the pharmacodynamic and adverse effects of the drug. However, the therapeutic concentration for any given patient is the amount of drug required to suppress or terminate the specific cardiac arrhythmia without producing adverse side effects.
Table 10–2
■
Factors that Predispose to Q-T Interval Prolongation
Congenital or acquired long QT syndromes Coexisting disease Hypothyroidism Cardiomyopathies Bradycardia Physiologic imbalance Hypokalemia Hypomagnesemia Hypocalcemia Antiarrhythmics Class IA, IC, and III drugs Combined class IA and III drugs Other drugs Potassium-wasting diuretics Tricyclic antidepressants Phenothiazines Erythromycin Terfenadine Astemizole Liquid protein diets For a more complete listing, see Chapter 81 or go to http.//www.torsades.org.
Given the fact that automaticity, triggered activity, or reentry can cause cardiac arrhythmias, the mechanisms by which antiarrhythmic agents suppress cardiac arrhythmias can be postulated. Antiarrhythmic agents can slow the spontaneous discharge frequency of an automatic pacemaker by depressing the slope of diastolic depolarization, shifting the threshold voltage toward zero, or hyperpolarizing the resting membrane potential. Mechanisms by which different drugs suppress normal or abnormal automaticity may not be the same. In general, most antiarrhythmic drugs in therapeutic doses depress automaticity at ectopic sites while minimally affecting automaticity of the sinus node. However, calcium channel blockers (e.g., verapamil) and β-blockers (e.g., propranolol) can depress the sinus rate, and drugs that exert vagolytic effects (e.g., disopyramide, quinidine) can increase the sinus rate. Drugs can also suppress early or delayed afterdepolarizations to eliminate triggered arrhythmias. Proarrhythmia with antiarrhythmic drugs is an important clinical problem. Electrophysiologic mechanisms include prolongation of repolarization, development of delayed after depolarizations (e.g., arrhythmias with digitalis toxicity) or EADs (to initiate TDP), or alterations in conduction and refractoriness that are conducive to reentry and the initiation or maintenance of VT or ventricular fibrillation. The acquired form of Q-T interval prolongation (see Table 10-2) is caused by various agents and conditions that reduce the magnitude of outward repolarizing K+ currents, enhance inward depolarizing Na+ or Ca2+ currents, or both, which leads to the development of EADs that initiate TDP. Proarrhythmic events can occur in as many as 5% to 10% of patients. Congestive heart failure increases proarrhythmic risk. In one recent study, patients with atrial fibrillation receiving antiarrhythmic drugs had a 4.7 relative risk of cardiac death if they had a history of heart failure, compared with a 3.7 relative risk among those not receiving antiarrhythmic drugs. Patients without a history of congestive heart failure had no increased risk of cardiac mortality during antiarrhythmic drug therapy. Reduced left ventricular function, treatment with digitalis and diuretics, and longer pretreatment Q-T interval are often seen in patients who develop drug-induced ventricular fibrillation. Usually the proarrhythmic events occur within several days of beginning drug therapy or after a change in dosage and are manifest by the development of VT, Q-T interval prolongation, or TDP (long QT syndrome). Doses for class I antiarrhythmic drugs are listed in Table 10-3. Proarrhythmic effects are likely additive when multiple drugs are used. Mortality with TDP is approximately 30%. With acquired long QT syndromes, the therapeutic challenge is to maintain prolonged repolarization but interrupt the arrhythmogenic cascade.
MANAGEMENT It is possible that multiple drugs have a cumulative effect in provoking EADs and TDP. Antiarrhythmics may paradoxically produce malignant ventricular tachyarrhythmias via proarrhythmia, and preoperative antiarrhythmic treatment does not preclude the generation of more ominous perioperative arrhythmias. The ECG should be carefully scrutinized
Ch010-X2215
8/12/06
3:19 PM
Page 39
Chapter 10
■
Class I Antiarrhythmic Drugs: Ventricular Proarrhythmia
39
Dosing for Class I Antiarrhythmic Agents
Drug
IV Loading
IV Maintenance
PO Loading
PO Maintenance
Quinidine Procainamide Disopyramide Lidocaine Mexiletine Tocainide Phenytoin Flecainide Propafenone Moricizine
6-10 mg/kg at 0.3-0.5 mg/kg/min 6-13 mg/kg at 0.2-0.5 mg/kg/min 1-2 mg/kg over 15-45 min 1-3 mg/kg at 20-50 mg/min 500 mg 750 mg 100 mg q5min to <1000 mg 2 mg/kg 1-2 mg/kg
600-1000 mg 2-6 mg/min 1 mg/kg/hr 1-4 mg/min 0.5-1.0 g/24 hr
300-600 mg q6h 500-1000 mg NA 400-600 mg 400-600 mg 1000 mg
300-600 mg q6h 350-1000 mg q3-6h 100-400 mg q6-8h NA 150-300 mg q6-8h 400-600 mg q8-12h 100-400 mg q12-24h
600-900 mg 300 mg
150-300 mg q8-12h 100-400 q8h
100-200 mg q12h
NA, not applicable.
preoperatively for signs of toxic effects caused by drugs (e.g., prolonged Q-Tc interval or widened QRS complex). Specific management for TDP includes the following: ●
● ●
●
●
Atrial or ventricular pacing to increase the K+ current and shorten refractoriness at faster heart rates Intravenous bolus magnesium sulfate Lidocaine by intravenous bolus (does not prolong the Q-T interval) Calcium channel blocker by intravenous bolus (if other interventions fail) Cautious use of isoproterenol to increase the heart rate if pacing is not available
PREVENTION Prevention includes providing a stress-free perioperative period (to the extent possible) to reduce myocardial ischemia and related increased dispersion of myocardial refractoriness. In addition, the following points should be noted: ● ●
●
●
Regional anesthesia is advised. Consider cardiology reevaluation for drug dosing and appropriateness. Consider stopping quinidine before anesthesia administration. Avoid conditions that prolong the Q-T interval (see Table 10-2).
Booker and colleagues have provided a comprehensive review of anesthetic management for patients with
congenital and acquired long QT syndromes, including specific recommendations for the perioperative management of such patients.
Further Reading Atlee JL: Drug treatment for arrhythmias. In Atlee JL (ed): Arrhythmias and Pacemakers: Practical Management for Anesthesia and Critical Care Medicine. Philadelphia, WB Saunders, 1996, pp 154-204. Atlee JL: Overview of mechanisms for arrhythmias. In Atlee JL (ed): Arrhythmias and Pacemakers: Practical Management for Anesthesia and Critical Care Medicine. Philadelphia, WB Saunders, 1996, pp 25-58. Booker PD, Whyte SD, Ladusans EJ: Long QT syndrome and anaesthesia. Br J Anaesth 90:349-366, 2003. Charbit B, Albaladejo P, Funck-Brentano C, et al: Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 102:1094-1100, 2005. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II investigators. N Engl J Med 327:227-233, 1992. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) investigators. N Engl J Med 321:406-412, 1989. Soroker D, Ezri T, Szmuki P, et al: Perioperative torsades de pointes ventricular tachycardia induced by hypocalcemia and hypokalemia. Anesth Analg 80:630-633, 1995. Tan HL, Hou CJ, Laver MR, et al: Electrophysiologic mechanisms of the long QT interval syndromes and torsades de pointes. Ann Intern Med 122:701-714, 1995. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology: The Sicilian gambit: A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 84:1831-1851, 1991.
PHARMACOLOGY
Table 10–3
■
Ch011-X2215
8/12/06
3:19 PM
Page 40
Class II Antiarrhythmic Drugs: β-Blockers—Heart Block or Bradycardia
11
Charles A. Napolitano and Maria I. Castro Case Synopsis A 60-year-old woman with a history of mitral valve stenosis and atrial fibrillation is scheduled for abdominal hysterectomy. Her current medications include verapamil and digoxin. Following induction of anesthesia with etomidate and maintenance with sevoflurane, oxygen, fentanyl, and vecuronium, her ventricular rate increases acutely to 140 beats per minute. Esmolol therapy results in acute bradycardia (30 beats per minute). Electrocardiogram (ECG) monitoring reveals third degree atrioventricular (AV) heart block with regular, wide QRS complexes.
PROBLEM ANALYSIS Definition β-Blockers are commonly used in the management of arrhythmias, hypertension, and heart failure. However, by producing β-adrenergic block, they have the potential to cause sinus bradycardia or sinoatrial (SA) or AV heart block at the AV node. These effects can be aggravated by drugs used during anesthesia (e.g., potent volatile anesthetics, high-dose opiates, local anesthetic toxicity, succinylcholine). Some β-blockers also have vasodilator activity (e.g., carvedilol, labetalol) and may be better tolerated in patients with heart failure. Sinus bradycardia in adults is a heart rate less than 60 beats per minute with a rhythm that originates in the SA node. Third degree AV heart block is the complete absence of impulses conducted from the atria to the ventricles, with the ventricles controlled by impulses originating in subsidiary (latent) cardiac pacemakers located distal to the site of block. If the site of conduction block is perinodal (SA exit block or AV node block), the heart rate typically ranges from 45 to 55 beats per minute, and the QRS interval is of normal duration (~−120 msec). Infranodal block (below the AV node) is characterized by a ventricular rate of 30 to 40 beats per minute and wide QRS complexes. The conduction defect depicted in the case synopsis represents infranodal third degree block with slow secondary pacemaker activity; this can lead to cardiac arrest. Although the third degree AV heart block in this case likely resulted from synergistic depression of AV node function by esmolol (a class II antiarrhythmic) and verapamil (a class IV antiarrhythmic), the other drugs, including digoxin, sevoflurane, and fentanyl, likely contributed. Esmolol, a shortacting β1-selective adrenergic antagonist (β-blocker), is indicated when immediate control of the heart rate or blood pressure is needed and prolonged β-blockade is undesirable. The peak onset of action (6 to 10 minutes) and short halflife (8 minutes) make esmolol appropriate for the management 40
of perioperative tachyarrhythmias. Like all β-blockers, esmolol reduces the sinus rate and AV node conduction time while increasing AV node functional refractoriness. Owing to its inhibitory effects on AV node conduction, verapamil, a calcium channel antagonist, is also useful for reducing the ventricular rate in patients with atrial flutter or fibrillation. However, the effects of verapamil can be potentiated by the concomitant use of β-blockers. As mentioned, the use of sevoflurane, digoxin, and fentanyl, and possibly the surgical procedure itself, likely contributed to the development of heart block in this case. To maintain cardiac output and prevent left ventricular failure or pulmonary edema, tight control of left ventricular preload, heart rate, and systemic vascular resistance is critical for patients with mitral or aortic stenosis and restrictive cardiomyopathies. Thus, the selection of etomidate as an anesthetic induction agent was, at least in theory, a good choice, because etomidate minimizes reflex increases in heart rate and generally maintains systemic vascular resistance and blood pressure within normal limits. However, like other potent inhalational agents, sevoflurane reduces systemic vascular resistance and preload (by dilating the venous capacitance bed to decrease venous return) and may have contributed to the intraoperative increase in ventricular rate via a reflex increase in adrenergic tone. Further, it may have contributed to the third degree AV block and bradycardia by direct effects on AV node conduction and refractoriness. Other potent volatile anesthetics, with the possible exception of desflurane, may also decrease the rate of AV node conduction and SA node discharge. Digoxin’s central actions stimulate vagal tone to reduce heart rate and increase AV node conduction time and refractoriness. Fentanyl, especially at high doses, may inhibit AV node function by causing centrally increased parasympathomimetic and reduced sympathomimetic tone. Finally, peritoneal retraction slows the heart rate and AV node conduction by increasing vagal tone. Thus, any of these factors could have exacerbated the effects of verapamil and esmolol on SA and AV node function.
Ch011-X2215
8/12/06
3:19 PM
Page 41
Chapter 11
■
Class II Antiarrhythmic Drugs: β-Blockers—Heart Block or Bradycardia
Recognition ECG monitoring is the definitive means of detecting bradycardia or AV conduction block. Sinus bradycardia (<60 beats per minute) or asystole is easily recognized on ECG. AV node or infranodal third degree conduction block requires closer ECG inspection (Fig. 11-1). With AV node or perinodal heart block, P waves are dissociated from the QRS complex, but with an AV junctional pacemaker and normal conduction through the ventricles. The QRS complex is of normal ~120 msec duration). In contrast, with infranodal width (~ block, conduction from latent pacemakers below the AV node or His bundle leads to wide QRS complexes. Other, less reliable methods of detecting bradycardia or heart block include the following: ●
●
●
Pulse oximetry plethysmographs reveal a reduced heart rate and possibly reduced arterial oxygen saturation. Capnography may show low end-tidal carbon dioxide values due to reduced pulmonary flow. Noninvasive blood pressure monitoring may reveal hypotension and a reduced heart rate or may simply provide a default “error” message.
Figure 11–1 ■ Atrioventricular (AV) block. Diagrammatic representation of the conduction pathology and resultant electrocardiogram. S-A, sinoatrial. (Adapted with permission from the American Heart Association: Textbook of Advanced Cardiac Life Support, 2nd ed. New York, AHA, 1990; and Netter FH: CIBA Collection of Medical Illustrations. West Caldwell, New Jersey, CIBA Medical Education Division, 1987.)
●
●
Invasive blood pressure monitoring reveals reduced frequency and possibly amplitude of the arterial waveform. Palpation of peripheral pulses indicates decreased frequency and intensity of the pulses.
Although these modalities can assist in assessing the hemodynamic impact of bradycardia, only ECG allows definitive diagnosis of its cause.
Risk Assessment Although the incidence of new intraoperative heart block is unknown, its incidence in animal and prospective clinical studies appears to be greater when antagonists and β-blockers are used in combination. The potential risk of developing bradyarrhythmias and AV node conduction disturbances in patients receiving β-blockers varies. It is greatest with verapamil, somewhat less with diltiazem, and least with dihydropyridine (DHP) calcium channel antagonists such as nicardipine, amlodipine, and nifedipine. DHP calcium channel antagonists have a much higher affinity for L-type Ca2+ channels in vascular smooth muscle as opposed to cardiac myocytes. Animal studies show synergism between the cardiac electrophysiologic effects of β-blockers and calcium channel antagonists (e.g., verapamil, diltiazem). When the latter are given at low doses, propranolol enhances their effect on heart rate and AV node conduction. When given at high doses
PHARMACOLOGY
Although this patient had third degree AV heart block and severe bradycardia, any condition within the spectrum of bradycardia (including asystole) could have occurred. Anesthesiologists must be prepared for this possibility with the appearance of severe bradycardia.
41
Ch011-X2215
42
8/12/06
3:19 PM
Section 1
■
Page 42
Pharmacology
with verapamil or diltiazem, propranolol causes significant heart block, hypotension, or left ventricular dysfunction. Clinical studies support the findings in animal models. In patients with chronic stable angina, therapy with a β-blocker and verapamil (versus diltiazem or nifedipine) causes a significant (10% to 15%) increase in the incidence of adverse cardiac or hemodynamic effects (bradycardia, heart block, hypotension, syncope, or congestive heart failure). However, diltiazem in combination with various β-blockers does not cause significant AV heart block, although it does increase the risk for P-R interval prolongation and bradycardia. Also, intraoperative bradycardia, first degree AV block, and AV junctional rhythms occurred more often in patients having coronary artery bypass graft surgery who took nonDHP calcium channel antagonists and β-blockers before surgery. Finally, transient AV block after aortic cross-clamp release during coronary artery bypass surgery was significantly increased in patients receiving preoperative propranolol (5% higher) or propranolol-nifedipine (15% higher). Patients whose medical treatment may include a β-blocker, calcium channel antagonist, or both are listed in Table 11-1. Other preoperative and intraoperative factors that place patients at increased risk for heart block during anesthesia and surgery are listed in Tables 11-2 and 11-3.
Implications Bradycardia with AV heart block can lead to severe hemodynamic compromise. In the absence of SA node activity, cardiac arrest is possible if perinodal or ventricular escape rhythms do not occur promptly. Severe hypotension due to reduced heart rate and lack of AV synchrony may cause myocardial ischemia. Heart failure may follow if cardiac output is not maintained by a compensatory increase in stroke volume. Hypotension, increased pulmonary artery pressure, and increased left ventricular end-diastolic pressure
Table 11–2
■
Patient Populations Managed with β-Blockers or Calcium Channel Blockers
Coronary Artery Disease Chronic stable angina or previous myocardial infarction Native coronary arteries or autografts prone to spasm Perioperative management of myocardial ischemia in selected patients
Arrhythmias Prevention or treatment of supraventricular tachyarrhythmias (especially paroxysmal supraventricular tachycardia) Prevention or treatment of focal ventricular tachycardia in patients without structural heart disease (e.g., right ventricular outflow tract tachycardia, idiopathic left ventricular tachycardia*)
Cardiovascular Disease Hypertension Heart failure (β-blockers along with other drugs, such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers) Symptomatic patients treated with β-blockers for mitral valve prolapse *Focal ventricular tachycardias that originate in the left ventricular outflow tract, epicardium, or midseptum.
Preoperative Risk Factors for the Development of Intraoperative Heart Block
Age older than 60 years Chronic administration of β-blockers, calcium channel antagonists, amiodarone, or other drugs that prolong AV node or AV conduction (e.g., class IC antiarrhythmics, long-acting local anesthetics) Underlying conduction system disease (e.g., congenital heart disease, repair of atrial secundum defects, repair of transposition of the great vessels) Electrolyte or metabolic imbalance (e.g., hyperkalemia, hypothermia) Systemic disease (e.g., hypothyroidism-myxedema, intracardiac rheumatoid nodules, rheumatic heart disease) Preexisting heart disease (e.g., coronary artery disease, idiopathic degeneration or fibrosis, aortic or mitral valve surgery, Lyme disease, bacterial endocarditis, chagasic myocarditis,* calcific aortic stenosis) Preoperative bradycardia (<60 beats per minute) Myocardial infiltrative processes (e.g., sarcoidosis, amyloidosis, scleroderma) *Common in Central and South America. AV, atrioventricular.
have been observed in both animal and clinical studies of combined β-blocker and non-DHP calcium channel antagonist therapy.
MANAGEMENT After verification of third degree AV heart block and hemodynamic assessment, optimal oxygenation, ventilation, and perfusion are ensured by increasing the fraction of inspired
Table 11–3 Table 11–1
■
■
Intraoperative Risk Factors Associated with the Development of Atrioventricular Heart Block
Drugs β-blockers Calcium channel antagonists High-dose volatile anesthetics or opiates IV anesthetic drugs (e.g., propofol, high-dose opiates, succinylcholine) Anticholinesterase therapy Digitalis glycosides IV amiodarone or sotalol Class IA or IB antiarrhythmic drugs, especially high IV doses
Increased Vagal Tone or Stimulation Peritoneal retraction or retraction of ocular muscles Direct laryngoscopy and endotracheal intubation Urinary bladder catheterization Esophageal instrumentation Baroreceptor reflex activation with acute hypertensive episodes (e.g., aortic cross-clamp application) Rectal or cervical dilatation
Imbalance Hypoxia Hypothermia Hyperkalemia
Ch011-X2215
8/12/06
3:19 PM
Page 43
Chapter 11
■
Class II Antiarrhythmic Drugs: β-Blockers—Heart Block or Bradycardia
● ●
● ● ● ●
●
● ● ● ● ●
Ephedrine 5 to 10 mg intravenously (IV); repeat if necessary Atropine 0.4 mg IV or glycopyrrolate 0.2 mg IV (up to a total of 2 or 1 mg IV, respectively, if necessary) Calcium 250 mg IV; repeat up to a total of 1 g if necessary Epinephrine 10 mg IV; repeat with increased doses as needed Isoproterenol 1 to 10 mg/minute IV Perform noninvasive (transcutaneous) pacing before instituting invasive transvenous pacing; noninvasive esophageal atrial pacing is ineffective in third degree AV block. Perform cardiopulmonary resuscitation if systolic blood pressure is 40 to 50 mm Hg (while attempting or repeating the above measures). Anticipate adverse drug interactions. Maintain hemodynamic stability. Perform intraoperative hemodynamic monitoring. Select drugs to treat tachycardia. Consider cardioversion in place of drugs for symptomatic supraventricular tachycardia.
PREVENTION The patient in the case synopsis developed third degree AV heart block after esmolol was given to control a rapid ventricular rate with atrial fibrillation. Her preexisting heart disease required the avoidance of extreme increases or decreases in heart rate to maintain hemodynamic stability and vital organ perfusion. Prevention of hemodynamic instability in such patients requires careful preoperative assessment, anticipation of adverse drug interactions, and attention to surgical or procedure-related interventions that might lead to wide fluctuations in heart rate or blood pressure. In addition to a thorough history and physical examination and the necessary laboratory tests, the preoperative assessment should include knowledge of the patient’s baseline heart rate, blood pressure, and intravascular volume status. Anesthesiologists should be able to anticipate adverse events and must be prepared to manage them early to minimize complications. Intraoperatively, care should be taken to ensure an adequate depth of anesthesia and analgesia and to maintain appropriate hydration. The placement of a Swan-Ganz catheter or intraoperative transesophageal echocardiography to monitor cardiac hemodynamic parameters should be considered for high-risk patients. If significant tachycardia develops in a patient receiving a non-DHP calcium channel antagonist, a reduced dose of esmolol (0.1 to 0.25 mg/kg) can be given to minimize any synergistic effect. To terminate
reentrant supraventricular tachycardia involving the AV node, adenosine (6 to 12 mg IV) can be used; it is an ultra-shortacting nucleoside with an efficacy equal to or better than that of the DHP calcium channel antagonists. Other alternatives are diltiazem (0.25 to 0.35 mg/kg IV), neostigmine (1 mg IV), edrophonium (10 mg IV), or phenylephrine (50 to 100 μg IV); vagal maneuvers (e.g., carotid sinus massage, Valsalva’s maneuver, ocular massage); or medications the patient is already receiving (e.g., verapamil 1.25 to 2.5 mg or digoxin 0.125 to 0.5 mg IV). Although synergistic effects with β-blockers are most often reported with verapamil, heart block is a theoretical possibility with any of the previously mentioned drugs, particularly when they depress AV node function by different cellular mechanisms. Finally, early direct-current cardioversion is the treatment of choice for atrial fibrillation or flutter causing hemodynamic compromise due to a rapid ventricular response.
Further Reading Atlee JL: Perioperative cardiac dysrhythmias: Diagnosis and management. Anesthesiology 86:1397-1424, 1997. Auerbach AD, Goldman L: Beta-blockers and reduction of cardiac events in noncardiac surgery: Scientific review. JAMA 287:1435-1444, 2002. Baraka AS, Taha SK, Yasbeck VK, et al: Transient atrioventricular block after release of aortic cross-clamp. Anesth Analg 80:54-57, 1995. Devereaux PJ, Beattie WS, Choi PT, et al: How strong is the evidence for the use of perioperative beta-blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 331:313-321, 2005. Henling CE, Slogoff S, Kodal SV, et al: Heart block after coronary artery bypass: Effects of chronic administration of calcium-entry blockers and β-blockers. Anesth Analg 63:515-520, 1984. Hoffman BB: Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In Hardman JG, Limbird LE (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. New York, McGraw-Hill, 2001, pp 215-268. Kapur PA, Matarazzo DA, Fung OM, et al: The cardiovascular and adrenergic actions of verapamil or diltiazem in combination with propranolol during halothane anesthesia in the dog. Anesthesiology 66:122-129, 1987. Kerins DM, Robertson RM, Robertson D: Drugs used for the treatment of myocardial ischemia. In Hardman JG, Limbird LE (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. New York, McGraw-Hill, 2001, pp 843-870. Krum H: Tolerability of carvedilol in heart failure: Clinical trials experience. Am J Cardiol 93:58B-63B, 2004. Lopez-Sendon J, Swedberg K, McMurray J, et al: Task Force on BetaBlockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 25: 1341-1362, 2004. McMurray JJ, Pfeffer MA: Heart failure. Lancet 365:1877-1889, 2005. Messerli FH, Grossman E: Beta-blockers in hypertension: Is carvedilol different? Am J Cardiol 93:7B-12B, 2004. Oates JA, Brown NJ: Antihypertensive agents and the drug therapy of hypertension. In Hardman JG, Limbird LE (eds): Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. New York, McGraw-Hill, 2001, pp 871-900. Priebe HJ: Perioperative myocardial infarction—aetiology and prevention. Br J Anaesth 95:3-19, 2005. Schwartz AB, Moskowitz RM, Klausner SC: The electrophysiological effects of nicardipine hydrochloride in man. Can J Cardiol 3:14-17, 1987. Strauss WE, Parisi AF: Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina: Rationale, efficacy, and adverse effects. Ann Intern Med 109:570-581, 1988.
PHARMACOLOGY
oxygen to 1.0 and discontinuing the use of volatile anesthetics. If the blood pressure and cardiac output are not adequate, cardiopulmonary resuscitation should be started immediately. The surgeon should discontinue any maneuvers that could increase vagal tone (e.g., peritoneal retraction) until the condition has been resolved. The treatment of mild (sinus bradycardia) to severe (asystole) complications includes the following:
43
Ch012-X2215
8/12/06
3:19 PM
Page 44
Class III Antiarrhythmic Drugs: Potassium Channel Blockers
12
M. J. Pekka Raatikainen and Donn M. Dennis Case Synopsis A 76-year-old woman with a history of paroxysmal atrial fibrillation is admitted to the hospital for elective surgery. Her antiarrhythmic medication is 80 mg of sotalol twice daily. Before the operation, she has a sudden syncopal attack, and an electrocardiogram (ECG) shows a wide QRS self-terminating tachycardia.
PROBLEM ANALYSIS Definition The patient’s medical history and ECG (Fig. 12-1) are consistent with drug-induced Q-T prolongation and proarrhythmia. It is well known that prolongation of ventricular repolarization (i.e., long Q-T interval), the electrophysiologic basis for class III antiarrhythmic drug action, can paradoxically cause polymorphic torsades de pointes (TDP). TDP is a polymorphic ventricular tachycardia (VT) that occurs in the setting of Q-T interval prolongation; in the absence of Q-T prolongation, it is known as simply polymorphic VT. With TDP or polymorphic VT, the distinctive ECG pattern is characterized by a continuous twisting of the QRS axis around the isoelectric ECG baseline.
Although the precise mechanisms underlying TDP are unclear, most experimental and clinical evidence suggests that triggered activity initiated by early afterdepolarizations, along with delayed ventricular repolarization, provokes the onset of TDP. In general, TDP manifests as brief, repetitive episodes of self-terminating VT. Unabated, it can deteriorate into ventricular fibrillation.
Recognition The diagnosis of drug-induced long QT syndrome and TDP (see also Chapter 81) is based on the characteristic ECG findings and the patient’s medical history. In particular, special attention should be focused on concurrent use of other Q-T–prolonging drugs, including class IA antiarrhythmics (e.g., quinidine), macrolide antibiotics (e.g., erythromycin), nonsedating antihistamines (e.g., terfenadine), and psychotropic drugs (e.g., antipsychotics, tricyclic antidepressants). A more complete listing can be found at http:// www.torsades.org. ECG features of long QT syndrome include the following: ●
0.80 s
A Rhythm strip during the tachycardia
● ●
Prolonged ventricular repolarization (Q-Tc >0.44 second) Alternating T waves or prominent U waves Increased dispersion of ventricular repolarization (Q-T dispersion) ECG features of drug-induced TDP include the following:
●
0.56 s
B ECG (lead II) before the syncope Figure 12–1 A, Electrocardiogram (ECG) rhythm strip obtained from a 76-year-old woman immediately after syncope. Note the extremely long Q-T interval (0.80 second) immediately before the onset of the arrhythmia and twisting of the QRS axis around the isoelectric baseline during the tachycardia (220 beats per minute) (paper speed 25 mm/second). B, ECG (lead II) from the same patient showing a significant prolongation of the Q-T interval (Q-Tc = 0.56 second) during normal sinus rhythm (62 beats per minute) (paper speed 25 mm/second). After cessation of class III antiarrhythmic drugs (sotalol 80 mg twice daily), the Q-Tc interval returned to a value of 0.40 second.
●
■
44
●
Polymorphic tachycardia (160 to 250 beats per minute), with characteristic twisting of the QRS axis around the isoelectric ECG baseline Characteristic “short-long-short” initiation sequence (i.e., R-R intervals) Initiation frequently caused by extra systoles with a long coupling interval
In patients with acquired long QT syndrome, TDP typically follows long pauses, whereas in patients with congenital (idiopathic) long QT syndrome, the initiation of TDP is commonly associated with an increase in catecholamines and heart rate (e.g., stress, fright, physical exercise).
Ch012-X2215
8/12/06
3:19 PM
Page 45
Chapter 12
■
Class III Antiarrhythmic Drugs: Potassium Channel Blockers
Risk Assessment Experience with the perioperative use of class III antiarrhythmic agents is limited, and there is little information on interactions between these drugs and anesthetic agents. The major perioperative complications related to long-term therapy with class III antiarrhythmics include proarrhythmia (e.g., TDP) and noncardiac amiodarone interactions and toxicity. The latter is discussed in more detail later in this chapter.
studies have yet to be conducted, one could speculate that anesthetics that reduce heart rate, depress atrioventricular (AV) node conduction, and lengthen ventricular repolarization might increase the proarrhythmic effects of class III antiarrhythmic drugs during surgery. Given the data indicating that patients with acquired long QT syndrome may suffer from variant forms of the congenital syndrome (e.g., electrically silent gene defects that manifest only with Q-T interval–prolonging drugs), genetic analyses of genes encoding the cardiac sodium and potassium channels may provide valuable information about the risk of drug-induced proarrhythmias. The following ECG findings before anesthesia indicate an increased risk for perioperative proarrhythmia: ● ● ● ● ● ●
Excessive prolongation of the Q-T interval Increased Q-T interval dispersion T-wave alternans or prominent U waves Polymorphic premature ventricular complexes Sinus bradycardia and AV conduction disturbances Abrupt slowing of the heart rate (e.g., conversion of atrial fibrillation to normal sinus rhythm)
PROARRHYTHMIC RISK
AMIODARONE INTERACTIONS
The following factors predispose to the development of class III antiarrhythmic drug-induced TDP during anesthesia:
Several groups have noted a greater incidence of cardiac rhythm and conduction disturbances (e.g., atropineresistant bradycardia, slow AV junctional rhythms, complete AV heart block, pacemaker dependency), an increased need for perioperative circulatory support (including inotropes or intra-aortic balloon counterpulsation), and more noncardiac complications in patients receiving amiodarone. However, perioperative hemodynamic instability with amiodarone and a poor response to inotropic drugs may be explained, in part, by the drug’s antiarrhythmic actions. In addition to class III activity, these include sodium channel blockade (class I), noncompetitive blockade of β- and α-adrenergic receptors (class II), and inhibition of calcium channels (class IV). The reader is referred to Chapters 10, 11, and 13, respectively, for complications related to these antiarrhythmic classes of drugs. The role of general anesthetic agents in the development of amiodarone’s pulmonary toxicity remains controversial. Although some groups have found a higher incidence of postoperative acute respiratory distress syndrome and other pulmonary disorders in patients receiving amiodarone, others have been unable to show this relationship. Nonetheless, pulmonary toxicity is the most feared long-term complication of amiodarone therapy and should not be forgotten in the risk assessment of patients receiving this drug.
● ●
● ● ●
●
Female gender Electrolyte disturbances (e.g., hypokalemia, hypomagnesemia, severe hypocalcemia) Structural heart disease and myocardial ischemia Excessive dosing Genetic defects behind the enzymes metabolizing the drug or defective cardiac ion channels responsible for congenital long QT syndrome (see Chapter 81) Drug interactions or simultaneous use of drugs that prolong ventricular repolarization
Critical values for Q-T prolongation are lacking. Available data indicate that Q-T dispersion (i.e., difference between the longest and shortest Q-T intervals assessed by 12-lead ECG) may predict the proarrhythmia more accurately than absolute Q-T interval prolongation or the latter corrected for heart rate (Q-Tc interval). For example, amiodarone—which, unlike the other class III agents, prolongs the Q-T interval uniformly (i.e., does not increase Q-T interval dispersion)—has a significantly lower proarrhythmic risk (2% to 3%) than the other class III antiarrhythmics (5% to 10%). Other factors that may explain amiodarone’s lower proarrhythmic risk compared with “pure” class III antiarrhythmics (which selectively inhibit cardiac potassium channels) include a heart rate–independent action on ventricular repolarization, and β-adrenergic blocking, α-adrenergic blocking, and calcium channel blocking properties. The incidence of TDP with amiodarone is only 0.7%, whereas sotalol and quinidine induce TDP in about 5% and 8% of cases, respectively. Further, in contrast to sotalol and ibutilide (a class III antiarrhythmic), acute intravenous amiodarone seldom if ever prolongs the Q-T interval. However, in the setting of electrolyte abnormalities, bradycardia, or abrupt changes in the heart rate, the proarrhythmic risk increases significantly. Thus, although definitive clinical
AND
TOXICITY
Implications Owing to their potent cardiac electrophysiologic properties, class III drugs not only exhibit important antiarrhythmic actions but also have the potential to induce life-threatening proarrhythmias, typically TDP. Therefore, anesthesiologists should be familiar with the adverse effects of these drugs and their interactions with other Q-T interval–prolonging drugs and anesthetics. Also, amiodarone has special implications in terms of pulmonary complications.
PHARMACOLOGY
Although TDP may present as a monomorphic VT in a single monitored ECG lead, confusion with monomorphic ventricular arrhythmias is rare when a 12-lead ECG is obtained. The characteristic “short-long-short” initiation sequence and the patient’s medical history help distinguish TDP from other forms of polymorphic VT. Importantly, these other forms of polymorphic VT occur without ECG evidence of Q-T interval prolongation, and often in the setting of an acute coronary syndrome (e.g., myocardial ischemia or infarction, reperfusion injury).
45
Ch012-X2215
8/12/06
46
3:19 PM
Section 1
■
Page 46
Pharmacology
MANAGEMENT Actions to take when treating drug-induced TDP include the following: ●
● ●
●
●
Immediate electrical cardioversion in hemodynamically unstable patients Infusion of magnesium sulfate (MgSO4) Interventions that shorten the Q-T interval and prevent pause-dependent bradycardia (preferably atrial or ventricular overdrive pacing, or atropine or isoproterenol) Alleviation of electrolyte disturbances and bradycardia (preferably with temporary pacing) and other permissive factors Withdrawal of any offending drugs, along with correction of imbalance
Therapy of drug-induced TDP must focus on immediate TDP termination and the prevention of early recurrence. If TDP causes early hemodynamic collapse, it must be treated with prompt direct-current cardioversion or defibrillation, depending on whether the ECG R or S waves are distinct (cardioversion) or not (defibrillation). Other therapy includes intravenous MgSO4, which is effective against TDP even in patients with normal serum magnesium levels. MgSO4 is given as a 1- to 2-g intravenous bolus. If necessary, it is repeated after 10 to 15 minutes, followed by continuous intravenous infusion at 3 to 20 mg/minute for 24 to 48 hours. If this is ineffective, atropine, isoproterenol, or overdrive pacing is used to prevent long sinus pauses to shorten the Q-T interval. Isoproterenol infused at a dose that maintains the ventricular rate at about 90 beats per minute (1 to 8 μg/minute) may suppress TDP within minutes. However, given this drug’s proarrhythmic actions and other adverse effects, isoproterenol should be used only while pacing is instituted, especially in patients with ischemic heart disease. Preferably, temporary atrial or ventricular overdrive pacing is initiated at a rate of 120 to 130 beats per minute and adjusted to the lowest effective rate. Temporary pacing should be continued until the offending drug is completely eliminated. The role of antiarrhythmic drugs in the treatment of TDP is controversial. In experimental preparations and in some patients, calcium channel blockers, lidocaine, mexiletine, and recently developed potassium channel openers (e.g., nicorandil, pinacidil) have been effective. However, the clinical evidence is marginal and has yet to be verified in large prospective clinical studies. Drugs that prolong ventricular repolarization should be avoided in the therapy of acquired long QT syndrome. Once acute TDP episodes have been controlled, attention should focus on identifying and correcting predisposing metabolic and electrolyte factors and eliminating causative drugs. In patients with congenital long QT syndrome, β-blockers are the drugs of choice, and catecholamines must be avoided. Patients receiving class III antiarrhythmics, especially amiodarone, may be more vulnerable to the development of perioperative bradycardia, AV node conduction disturbances, and circulatory failure. If these conditions do not respond
to atropine, adrenergics, or other positive chronotropes, cardiac pacing or intra-aortic counterpulsation should be instituted.
PREVENTION Prevention includes the following measures: ●
●
●
●
●
Identify and correct any factors that predispose patients to proarrhythmia (e.g., electrolyte imbalance, bradycardia, myocardial ischemia). Stop any drugs that prolong the Q-T interval (e.g., macrolide antibiotics, nonsedating antihistamines, tricyclic antidepressants). Consider reassessing the dosage or withdrawing class III antiarrhythmics and postponing elective operations, especially if the Q-Tc is greater than 0.60 second. Consider regional anesthesia in patients receiving amiodarone. Monitor hemodynamic and respiratory functions throughout the perioperative period.
Q-T prolongation with class III antiarrhythmic drugs is a therapeutic end point. Mechanisms by which this effect becomes proarrhythmic are not easily separated from antiarrhythmic actions. Thus, the cornerstone of preoperative risk reduction in patients receiving class III antiarrhythmics is identification and elimination of predisposing risk factors. Of special importance is correction of electrolyte imbalance and withdrawal of drugs that cause additional Q-T interval prolongation (e.g., macrolide antibiotics, nonsedating antihistamines, tricyclic antidepressants). Likewise, patient reassurance and adequate sedation and analgesia can eliminate preoperative catecholamine increases and help prevent abrupt changes in heart rate during the induction of anesthesia. Amiodarone is the most effective intravenous antiarrhythmic for life-threatening arrhythmias. However, its extremely long elimination half-life and serious adverse extracardiac effects (especially with chronic therapy) make it the most complicated of the class III agents. Importantly, amiodarone significantly augments the cardiac depressant effects of general anesthesia. In addition, amiodaroneassociated pulmonary toxicity may become apparent during emergence and recovery from general anesthesia. Attention to these shortcomings and careful intraoperative monitoring of respiratory and hemodynamic parameters should help anesthesiologists avoid these severe complications. Some case reports suggest that regional anesthesia is preferable in patients receiving amiodarone, but this remains to be confirmed in controlled clinical studies. Likewise, although some experimental data suggest that intravenous anesthetics have different effects on ventricular repolarization in acquired (drug-induced) long QT syndrome, until clinical trials are completed, no specific advice can be given on the selection of general anesthetics for patients receiving class III antiarrhythmics. Finally, because most patients receiving class III agents have severe arrhythmias and other cardiac disease, it is prudent to consult a cardiologist before anesthesia and surgery.
Ch012-X2215
8/12/06
3:19 PM
Page 47
Chapter 12
■
Class III Antiarrhythmic Drugs: Potassium Channel Blockers
Atlee JL: Perioperative cardiac dysrhythmias: Diagnosis and management. Anesthesiology 86:1397-1424, 1997. Balser JR: The rational use of intravenous amiodarone in the perioperative period. Anesthesiology 84:974-987, 1997. Belardinelli L, Antzelevitch C, Vos MA: Assessing predictors of drug-induced torsades de pointes. Trends Pharmacol Sci 24:619-625, 2003. Haverkamp W, Breithardt G, Camm AJ, et al: The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 21:1216-1231, 2000.
Priori SG, Napolitano C: Genetic defects of cardiac ion channels: The hidden substrate for torsades de pointes. Cardiovasc Drugs Ther 16: 89-92, 2002. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 350:1013-1022, 2004. Shah RR: Pharmacogenetic aspects of drug-induced torsades de pointes: Potential tool for improving clinical drug development and prescribing. Drug Saf 27:145-172, 2004. Viskin S, Justo D, Halkin A, et al: Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 45:415-427, 2003. Wolbrette DL: Risk of proarrhythmia with class III antiarrhythmic agents: Sex-based differences and other issues. Am J Cardiol 91:39D-44D, 2003.
PHARMACOLOGY
Further Reading
47
Ch013-X2215
8/12/06
3:20 PM
Page 48
Class IV Antiarrhythmic Drugs: Calcium Channel Blockers
13
J. Michael Jaeger and Donn M. Dennis Case Synopsis An obese 48-year-old woman with a history of hypertension treated with diltiazem undergoes a laparoscopic cholecystectomy. Following insufflation of the abdomen with carbon dioxide, she becomes hypertensive and develops sinus tachycardia at a rate of 110 beats per minute; the tachycardia is unresponsive to deepening the level of anesthesia with isoflurane and fentanyl. Propranolol 1 mg is administered intravenously. The patient develops a marked sinus bradycardia, with a P-R interval of 0.24 second on the electrocardiogram (ECG), and becomes hypotensive.
PROBLEM ANALYSIS Definition This case illustrates many of the common toxic effects of L-type (long-lasting) calcium channel antagonists (specifically the class IV antiarrhythmic drugs verapamil and diltiazem) or of interactions between calcium channel antagonists and other cardiodepressant drugs. The marked bradycardia, first degree atrioventricular (AV) node block, and hypotension are manifestations of the pharmacologic interaction of several drugs, most notably diltiazem and propranolol. Each drug has a depressive effect on conduction in both the sinoatrial (SA) node and the AV node, although by different cellular mechanisms. However, both diltiazem and propranolol have little effect on ventricular conduction (Fig. 13-1). Although therapeutic doses of diltiazem and propranolol by themselves generally do not produce this magnitude of response, the concurrent use of a calcium channel antagonist and a β-receptor antagonist can lead to cardiovascular collapse, particularly when other cardiac depressants (e.g., volatile inhalational anesthetics) are involved. Such patients require heightened vigilance by anesthesiologists because AV node conduction blockade can reduce the compensatory reflex increase in cardiac output observed with pathophysiologic conditions (e.g., hypercarbia, hypoxemia, hypovolemia, anemia). In addition to SA and AV node conduction block, this drug combination can precipitate acute heart failure in patients with cardiac disease and limited functional reserve. Both L-type (e.g., verapamil, diltiazem, nifedipine) and T-type (transient) calcium channel antagonists (e.g., mibefradil) have been implicated as the cause of adverse drug interactions. They alter the pharmacokinetics and pharmacodynamics of a wide variety of drugs, including carbamazepine, neuromuscular blockers, digoxin, quinidine, statins, theophylline, and volatile inhalational anesthetics (Table 13-1). 48
Recognition The toxic effects of class IV antiarrhythmic drugs, or their interactions with other depressants of cardiac conduction, can be recognized by the following ECG features: ● ●
● ●
Sinus bradycardia (<60 beats per minute) P-R intervals greater than 0.2 second (first degree block) or P waves not always followed by QRS complexes (second degree block) Normal QRS complex duration (£ 0.1 second) Normal Q-T interval relationships and ST segment configurations unless myocardial ischemia is present
Note that the QRS complex and ST segment remain normal in duration and configuration. This distinguishes direct toxicity by class IV antiarrhythmics or indirect toxicity through their interaction with other depressants of myocardial conduction (e.g., β-blockers) from other disturbances of conduction (e.g., bundle branch or fascicular block, myocardial ischemia). In addition, the interaction of calcium channel antagonists with other drugs should not be confused with preexisting conditions that can have a similar clinical presentation. For example, sick sinus syndrome, preexisting AV node block of varying degrees, amyloidosis, myotonic dystrophy, or cardiomyopathy may confound the ECG diagnosis, although the clinical history and presentation should allow clarification.
Risk Assessment The following factors influence the risk of toxicity: ● ● ●
Therapeutic spectrum Clinical pharmacology Mechanism of action
Verapamil and diltiazem are widely used to treat and prevent supraventricular tachycardias, to limit ventricular rates with atrial fluttter or fibrillation, and as adjuncts for the
Ch013-X2215
8/12/06
3:20 PM
Page 49
Chapter 13
Class IV Antiarrhythmic Drugs: Calcium Channel Blockers
SA Node Action Potential Purkinje Fiber Action Potential (Bundle Branch)
SA Node ↓ conduction
Verapamil & AV Node Diltiazem ↓↓ conduction His Bundle/Bundle Branches AV Node Action Potential
↓ contractility
Table 13–1
■
Verapamil & Diltiazem
Selected Drug Interactions with Calcium Channel Antagonists
Drug Antiarrhythmics Amiodarone (AM)
Adenosine Quinidine β-Blockers Atenolol Metoprolol Propranolol Carbamazepine Clonidine Cyclosporine Digoxin Lithium Magnesium sulfate Midazolam Phenytoin Quinidine Rifampin Statin drugs Succinylcholine Theophylline Vecuronium Volatile anesthetics Desflurane Enflurane Halothane Isoflurane Sevoflurane
49
Nature of Interaction
Effect of Interaction
Possible potentiation of AM class IV activity at SA and AV nodes* Possible increase in L-type Ca2+ channel block by AM in vascular smooth muscle* Additive effect ↓ Clearance
AV node block and hypotension; possible bradycardia Prolonged bradycardia AV node block
Noncompetitive Potentiation Potentiation ↓ Clearance Additive effect ↑ Serum concentration Modest ↑ serum concentration Synergism Potentiation ↓ Clearance ↑ Serum concentration ↑ Serum concentration ↑ Clearance of verapamil ↑ Serum concentration Potentiation ↓ Clearance Potentiation
Hypotension; AV node block Hypotension; AV node block Hypotension; AV node block Neurotoxicity; Hypotension; AV node block Nephrotoxicity AV node block Muscle weakness, ataxia Muscle weakness, hypotension Profound and prolonged sedation Neurotoxicity Potentiate hypotensive effects Supraventricular tachycardia Rhabdomyolysis Possible prolonged effect Theophylline toxic effects Prolonged neuromuscular block
Unknown† (possible ↓ heart rate?) Potentiation Potentiation Potentiation Unknown
No reported interactions in humans† Rare AV node block ↓ Cardiac output, AV node block No significant interactions in humans No reported interactions in humans†
*Speculation. † MEDLINE database search Sept 27, 2005: no reports of adverse interactions in animal models or humans. AV, atrioventricular; SA, sinoatrial.
PHARMACOLOGY
Figure 13–1 ■ Cardiac conduction system, with examples of “slow-response” action potentials recorded from the sinoatrial (SA) and atrioventricular (AV) nodes and a “fast-response” action potential recorded from a Purkinje fiber in a bundle branch. Note the smaller action potential upstrokes characteristic of slow-conducting SA and AV node (i.e., slow-response) cells versus the much faster and larger action potential upstroke typical of fast-conducting (i.e., fast-response) Purkinje fibers. Atrial and ventricular muscle fibers also have fast-response action potentials (not shown), similar to those of Purkinje fibers. Verapamil and diltiazem have a greater impact on the conduction of slow-response action potentials in the heart. Contractility is also reduced because of the reduced influx of calcium ions during the cardiac action potential plateau.
■
Ch013-X2215
8/12/06
50
3:20 PM
Section 1
■
Page 50
Pharmacology
treatment of vasospastic angina and essential hypertension. Although the probability of having to administer an anesthetic to a patient taking either of these calcium channel antagonists is high, actual clinical experience reveals that doing so is generally not a significant problem for anesthesiologists. Nonetheless, the potential for problems exists, and vigilance is important. In large clinical trials, verapamil and diltiazem caused the following cardiovascular abnormalities, in decreasing order of frequency: first degree AV block (2.4%), bradycardia (1.7%), second or third degree AV block (0.8%), and congestive heart failure (<1% to 1.8%). Understanding the clinical problem and identifying patients at risk for complications require an appreciation of the relevant cardiac electrophysiology and pharmacology of all classes of calcium channel antagonists. Six types (T, L, N, P/Q, and R) of mammalian voltage-dependent calcium channels (VDCCs) have been identified. They are distinguishable by location and electrophysiologic characteristics (voltage thresholds for activation; kinetics of channel opening and closing). VDCCs have been classified into two general groups: (1) high-voltage-activated (HVA) calcium channels (threshold activation = −40 to −10 mV), and (2) low-voltage-activated (LVA) calcium channels (threshold activation = −60 to −70 mV). HVA channels include calcium channels of the L, N, P/Q, and R types, whereas LVA channels include only the T type. At times, the R-type channel is classified as an intermediate voltage activated (IVA) calcium channel with threshold activation voltages being intermediate between those of HVA and LVA. Key characteristics of the different types of calcium channels include the following: ●
●
●
●
●
●
T-type calcium channels include a heterogeneous group of Transient (or low voltage) activated–type calcium channels, which are primarily located in the SA and AV nodes, cardiac Purkinje cells, and central nervous system. L-type calcium channels are Long-lasting voltage-gated channels located in both excitable and nonexcitable tissue, which are responsible for normal myocardial and vascular smooth muscle contractility. The alpha-1 subunit of L-type calcium channel is the binding site for calcium channel blockers (e.g., dihydropyridine [DHP]-based calcium channel antagonists. N-type calcium channels are widely distributed in Neural tissue. Omega toxins inhibit the function of these types of calcium channels by changing their voltage dependence. P-type calcium channels were first identified within the Purkinje cells of the cerebellum. They play a role in regulating neuronal stimulation-secretion coupling. Q-type calcium channels are located in neurons. Because Q- (letter derived from the following letter of P) type current is rapidly inactivated, it requires prior blockade of P- and N-type calcium current components to isolate this current for study. R-type calcium channels are located in neurons. They are inhibited by the marine snail toxin, omega conotoxin MVIIC. A notable feature of the R-type channels is their resistance to all known calcium channel blockers. The R-type current (which was named after the following letter of Q, or Remaining channel) is defined as the residual
HVA calcium current observed after the application of toxins that selectively block N, L, P, and Q-type currents. Calcium channels in cardiac muscle and vascular smooth muscle cells are generally of the T and L types, which impart distinct characteristics to the cardiac action potential and influx of calcium into the cell. The T-type channel contributes significantly to the slow upstroke of the action potential found in the SA and AV nodes and, therefore, controls one of the pacemaker currents responsible for the initiation of the heartbeat. This channel exists in ventricular muscle but plays a less significant role in initiating the action potential. The L-type calcium channel produces the plateau of the cardiac action potential and is responsible for the influx of extracellular Ca2+ into the cell. This influx of extracellular Ca2+ is thought to serve as the trigger for the release of internally stored (sarcolemmal) Ca2+. The latter leads to cardiac contraction. The entire process is known as excitation-contraction coupling. Verapamil and diltiazem alter the function of L-type but not T-type calcium channels. Hence, they have a greater impact on the conduction and repolarization of cardiac action potentials (especially within the SA and AV nodes) and on the influx of extracellular Ca2+ than they do on the initiation of cardiac (or smooth) muscle action potentials (see Fig. 13-1). At first, this might seem counterintuitive, given that sinus bradycardia is occasionally observed with verapamil (less often with diltiazem). However, for heartbeats to occur, the SA node must first generate an action potential. In turn, it must be propagated to surrounding atrial muscle and the rest of the heart in a properly synchronized fashion. As more and more L-type calcium channels become blocked, SA node impulse formation slows, and SA conduction and refractoriness increase. Together, these lead to failure of SA node impulse formation and propagation. Reduction of the magnitude of extracellular Ca2+ influx— through fewer functional L-type calcium channels or a shorter duration of their open state—also reduces the strength of cardiac contraction. Because L-type calcium channels are also found in vascular smooth muscle, inhibition of excitation-contraction coupling here leads to vasodilatation. Whereas verapamil affects primarily cardiac L-type calcium channels, diltiazem affects L-type calcium channels in both cardiac and vascular smooth muscle. Finally, the dihydropyridine (DHP) calcium channel blockers (e.g., nifedipine, nicardipine, nimodipine) are highly selective for L-type calcium channels in vascular smooth muscle. Among the L-type calcium channel blockers, verapamil (a diphenylalkylamine) and diltiazem (a benzothiazepine) markedly depress AV node conduction and increase refractoriness, whereas the DHP calcium channel blockers mentioned earlier are primarily vasodilators and have minimal to no effect on SA or AV node tissue or cardiac contractility. Verapamil and diltiazem are useful for treating reentrant supraventricular tachycardias involving the AV node and for achieving ventricular rate control in most patients with atrial flutter or fibrillation. They are also used as therapy for essential hypertension and chronic stable angina, especially vasospastic angina. However, DHP calcium channel blockers are increasingly used in these conditions, especially for patients who are also receiving β-blockers.
Ch013-X2215
8/12/06
3:20 PM
Page 51
Chapter 13
■
Class IV Antiarrhythmic Drugs: Calcium Channel Blockers
Increased AV node refractoriness with non-DHP calcium channel blockers increases the risk for high-degree AV block when combined with other drugs that also slow AV node conduction. Although this list is lengthy, it includes any drugs that are vagomimetic (e.g., opioids, anticholinesterases, digoxin) or sympatholytic (β-receptor antagonists, clonidine), as well as other drugs (e.g., adenosine, amiodarone, volatile inhalational anesthetics). Accentuation of high-degree AV heart block can lead to cardiovascular collapse. Also, because non-DHP calcium channel blockers have the potential to increase the ventricular rate with atrial flutter or fibrillation and precipitate fatal ventricular tachyarrhythmias, diltiazem or verapamil should not be used in patients with Wolff-Parkinson-White syndrome or its variants, especially when the state of accessory pathway refractoriness is unknown. Essentially, accessory pathways are extensions of atrial muscle and have similar electrophysiologic properties (i.e., they are “fast-response” fibers). Thus, accessory pathway conduction is not blocked, nor is its refractoriness increased. However, both conduction and refractoriness at the AV node are impaired by diltiazem or verapamil. Because low-dose non-DHP calcium channel blockers (diltiazem more so than verapamil) cause vascular relaxation and hypotension before significant AV node block, reflex tachycardia can occur and cause angina in susceptible patients with nonvasospastic (fixed) coronary artery disease. Also, patients with limited cardiovascular reserve (i.e., cardiomyopathy) are at risk for acute worsening of heart failure when subjected to the additional negative inotropic effect of non-DHP calcium channel blockers. Last, aside from their cardiac effects, calcium channel blockers may significantly inhibit hepatic cytochrome enzymes and alter hepatic or renal blood flow and drug binding. Thus, the pharmacologic properties of a wide variety of drugs may be affected (see Table 13-1). This problem was most pronounced with mibefradil, a T-type calcium channel blocker that was developed for the treatment of hypertension and chronic stable angina. Because mibefradil was a very potent inhibitor of CYP3A4, the single most important P-450 enzyme for metabolizing therapeutic agents, it caused many severe adverse drug reactions and was removed from the market. One interesting drug-drug interaction with mibefradil was increased blood levels of HMG-CoA reductase inhibitors (statin cholesterol-lowering agents) that depended on CYP3A4 for metabolic clearance (e.g., lovastatin, simvastatin, atorvastatin), leading to severe rhabdomyolysis.
MANAGEMENT Because bradycardia, AV block, and hypotension can occur in patients receiving regional or general anesthesia, the first step is to determine the level of consciousness and then the adequacy of the airway and ventilation. Administer 100% oxygen and, if bradycardia is hemodynamically significant, immediately send for a transcutaneous or transvenous pacing device. Transesophageal atrial pacing is ineffective with
high-degree (second or third degree) AV node block. Secure the airway if necessary. In the interim, attempt to reduce as many negative chronotropic, dromotropic, and inotropic influences as possible by decreasing (or turning off) the inspired concentration of volatile inhalational agents and ceasing the manipulation of any organs (e.g., bowel, reproductive organs, eyes) known to elicit vagal responses. Atropine can be given as a first-line drug to reduce vagal tone and enhance SA and AV node conduction. If the patient remains hypotensive and does not respond to atropine, β-sympathomimetic drugs, such as epinephrine or isoproterenol, are used to enhance SA and AV node conduction if pacing is not yet available, especially if reduced myocardial contractility is evident. Intravenous calcium chloride has been used successfully in cases of deliberate verapamil overdose. In some cases, high-degree AV heart block resistant to pharmacologic intervention may require cardiac pacing. Once stabilized, the patient requires prolonged monitoring because the α-elimination half-life of calcium channel blockers ranges from 10 to 35 minutes (depending on age), and the β-elimination half-life is 5 to 12 hours. Depending on the duration of calcium channel blocker therapy, the latter parameter is variable and may increase to 16 hours or more with hepatic insufficiency.
PREVENTION Prevention relies on a full understanding of the patient’s underlying pathophysiology and the effects of all concurrent drugs, including antiarrhythmics, calcium channel blockers, β-adrenergic blockers, opiates, and digitalis; automaticity of the sinus node; subsidiary atrial, AV junctional, or ventricular escape pacemakers; electrophysiologic properties of specialized atrial, AV, and ventricular conducting tissues (i.e., conduction times and refractoriness); and potential interactions with any drugs used during anesthesia or in perioperative settings. Take the following specific precautions: ●
●
●
●
●
Assess the patient’s history (duration of drug use, dose, side effects, response). Determine the presence of heart failure or arrhythmias by a focused cardiac and pulmonary examination, and assess a 12-lead ECG for arrhythmias and AV conduction abnormalities. Use caution if block of the cardioaccelerator nerves is anticipated (e.g., activation of vagal, cardioinhibitory reflexes), and evaluate whether regional anesthesia might be preferable to intravenous or inhalation general anesthesia. If inhalation anesthesia is chosen, isoflurane, sevoflurane, or desflurane is preferable to enflurane or halothane in patients receiving calcium channel blockers (or β-adrenergic blockers). Use careful opiate dosing. Use of muscle relaxants must be guided by neuromuscular function monitoring.
Many patients receiving calcium channel blockers have successfully undergone a variety of surgical procedures under both regional and general anesthesia. Although the
PHARMACOLOGY
Implications
51
Ch013-X2215
52
8/12/06
3:20 PM
Section 1
■
Page 52
Pharmacology
safety of these drugs in perioperative settings is supported by the paucity of reports of adverse outcomes, calcium channel blockers have a recognized potential to cause significant adverse events in perioperative settings. Given recent clinical trials showing the safety and efficacy of calcium channel blockers for the treatment of cardiovascular disease, anesthesiologists can expect to see a substantial increase in the number of patients receiving these drugs. Large prospective, controlled clinical trials (e.g., the INVEST trial) have shown that (1) for patients with hypertension, therapy with calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers reduces the risk for diabetes more effectively than does therapy with β-blockers and diuretics; and (2) for patients with hypertension and coronary artery disease, therapy with sustainedrelease verapamil or trandolapril was as clinically effective as atenolol-hydrochlorothiazide.
Further Reading Altier C, Zamponi GW: Targeting Ca2+ channels to treat pain: T-type versus N-type. Trends Pharmacol Sci 25:465-470, 2004. Atlee JL: Perioperative cardiac dysrhythmias: Diagnosis and management. Anesthesiology 86:1397-1424, 1997.
Atlee JL, Hamann SR, Brownlee SW, et al: Conscious state comparisons of the effects of the inhalation anesthetics and diltiazem, nifedipine, or verapamil on specialized atrioventricular conduction times in spontaneously beating dog hearts. Anesthesiology 68:519-528, 1988. Bakris GL, Gaxiola E, Messerli FH, et al: Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril [INVEST] study. Hypertension 44:637-642, 2004. Durant NN, Nguyen N, Katz R, et al: Potentiation of neuromuscular blockade by verapamil. Anesthesiology 60:298-303, 1984. Elmslie KS: Neurotransmitter modulation of neuronal calcium channels. J Bioenerg Biomembr 35:477-489, 2003. Opie L: Calcium channel antagonists in the treatment of coronary artery disease: Fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis 38:273-290, 1996. Packer M, Meller J, Medina N, et al: Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 65:660-668, 1982. Pepine CJ, Cooper-Dehoff RM: Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol. 44:509-512, 2004. Reves JG, Kissin I, Lell W, et al: Calcium entry blockers: Uses and implications for anesthesiologists. Anesthesiology 57:504-518, 1985. Rosenthal T, Ezra D: Calcium antagonists: Drug interactions of clinical significance. Drug Saf 13:157-187, 1995.
Ch014-X2215
8/12/06
3:20 PM
Page 53
Disorders of Potassium Balance
REGIONAL ANESTHESIA & PAIN PHARMACOLOGY MANAGMENT
ADJUNCT THERAPY
14
John L. Atlee and Kai T. Kiviluoma Case Synopses Hypokalemia A 56-year-old man with chronic renal failure underwent cardiopulmonary bypass (CPB) for coronary artery revascularization. His pre-CPB serum potassium (K+) concentrations ranged between 5.5 and 6.6 mEq/L. After separation from CPB, the patient had frequent premature atrial beats and nonsustained ectopic atrial tachycardia (≤15 seconds). Lead II of the monitored electrocardiogram (ECG) revealed prominent U waves (Fig. 14-1). Repeated post-CPB serum K+ concentrations were 4.5 and 4.7 mEq/L. Hyperkalemia A 74-year-old man with severe coronary artery disease had coronary artery bypass grafting with five distal anastomoses. Because of impaired myocardial function (ejection fraction 22%), a high-dose glucose-insulin-potassium infusion was started intraoperatively. Postoperatively the patient was hemodynamically stable, and he was extubated 12 hours after surgery. However, 2 days later, ventricular arrhythmias, peaked T waves, and transient second degree atrioventricular (AV) block developed.
PROBLEM ANALYSIS Definition HYPOKALEMIA There is a lack of consensus over what constitutes hypokalemia. Although a number of studies have addressed this issue, many fall short because (1) a single K+ value is not confirmed, (2) there is no information regarding the patient’s usual range of K+ values (i.e., is the hypokalemia acute or chronic?), and (3) possible confounding effects of concurrent diseases and other metabolic imbalances are not considered. As the case synopsis illustrates, the reported “normal” serum K+ values may be misleading unless interpreted within the context of the patient’s history and clinical status. Notably, the patient has ECG changes and arrhythmias consistent with hypokalemia, despite seemingly “normal” serum K+ concentrations of 4.5 and 4.7 mEq/L.
speed of repolarization and reduce action potential duration. In moderate hyperkalemia, these actions may even reduce the likelihood for arrhythmias. The increase in K+ permeability with hyperkalemia decreases the rate of spontaneous diastolic (phase 4) depolarization in the sinus node and subsidiary pacemakers to cause bradycardia and even asystole at very high extracellular K+ concentrations. AV and intraventricular conduction abnormalities are also observed with severe hyperkalemia. This latter group of patients has
ECG
ECG
ART
HYPERKALEMIA With regard to the patient described in the case synopsis, it is probable that after stopping glucose-insulin treatment, a new balance between intracellular and extracellular K+ concentrations was established. Because up to 98% of the total body potassium pool is located intracellularly, dramatic changes in serum K+ may be observed. Normal values for serum K+ range from 3.5 to 5.3 mEq/L. Hyperkalemia increases myocardial membrane permeability to K+ to increase the
PAP
Figure 14–1 ■ Electrocardiogram changes after separation from cardiopulmonary bypass. Note the prominent U waves (arrows). (From Atlee JL: Arrhythmias and Pacemakers. Philadelphia, WB Saunders, 1996, p 90.)
53
Ch014-X2215
8/12/06
54
3:20 PM
Section 1
■
Page 54
Pharmacology
a very high risk of developing fatal arrhythmias, including persistent ventricular fibrillation or asystole. Excessive serum K+ concentrations not only profoundly affect the electrical properties of the heart but also cause severely depressed myocardial contractility. These myocardial effects of hyperkalemia are potentiated in patients with concomitant hypocalcemia or hyponatremia.
Recognition HYPOKALEMIA Low serum K+ concentrations can exist without significant associated ECG changes. The following are common ECG changes with acute hypokalemia (serum K+ ≤ 3.0 mEq/L) in normokalemic patients (serum K+ 3.5 to 4.5 mEq/L): ●
●
● ● ●
The appearance of U waves (see Fig. 14-1, lead II), which may fuse with T waves to cause apparent Q-T interval prolongation “Bowl-shaped” (concave or scooped) ST segment depression (see the last four QRS complexes in Fig. 14-1, lead II) Increased amplitude of QRS complexes (see Fig. 14-1, lead II) Flattened or inverted T waves Arrhythmias: atrial or ventricular extrasystoles or ectopic atrial tachycardia
plasma K+ concentrations exceed 5.5 mEq/L (Fig. 14-2). These T-wave changes are seen most clearly in the precordial leads of the ECG. With more severe hyperkalemia, the P-Q interval is prolonged, the QRS amplitude is decreased, and the QRS interval widens (usually seen at potassium concentrations > 6.5 mEq/L). Ultimately, the P wave disappears. With preterminal hyperkalemia, the markedly widened QRS complex merges with the T wave, giving the ECG a “sine-wave” appearance (see Fig. 14-2). Ventricular flutter, fibrillation, or asystole usually ensues shortly thereafter. The correlation between the degree of hyperkalemia and tissue effects is better at higher K+ concentrations than at lower ones. Thus, widening of the QRS complex more reliably predicts serum K+ levels than does peaking of the T wave. Although ECG changes can be detected during the early phase of hyperkalemia, a high index of clinical suspicion and serial measurement of serum K+ concentrations are essential for the definitive diagnosis of hyperkalemia and to avoid the morbidity and mortality associated with it.
Aside from arrhythmias and ECG changes, hypokalemia can affect cardiovascular, central nervous system, neuromuscular, renal, or metabolic function (Table 14-1). HYPERKALEMIA To recognize hyperkalemia, one must be aware of the possibility. It is confirmed by measuring serial serum K+ concentrations. Also, the ECG is analyzed for the following features: ● ●
●
Peaking and narrowing of the T wave Progressive widening of the QRS complex as hyperkalemia worsens Prolongation of the P-Q and disappearance of P waves
The earliest manifestation of hyperkalemia is peaking and narrowing of the T wave. This is usually observed when Table 14–1
■
Effects of Hypokalemia
Cardiovascular Autonomic neuropathy with postural hypotension Impaired contractility and vasopressor responses Potentiation of toxic effects of digitalis
Neuromuscular and Central Nervous System Potentiation of neuromuscular blockade Weakness and lethargy Peripheral neuropathy and hyporeflexia Respiratory depression Confusion and depression
Renal and Gastrointestinal Polyuria; reduced urine concentrating ability Hypoperistalsis
Metabolic Glucose intolerance Potentiation of hypomagnesemia and hypocalcemia
Figure 14–2 ■ Schematized electrocardiogram (ECG) changes accompanying acute changes in serum potassium (K+) concentration. Note flattening of the T wave and prominent U waves with hypokalemia. As the serum K+ increases toward hyperkalemia, there is a small reduction in the QRS amplitude, QRS complex widening, P-R interval prolongation, reduced P-wave amplitude, and increased T-wave amplitude. Finally, the QRS and T waves merge, giving the ECG a sine-wave appearance. (From Sandøe E, Sigurd B: Arrhythmia. St. Galen, Belgium, Fachmed AG, 1984, p 403.)
Ch014-X2215
8/12/06
3:20 PM
Page 55
Chapter 14
Table 14–2
HYPOKALEMIA Hypokalemia is more likely than hyperkalemia to cause clinically important arrhythmias. It often results from excessive dialysis, thiazide or loop diuretics, mechanical hyperventilation, or therapy with insulin or β-adrenergic agonists. Cellular repolarization abnormalities and loss of transmembrane potential with hypokalemia alter cardiac conduction and refractoriness to facilitate reentry. They are also conducive to disturbed automaticity or triggered activity. Arrhythmias caused by severe hypokalemia resemble those accompanying digitalis toxicity (see Chapter 7) and likely have similar mechanisms. Arrhythmias include atrial and ventricular extrasystoles, ectopic atrial tachycardia, reentrant (paroxysmal) supraventricular tachycardia, and AV heart block. These are not caused by changes in serum K+ concentration per se, but rather by changes in the ratio between intra- and extracellular K+. This is the most important determinant of resting cell membrane potential and cellular electrophysiologic properties. Only extreme extracellular K+ changes (<2.7 or >10 mEq/L) significantly depolarize cell transmembrane potential in atrial, Purkinje, or ventricular muscle fibers. However, loss of transmembrane potential is conducive to automatic, triggered, or reentrant arrhythmias. Between these values, transmembrane potential increases toward more normal values. Further, electrophysiologic changes due to K+ imbalance are likely heterogeneous, with some cells or tissues affected more than others. Thus, the patient described in the first case synopsis was likely relatively hypokalemic, because his pre-CPB serum K+ concentrations ranged from 5.5 to 6.5 mEq/L. Indeed, treatment with intravenous potassium chloride (KCl) restored this patient’s serum K+ concentration to his normal range and abolished the U waves, ectopic atrial beats, and nonsustained ectopic atrial tachycardia. HYPERKALEMIA Causes of hyperkalemia are listed in Table 14-2. Surgery or underlying pathophysiology can cause large changes in potassium excretion and balance. Patients receiving potassium therapy or potassium-sparing diuretics preoperatively are at risk for the development of intra- and postoperative hyperkalemia. Renal failure also renders patients extremely susceptible to hyperkalemia. Patients with advanced renal failure do not respond normally to aldosterone. Thus, their ability to excrete potassium is impaired. Cell disruption of any kind causes intracellular potassium leak and is often associated with hyperkalemia. Hyperkalemia is commonly associated with major trauma, large surface area third-degree burns, and rhabdomyolysis. During hemolytic processes, massive amounts of potassium are liberated over a short period. Reperfusion of ischemic areas can mobilize potassium, and hyperkalemia is worsened by ischemic acidosis. Anesthesiologists commonly encounter these problems in patients having vascular surgery that requires the application of an aortic cross-clamp. Succinylcholine muscle depolarization causes transient increases in serum K+ that are especially dangerous in the setting of chronic hyperkalemia. Owing to a proliferation in
■
Disorders of Potassium Balance
55
Causes of Hyperkalemia
Potassium supplementation and potassium-sparing diuretics Acute or chronic renal insufficiency Trauma and large burns Succinylcholine Neuromuscular disorders, myopathies, muscle denervation, massive muscle injury, tetanus Hemiplegia or paraplegia Diffuse head injury and encephalitis Rhabdomyolysis, hemolysis, or massive blood transfusions Primary or secondary hypoaldosteronism Addison’s disease (chronic adrenocortical insufficiency) Angiotensin-converting enzyme inhibitors Prostaglandin synthetase inhibitors Heparin therapy or digitalis poisoning Respiratory or metabolic acidosis
the number of nicotinic receptors or alterations in the kinetics of potassium channel opening (i.e., the channels remain open longer), succinylcholine may cause life-threatening increases in serum K+ concentrations in a variety of disorders, especially large surface area third-degree burns, spinal cord injury leading to hemi- or quadriplegia, and neuromuscular diseases. Potassium distribution between the intra- and extracellular spaces is strongly pH dependent. A 0.1 decrease in pH causes about a 1.0 mEq/L increase in serum K+. Thus, acidemia of metabolic or respiratory origin can cause severe hyperkalemia by moving intracellular K+ out of the cell. Hypoventilation and respiratory acidosis are important causes of hyperkalemia during anesthesia. Likewise, diabetic ketoacidosis due to insulin-dependent diabetes, especially when compounded by acidosis due to circulatory or hemorrhagic shock, is a common cause of hyperkalemia in emergency rooms. However, despite seeming hyperkalemia, these patients actually have total body K+ depletion. A number of other conditions can cause clinically significant hyperkalemia, albeit more rarely. Massive blood transfusion can cause hyperkalemia by liberating potassium accumulated during blood preservation. Massive amounts of citrate can also bind calcium and worsen the cardiac effects of hyperkalemia. In addition, digitalis preparations have the potential to cause clinically significant hyperkalemia by inhibiting the Na+,K+-ATPase pump.
Implications HYPOKALEMIA There is no unequivocal serum K+ concentration below which the risk for arrhythmias is certain. The development of clinically significant hypokalemia is context sensitive and depends on the following factors: ● ●
●
Concurrent disease and associated pathophysiology Nature of the planned surgery or other therapeutic intervention Acute imbalance imposed by the circumstances of anesthesia and surgery
The last can include stress-induced catecholamine surges, exaggerated temperature changes, impaired ventilation and oxygenation, and the effects of drugs and other interventions.
PHARMACOLOGY
Risk Assessment
■
Ch014-X2215
8/12/06
56
3:20 PM
Section 1
■
Page 56
Pharmacology
Therefore, the decision to proceed with elective surgery in the face of chemical evidence of hypokalemia depends on many factors: whether the condition is acute or chronic, its effect on perioperative risk, the urgency of the planned surgery or intervention, and the implications of the associated imbalance and the patient’s current medications.
●
●
●
HYPERKALEMIA Concerns about anesthesia and surgery in a patient with hyperkalemia (especially if acute) involve the risk of cardiac electrical and mechanical dysfunction: ● ● ● ● ●
First, second, and third degree AV heart block Potential for bradycardia and asystole Ventricular and AV junctional escape rhythms Ventricular fibrillation Decreased contractility
Hyperkalemia can impair cardiac function by causing disturbances of cardiac rhythm or mechanical dysfunction. Although cardiac electrophysiologic abnormalities related to hyperkalemia can cause many different types of arrhythmias, heart block and bradycardia are most common. However, ventricular extrasystolic beats, ventricular fibrillation, and asystole are also possible. Importantly, far more adverse events occur with rapid changes in serum K+ concentration than with chronic hyperkalemia.
Based on the available evidence and the realization that context-sensitive and adequately powered outcome studies are lacking, we suggest the following guidelines for patients with hypokalemia. WHETHER ●
●
MANAGEMENT The decision to proceed with surgery or other major therapeutic interventions requiring anesthesia in patients with hypo- or hyperkalemia remains controversial. However, it is now clear that the duration of hypo- or hyperkalemia is more important than some arbitrary serum K+ value. Chronic imbalances are much better tolerated than their acute counterparts. Other considerations before proceeding with surgery in patients with hypokalemia or hyperkalemia include the following: ●
● ●
● ●
Severity and urgency of the planned surgery or therapeutic intervention Presence of associated physiologic or metabolic imbalances Presence of concurrent systemic disease that may be aggravated by acute hypokalemia or hyperkalemia, especially cardiovascular and central nervous system afflictions Presence of uncontrolled hypertension Presence of renal insufficiency, heart failure, or coronary heart disease
Hypokalemia Roizen and Fleisher addressed some unresolved issues concerning the perioperative management of patients with hypokalemia: ●
●
In patients with modest hypokalemia, should surgery be delayed to subject them to the risks of intravenous or even oral K+ supplementation therapy? What is the definition of modest hypokalemia: less than 3.4 mEq/L? less than 3.0 mEq/L?
Is modest hypokalemia context sensitive? That is, is modest hypokalemia (however defined) safe for some surgeries but not for others (e.g., coronary artery bypass grafting)? Are some individuals more sensitive than others to even minor K+ depletion? Are risk measures for modest hypokalemia (e.g., ventricular premature beats per hour) appropriate and context sensitive? (Such frequency might be more meaningful for patients with evolving myocardial infarction or following cardiopulmonary bypass.)
●
TO
PROCEED
WITH
ANESTHESIA
AND
SURGERY
Serum K+ below 2.5 mEq/L: Confirmed serum K+ values less than 2.5 mEq/L, especially if associated with ECG changes or arrhythmias, justify the delay of all but truly emergency interventions requiring anesthesia, owing to the increased risk of periprocedural complications. This delay provides the time needed to determine the cause and chronicity of the imbalance and to correct it. Serum K+ between 2.5 and 3.0 mEq/L: Confirmed values in this range, especially when associated with ECG changes consistent with hypokalemia or the anticipated presence of other factors that increase the risk for perioperative arrhythmias (Table 14-3), justify the postponement of elective surgery in order to identify the cause of hypokalemia and correct the imbalance. Emergent and urgent procedures can proceed as the imbalance is being corrected. Serum K+ between 3.1 and 3.5 mEq/L: With serum K+ values in this range, provided there has not been an acute decrease of 1.5 mEq/L or more, there is little risk of significant arrhythmias without overt digitalis toxicity, catecholamine excess, acute myocardial infarction, heart
Table 14–3
■
Risk Factors for Perioperative Arrhythmias
Unstable coronary artery disease Chronic pulmonary disease Hypertensive urgencies* or emergencies† NYHA class III or IV or ACC/AHA stage C or D heart failure‡ Acute or chronic renal failure Morbid obesity Malnutrition or cachexia Excess catecholamines Autonomic dysfunction Sick sinus syndrome Increased intracranial pressure *Subacute or chronic stage 2 blood pressure increase to ≥160/100 mm Hg; no end-organ damage. † Acute stage 2 blood pressure increase with evidence of end-organ damage. ‡ New York Heart Association (NYHA): class I—no symptoms of heart failure (HF) at rest; class II—HF symptoms with ordinary exertion; class III—HF symptoms with less than ordinary exertion; class IV—HF symptoms at rest. The American College of Cardiology/American Heart Association (ACC/AHA) staging emphasizes the evolution and progression of HF: stage A—high risk for developing HF, but no structural heart disease; stage B—structural heart disease (SHD), but no HF symptoms; stage C—SHD and past or current HF symptoms; stage D—end-stage heart disease and need for advanced HF treatment (continuous inotropes, mechanical circulatory support, cardiac transplantation, hospice care).
Ch014-X2215
8/12/06
3:20 PM
Page 57
Chapter 14
POTASSIUM REPLACEMENT Treatment for hypokalemia, especially with arrhythmias, consists of K+ repletion, correction of alkalosis, and removal of drugs that are likely to exaggerate its effects (e.g., insulin, potassium-wasting diuretics, β2-adrenergic agonists, catecholamines). If total body K+ is depleted, as with chronic hypokalemia, oral repletion is prudent. For intravenous repletion, KCl is used because coexisting chloride depletion may limit the ability of the kidney to conserve K+. KCl is administered cautiously (no more than 10 to 20 mEq/hour), especially if the absolute deficit and its acuteness are not known. However, if the deficit is known to be acute and large (e.g., the result of massive diuresis or overly aggressive dialysis), intravenous KCl can be administered more rapidly; however, this should be done with simultaneous ECG monitoring. Special care should be exercised during K+ repletion in patients with diabetes, acidemia, and renal tubular acidosis and in those receiving angiotensin-converting enzyme inhibitors, β-adrenergic blockers, or nonsteroidal anti-inflammatory agents. All these conditions and drugs delay the movement of K+ into cells and could lead to significant hyperkalemia. Finally, keep in mind that hypomagnesemia is commonly associated with hypokalemia; it aggravates the effects of the latter by impairing K+ conservation. Hypomagnesemia is common in critically ill patients with chronic ethanolism, acute myocardial infarction, diarrhea, cachexia, malnutrition, and starvation. It is also common following CPB and dialysis and in patients receiving digitalis or chronic diuretic therapy.
Hyperkalemia It is unknown what a safe concentration of K+ is in patients with hyperkalemia. In experimental hyperkalemia, there is good correlation between the magnitude of serum K+ increases and ECG changes (see Fig. 14-2). In clinical hyperkalemia, however, abnormalities of impulse formation and propagation may occur at lower K+ concentrations than in experimental hyperkalemia; in addition, the correlation between serum K+ concentration and ECG changes is not as reliable. However, if hyperkalemia is associated with conduction disturbances, arrhythmias, or reduced contractility, acute therapy is warranted, as follows: ●
●
●
●
Antagonize the cardiac effects of K+ with intravenous calcium gluconate or chloride. Redistribute K+ into the cells with β-adrenergic agonists, sodium bicarbonate, hyperventilation, or glucose-insulin. Remove K+ from the body with furosemide or potassiumbinding resin (Kayexalate). Use hemo- or peritoneal dialysis.
In emergencies, one must rapidly reduce the extracellular concentration of K+ to counteract its effects on myocardial function. Although normalizing total body K+ is the long-term goal of therapy, calcium gluconate or chloride is used acutely to antagonize the effects of increased K+ on cardiac cell membranes. Insulin and β-adrenergic agents redistribute K+ intracellularly and produce a positive inotropic effect.
Disorders of Potassium Balance
57
Correction of acid-base imbalance and moderate alkalosis have the same effect. Sodium bicarbonate (1 to 2 mEq/kg) and moderate hyperventilation (pH 7.45 to 7.50) are also effective for acutely lowering serum K+. Infusion of glucose (1.5 g/kg) and insulin (1 unit/3 g glucose) are relatively rapid means of moving K+ intracellularly. One must measure serum K+ repeatedly, because marked hypokalemia can result from overly rapid intracellular K+ shifts. Total body K+ content is reduced with loop diuretics (e.g., furosemide) or cation exchange resins (e.g., Kayexalate). The latter bind K+ in the gut. Although both therapies are effective, their actions develop more slowly. Thus, they are used after initial treatment in emergencies. Dialysis (hemodialysis or peritoneal dialysis) or hemofiltration (our preference) is indicated in patients with severe renal insufficiency or when physiologic stability cannot be achieved by other means.
PREVENTION In the critically ill patient, sequential perioperative measurement of serum K+ and arterial blood gases for acid-base status is important. Although hypokalemia can be easily treated by giving potassium, the principles of potassium homeostasis must be kept in mind. Before and during anesthesia, it is often wise not to treat mild hypokalemia (K+ ≤ 3.0 to 3.4 mEq/L), or to do so very slowly (≤10 mEq KCl/hour). Circulatory insufficiency can cause tissue hypoperfusion and severe metabolic acidosis, which in turn moves intracellular K+ to the extracellular space. Respiratory acidosis acts similarly. In hyperkalemic patients, succinylcholine should be avoided because it causes a transient rise in serum K+. This rise can be dramatic and potentially lethal if succinylcholine is given to patients with large surface area burns, certain neuromuscular disorders (see Chapters 23 and 153), or a large mass of denervated muscle (i.e., spinal hemiplegia or paraplegia).
Hypokalemia One must be knowledgeable about the causes of hypokalemia and its associated conditions. Also, one must have a high index of suspicion for this condition in critically ill patients or those receiving chronic therapy with potassium-wasting diuretics (e.g., patients with hypertension or heart failure). Finally, one must be able to recognize the ECG signs of hypokalemia and monitor the ECG for evidence of its development.
Hyperkalemia Clinical awareness of the possibility of hyperkalemia is the most important factor in preventing it and its complications. To this end, take the following steps: ● ● ● ● ● ●
Identify patients at risk. Monitor the ECG for signs of hyperkalemia. Measure serial serum K+ concentrations. Monitor acid-base status. Avoid unnecessary potassium supplementation. Avoid respiratory or metabolic acidosis and succinylcholine.
PHARMACOLOGY
failure, or other significant comorbidities. In other words, there is no compelling reason to delay elective surgery or other therapeutic interventions to correct the imbalance.
■
Ch014-X2215
58
8/12/06
3:20 PM
Section 1
■
Page 58
Pharmacology
Preoperative use of potassium supplementation or the use of potassium-sparing diuretics must be kept in mind. During anesthesia, continuous ECG monitoring and end-tidal carbon dioxide monitoring are essential; with the latter, respiratory acidosis can be avoided. With suspected hyperkalemia, T-wave changes usually manifest well before heart block, bradycardia, escape rhythms, or deterioration in myocardial contractile function. Widening of the QRS complex indicates more severe changes. Asystole or ventricular fibrillation occurs with extreme hyperkalemia or after inadvertent intracardiac administration of potassium.
Further Reading Atlee JL: Perioperative cardiac arrhythmias. Anesthesiology 86:1397-1425, 1997. Atlee JL: Perioperative Cardiac Dysrhythmias, 2nd ed. Chicago, Year Book Medical Publishers, 1990, pp 128-129.
Cox M: The renal system and metabolic function. In Carlson RW, Geheb MA (eds): Principles and Practice of Medical Intensive Care, 3rd ed. Philadelphia, WB Saunders, 1993, pp 1155-1334. Davis RF: Etiology and treatment of perioperative cardiac arrhythmias. In Kaplan JA, Reich DL, Konstadt SN (eds): Cardiac Anesthesia, 4th ed. Philadelphia, WB Saunders, 1999, pp 177-213. Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351:543-551, 2004. Roizen MF, Fleisher LA: Anesthetic implications of concurrent diseases. In Miller RD (ed): Miller’s Anesthesia, 6th ed. Philadelphia, Churchill Livingstone, 2005, pp 1017-1149. Winkler AW, Hoff HE, Smith PK: Electrocardiographic changes and concentration of potassium in serum following intravenous injection of potassium chloride. Am J Physiol 124:478-483, 1948.
Ch015-X2215
8/12/06
3:20 PM
Page 59
REGIONAL ANESTHESIA & PAIN PHARMACOLOGY MANAGMENT
15
Magnesium Thomas S. Guyton and Timothy E. Morey Case Synopsis While recovering from hip surgery, a 54-year-old man suffering from alcoholism experiences recurrent episodes of ventricular tachycardia that are resistant to therapy with lidocaine. His serum magnesium level is 1.1 mEq/L. While receiving intravenous magnesium sulfate replacement, the patient complains of feeling hot and has difficulty breathing. Within 15 minutes of initiating replacement therapy, the patient has a respiratory arrest.
PROBLEM ANALYSIS Definition MAGNESIUM HOMEOSTASIS Magnesium is the fourth most abundant cation in the body, with total body stores of about 2000 mEq. Normal serum magnesium (Mg2+) concentrations are between 1.4 and 2.1 mEq/L, equivalent to 1.7 and 2.5 mg/dL, respectively (see Table 15-1 for unit conversions). Serum Mg2+ concentrations correlate poorly with total body stores, reflecting less than 1% of the amount stored. Gastrointestinal absorption in the duodenum and jejunum represents the principal source of Mg2+ (8 to 9 mEq/day). The amount of Mg2+ lost from the body via gastrointestinal secretions is relatively constant (2 mEq/day). In contrast, the kidney can dramatically affect losses in response to lowered serum Mg2+ concentrations due to reabsorption of Mg2+ in the proximal renal tubules and the loop of Henle. ROLE
IN
CELLULAR FUNCTION
Magnesium serves as an essential cofactor for many important cellular enzymes (e.g., adenylyl cyclase, Na+,K+-ATPase). In addition, the magnesium complex with adenosine triphosphate serves as a substrate for the enzymatic reaction mediating muscle contraction and relaxation. Magnesium also regulates cellular function by antagonizing the cellular effects of calcium and modulating several potassium currents (Table 15-2).
Increased serum Mg2+ concentrations cause vascular smooth muscle relaxation by directly competing with Ca2+ to inhibit muscle contraction. Alterations in serum Mg2+ concentrations affect multiple organ systems. For example, hypermagnesemia produces relaxation of vascular smooth muscle by directly competing with Ca2+ to inhibit smooth muscle contraction, increasing the release of prostacyclin and decreasing catecholamine release after sympathetic stimulation. At the motor neuromuscular junction, increased Mg2+ causes presynaptic inhibition of Ca2+ release; this facilitates acetylcholine release, which depresses sarcolemmic excitability. In the heart, reduced Mg2+ slows the heart rate owing to suppressed automaticity and depressed atrioventricular conduction. Hypermagnesemia also reduces the amplitude of early afterdepolarizations to oppose triggered arrhythmias (see later). In the brain, increased Mg2+ serves as an anticonvulsant by blocking neuronal Ca2+ channels associated with the N-methyl-D-aspartate receptor. ROLE
IN
THERAPEUTICS
Magnesium infusions may be therapeutic in the case of triggered ventricular arrhythmias. They are also used as adjunct therapy for atrial fibrillation in cardiac surgery, as tocolytic agents in preterm labor, and to prevent seizures with preeclampsia. The frequency of automatic or triggered ventricular arrhythmias with hypomagnesemia (e.g., torsades de pointes, digitalis ventricular arrhythmias) is reduced by intravenous magnesium infusions that double the serum Mg2+ concentration. Thus, such infusions may increase inwardly
Table 15–2 Table 15–1
■
Unit Conversions for Magnesium Compounds and Serum Concentrations
Compound
Unit Conversions
Magnesium sulfate (MgSO4) Magnesium oxide (MgO) Magnesium acetate (MgC4H6O4) Magnesium chloride (MgCl2) Serum concentrations (all compounds)
1 1 1 1 1
g = 8.13 mEq of Mg2+ g = 46 mEq of Mg2+ g = 9.35 mEq of Mg2+ g = 9.75 mEq of Mg2+ mg/dL = 0.83 mEq/L = 0.415 mmol/L
■
Mechanisms for Magnesium’s Effect on Cellular Function
Ca2+ Antagonism Modulates handling of Ca2+ by sarcoplasmic reticulum Inhibits Ca2+ influx into myocyte through sarcolemmal channels Modulates second messenger system (i.e., adenyl cyclase– adenosine monophosphate) Competes with Ca2+ for high affinity site on actin
K+ Current Enhances function of Na+,K+-ATPase Blocks outward K+ current to result in an increase in inward rectifying K+ current Mediates inwardly rectifying properties
59
Ch015-X2215
8/12/06
60
3:20 PM
Section 1
■
Page 60
Pharmacology
rectifying potassium currents to reduce the amplitude of the early afterdepolarizations that serve as the triggers for torsades de pointes. Proposed mechanisms for magnesium’s effect on digitalisinduced ventricular arrhythmias include improved function of the Na+,K+-ATPase pump and reduction in the amplitude of delayed afterdepolarizations owing to a reduction in the intracellular rise of Ca2+. However, most ventricular arrhythmias are due to reentry and do not respond to intravenous magnesium. In contrast, preoperative β-blockers and calcium channel antagonists with adjunct Mg2+ therapy can reduce the occurrence of atrial fibrillation in postoperative cardiac surgery patients. Hypomagnesemia can result from hemodilution with cardiopulmonary bypass and diuretic therapy. Finally, increasing the serum Mg2+ concentration by 4 to 6 mEq/L has been used to decrease uterine activity in preterm labor and to prevent seizure activity in women diagnosed with preeclampsia.
Recognition HYPOMAGNESEMIA Alterations in serum Mg2+ concentrations are often occult and occur along with alterations in other serum electrolytes, such as calcium and potassium. Hypomagnesemia is best diagnosed by recognizing those conditions associated with it (e.g., chronic ethanol abuse, diuretic or digitalis therapy). Hypomagnesemia alone does not result in electrocardiogram changes; however, the associated disturbances in calcium and potassium may do so. HYPERMAGNESEMIA Hypermagnesemia is most often diagnosed by associating the timing of adverse effects with the administration of magnesium. In patients with gastrointestinal diseases leading to increased absorption or renal failure leading to decreased excretion, large doses of cathartics, antacids, or analgesics containing magnesium salts may result in significant hypermagnesemia. Under these conditions, the temporal association with magnesium administration is often not apparent. Hypermagnesemia is also diagnosed by recognizing the progressive pattern of its adverse effects and then confirming that suspicion with serum Mg2+ measurements. Hypermagnesemia can produce the following adverse effects: ● ● ● ● ● ● ●
Generalized vasodilatation Lethargy Muscle weakness Respiratory depression Sinus bradycardia Atrioventricular block Asystole
Table 15-3 lists common adverse effects of hypermagnesemia and the associated serum Mg2+ concentration at which these effects first appear. It is noteworthy that the serum concentration at which a particular adverse reaction occurs in a given individual varies considerably, depending on the associated metabolic disturbances.
Table 15–3
■
Correlation between Serum Magnesium Concentration and Systemic Effects
Concentration (mEq/L)
Systemic Effects
<0.8
1.4-2.1 3-4
5-6
10 20 >25
Arrhythmias may be resistant to therapy When associated with hypocalcemia: disorientation, muscle twitching, choreiform movements, seizures Normal range Flushing 7%-13% increase in PR interval 0%-11% increase in QRS interval No change in Q-T interval Slight reduction in blood pressure Slight increase in heart rate 10% reduction in FEV1 and FVC Blurred vision from diminished accommodation and convergence Lethargy Loss of deep tendon reflexes Respiratory arrest Atrioventricular conduction block Progressive QRS widening and bradycardia Cardiac arrest
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Risk Assessment HYPOMAGNESEMIA Hypomagnesemia has an incidence of 470 per 1000 individuals suspected of having serum electrolyte abnormalities. Persons with congestive heart failure who are treated with diuretics and digitalis have a 7% to 37% incidence of hypomagnesemia. Alcoholics have a 30% to 40% incidence of hypomagnesemia. HYPERMAGNESEMIA Hypermagnesemia has an incidence of 57 per 1000 individuals suspected of having serum electrolyte abnormalities. Because of the kidney’s remarkable ability to reduce the reabsorption of magnesium, respiratory and cardiac arrests are extremely rare during continuous magnesium infusions for arrhythmias, tocolysis, or seizure prevention in preeclampsia. To prevent the adverse effects of hypermagnesemia, it is best to avoid administering magnesium to individuals with renal failure. In individuals with congestive heart failure, a therapeutic regimen consisting of 0.3 mEq/kg of magnesium given as an intravenous bolus over 10 minutes, followed by a continuous infusion of 0.08 mEq/kg per hour, resulted in serum Mg2+ concentrations of 3.5 mEq/L. In women with preeclampsia, an intravenous bolus of 32 mEq of magnesium sulfate over 20 minutes, followed by 16 mEq/hour, resulted in average serum Mg2+ levels of 4 to 6 mEq/L.
Implications Ventricular arrhythmias resulting from increased automaticity or triggered activity due to magnesium deficits
Ch015-X2215
8/12/06
3:20 PM
Page 61
Chapter 15
The best prevention for hypermagnesemia is to not give magnesium-containing salts or compounds to patients with renal failure. Magnesium-containing compounds include the following: ● ● ●
The key to the management of both hypomagnesemia and hypermagnesemia is recognition. Hypomagnesemia can be treated either orally or parenterally. Table 15-1 gives the elemental content of the various magnesium-containing formulations used to treat hypomagnesemia. In patients with normal renal function, 16 to 32 mEq of magnesium sulfate can be infused intravenously over 30 minutes to 1 hour for rapid correction or over 8 to 24 hours for slower correction. As stated earlier, serum Mg2+ represents less than 1% of the total body stores of magnesium. Thus, achieving sustained elevations in serum Mg2+ concentrations with hypomagnesemia involves multiple doses to replete total body stores. In contrast, the treatment of hypermagnesemia includes any or all of the following: ● ●
●
●
●
Removal of all potential ex vivo sources of magnesium In cases of respiratory arrest, intubation and support of ventilation Administration of furosemide and magnesium-free salt solutions to increase the renal excretion of magnesium Calcium chloride (5 to 10 mEq every 5 to 10 minutes) to antagonize hypermagnesemia Dialysis with magnesium-poor dialysate
61
PREVENTION
●
MANAGEMENT
Magnesium
Cathartics (e.g., magnesium citrate) Antacids (e.g., magnesium oxide) Analgesics (e.g., buffered aspirin) Magnesium supplements
During the administration of cathartics to individuals with gastrointestinal disturbances (e.g., paralytic ileus, ulcerative colitis, perforated duodenal ulcer), massive amounts of magnesium absorption can occur.
Further Reading Dube L, Granry JC: The therapeutic use of magnesium in anesthesiology, intensive care and emergency medicine: A review. Can J Anaesth 50: 732-746, 2003. Ducceschi V, Di Micco G, Sarubbi B, et al: Ionic mechanisms of ischemiarelated ventricular arrhythmias. Clin Cardiol 19:325-331, 1996. Hazelrigg SR, Boley TM, Cetindag IB, et al: The efficacy of supplemental magnesium in reducing atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 77:824-830, 2004. Kelepouris E, Agus ZS: Hypomagnesemia: Renal magnesium handling. Semin Nephrol 18:58-73, 1998. Sibai BM: Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol 190:1520-1526, 2004. Surawicz B: The interrelationship of electrolyte abnormalities and arrhythmias. In Mandel WJ (ed): Cardiac Arrhythmias: Their Mechanisms, Diagnosis, and Management. Philadelphia, JB Lippincott, 1995, pp 89-109.
PHARMACOLOGY
clearly warrant the replacement of those deficits. The use of magnesium infusions to reduce the risk of acute myocardial infarction is controversial and is still under investigation. The use of magnesium for preterm labor tocolysis seems to be a safe alternative to β-sympathomimetics. In comparison to phenytoin, magnesium appears to be more efficacious in preventing seizures in women with preeclampsia.
■
Ch016-X2215
8/12/06
3:21 PM
Page 62
Perioperative Fluid Management
16
Donald S. Prough and Christer H. Svensén Case Synopses Case 1 A 72-year-old man is scheduled to undergo transverse colectomy and primary reanastomosis for a nonobstructing carcinoma. He has a history of hypertension that is well controlled by a diuretic and is otherwise healthy. Case 2 A 35-year-old woman is scheduled to undergo laparoscopic cholecystectomy for cholelithiasis. Other than mild obesity (preoperative weight, 88 kg), she is healthy.
PROBLEM ANALYSIS Definition Complications are related to either insufficient or excessive fluid therapy, and in both instances, complications can range from relatively minor to life threatening. Recent studies strongly suggest that both the frequency and the importance of complications of perioperative fluid therapy have been underestimated in the past. Life-threatening complications of insufficient fluid therapy are hypoperfusion and related vital organ system complications. Acute renal failure and multisystem organ failure are associated with the worst outcomes. Less serious complications are postoperative thirst, dizziness, nausea, vomiting, fatigue, and drowsiness. Postoperative exercise capacity and pulmonary function may be transiently impaired by insufficient fluid therapy. The most feared complication of excessive fluid therapy is primary or secondary pulmonary edema. With primary pulmonary edema, there is increased venous return and right ventricular preload. This leads to increased right ventricular outflow and pulmonary artery flow and, ultimately, increased pulmonary capillary hydrostatic pressure. If this increase is sufficient and sustained, it can cause pulmonary alveolar capillary leak and alveolar flooding. This mechanism is similar to that associated with naloxone overreversal of opiates (see Chapter 33). Secondary pulmonary edema is due to left ventricular overload and “forward” (cardiogenic) failure. This is more likely in patients with at least some left ventricular functional impairment. Less threatening but still bothersome late complications related to excessive fluid therapy include peripheral edema, periorbital edema, and impaired gastrointestinal function or wound healing. These occur after discharge from the postanesthesia care unit or in the intensive care unit and are thus less readily apparent to anesthesia personnel.
complications of insufficient fluid administration have been emphasized for the past 40 years. In the 1960s, Shires and colleagues emphasized the concept that extracellular fluid volume was decreased during hemorrhage or major surgery and required replacement with crystalloid fluids. As a consequence of their studies, infusion of large amounts of crystalloids became the standard of care for combat casualties during the Vietnam conflict. This new treatment method was associated with an apparent reduction in the rate of renal failure and was subsequently adopted for the perioperative management of civilian surgical patients. Morris and associates reported in 1991 that of 72,757 admissions to nine regional trauma centers, only 78 patients (0.11%) required dialysis for acute renal failure, perhaps as a result of more liberal fluid therapy. Yet as the perioperative administration of larger crystalloid volumes became more prevalent, “shock lung” or the “Da Nang lung syndrome,” now termed acute respiratory distress syndrome (ARDS), was clinically recognized. Although a strict cause-and-effect relationship between increased fluid resuscitation and ARDS has never been established, the possible association has troubled clinicians. In 1999, Arieff reported 13 patients who developed postoperative pulmonary edema. Of these, 10 were generally healthy, and 3 had serious medical comorbidities. However, collectively, the group had a net fluid retention of 67 mL/kg within the first 24 intraoperative and postoperative hours. An accompanying retrospective review of the surgical experience during 1 year at a major teaching hospital found that among 8195 patients having major inpatient surgery, 7.6% developed postoperative pulmonary edema. One third of these patients had no preexisting comorbidity. The overall mortality rate was 11.9%, and the mortality rate among those without comorbidities was 3.9%. Based on this single-institution experience, Arieff projected that between 8300 and 74,000 patients die from perioperative pulmonary edema in the United States each year.
Historical Perspective
Recognition
Because fluid restriction was the predominant strategy of perioperative fluid management until the mid-1960s, the
Clinicians can easily recognize the extremes of insufficient or excessive fluid therapy. Hypotension, tachycardia, and oliguria
62
Ch016-X2215
8/12/06
3:21 PM
Page 63
Chapter 16
Perioperative Fluid Management
63
Urine output often declines precipitously during moderate to severe hypovolemia. Therefore, in the absence of glycosuria or diuretic administration, a urine output of 0.5 to 1.0 mL kg−1 hr−1 during anesthesia suggests adequate renal perfusion. Arterial pH may decrease only when tissue hypoperfusion becomes severe. Cardiac output may remain normal, despite severely reduced regional blood flow. Mixed venous oxygen saturation is a specific indicator of poor systemic tissue and vital perfusion; however, it reflects average perfusion in multiple organs and cannot supplant regional monitors such as urine output.
·
·
Risk Assessment Anesthesia personnel have considerable experience and expertise in recognizing patients at high risk for the extremes of perioperative hypovolemia and hypervolemia. Preoperative determination of the patient’s American Society of Anesthesiologists (ASA) physical status and assessment of the likely duration and magnitude of physiologic stress imposed by the planned surgery can be accomplished quickly. However, to date, anesthesia training has not adequately emphasized the relationship between intraoperative fluid therapy and (1) mild symptomatic outcomes (e.g., nausea, vomiting, drowsiness) or (2) less immediate but more important outcomes (e.g., integrity of bowel anastomosis, likelihood of satisfactory wound healing or postoperative wound infection). As further evidence accumulates, anesthesia personnel should approach fluid management for all patients with the expectation that careful attention to the rate and volume of fluid administration will improve the postoperative course.
Implications The potential complications of improper perioperative fluid management suggest that additional studies in certain patient populations are needed to develop specific and comprehensive fluid management algorithms. The input needed to develop such algorithms is now available for patients undergoing colon surgery or laparoscopic cholecystectomy. Brandstrup and colleagues randomized 172 elective colon surgery patients to restrictive or standard perioperative fluid management. In the fluid-restricted group, the primary measure was maintenance of preoperative body weight. All patients underwent combined epidural and general anesthesia. Important details of the standard (liberal) and restrictive protocols are detailed in Table 16-1. By design, the fluidrestricted group received less perioperative fluid and acutely gained less than 1 kg, in contrast to more than 3 kg in the standard fluid therapy group. More important, total postoperative complications were 33% in the fluid-restricted group and 51% in the standard fluid therapy group. Cardiopulmonary complications were also significantly reduced in association with fluid restriction (7% in the restricted group versus 24% in the liberal group), as were tissue healing complications (16% in the restricted group versus 31% in the liberal group). Holte and coworkers randomized 48 ASA I to II patients having laparoscopic cholecystectomy to receive either 15 or 40 mL/kg of lactated Ringer’s solution intraoperatively. They found that the higher dose was associated with improved
PHARMACOLOGY
are obvious, though not specific, signs of hypovolemia; pulmonary edema is an obvious but not specific sign of hypervolemia. Recognition of subtle hypovolemia or hypervolemia is often more difficult. The clinical assessment of blood and extracellular volume begins with the recognition of deficit-generating situations, such as bowel obstruction, preoperative bowel preparation, chronic diuretic use, sepsis, burns, and trauma. Physical signs suggesting hypovolemia include oliguria, supine hypotension, and a positive tilt test. Although oliguria implies hypovolemia, hypovolemic patients may be nonoliguric, and normovolemic patients may be oliguric because of renal failure or stressinduced endocrine responses. Supine hypotension implies a blood volume deficit of more than 30%, although a normal arterial blood pressure could represent relative hypotension in an elderly or chronically hypertensive patient. A positive tilt test is defined as an increase in heart rate of at least 20 beats per minute and a decrease in systolic blood pressure of 20 mm Hg or more when a patient assumes the upright position. However, young, healthy subjects can withstand acute loss of 20% of blood volume while exhibiting only postural tachycardia. In contrast, orthostasis may occur in 20% to 30% of elderly patients, despite normal blood volume. Laboratory evidence that suggests hypovolemia or extracellular volume depletion includes azotemia, low urinary sodium, metabolic alkalosis (if hypovolemia is mild), and lactic acidosis (if hypovolemia is severe). Hematocrit is virtually unchanged by acute hemorrhage until fluids are administered or fluid shifts from the interstitial to the intravascular space occur. Blood urea nitrogen (BUN), normally 8 to 20 mg/dL, is increased by hypovolemia, high protein intake, gastrointestinal bleeding, or accelerated catabolism; it is reduced by severe hepatic dysfunction. Serum creatinine (SCr), a product of muscle catabolism, may be misleadingly low in elderly adults, females, and debilitated or malnourished patients; however, in muscular or acutely catabolic patients, it may exceed the normal range (0.5 to 1.5 mg/dL). A BUN/SCr ratio exceeding the normal range (10 to 20) suggests dehydration. In prerenal oliguria, enhanced sodium reabsorption should reduce urinary [Na+] to 20 mEq/L or less. Enhanced water reabsorption should increase the urine concentration (urine osmolality >400; urine-plasma creatinine ratio >40:1). However, sensitivity and specificity of these urinary variables may be misleading. Assessment of the adequacy of intraoperative fluid resuscitation integrates multiple clinical variables, including sodium concentrations, estimates of intraoperative blood loss and monitoring of heart rate, blood pressure, urine output, arterial oxygenation, and pH. Visual estimation of intraoperative blood loss is notoriously inaccurate. Moreover, tachycardia is an insensitive, nonspecific indicator of hypovolemia. In patients receiving potent inhalational anesthetics, maintenance of a satisfactory blood pressure implies adequate intravascular volume, as does a central venous or pulmonary artery occlusion pressure within the normal range (6 to 12 mm Hg). However, during profound hypovolemia, indirect blood pressure measurements may underestimate direct arterial pressure. Another advantage of direct arterial pressure monitoring may be the recognition of increased systolic blood pressure variation accompanying positive-pressure ventilation with hypovolemia.
■
Ch016-X2215
8/12/06
64
3:21 PM
Section 1
Table 16–1
■
■
Page 64
Pharmacology
Restricted versus Liberal Perioperative Fluids
Group
Restricted Fluids
Liberal Fluids
Preload Maintenance Third-space fluid replacement Blood replacement
None 5% dextrose in water None Hydroxyethyl starch 1:1 for blood loss ≤1500 mL; components for blood loss >1500 mL
Hydroxyethyl starch 0.9% normal saline 0.9% normal saline 0.9% normal saline or hydroxyethyl starch for blood loss £1500 mL; components for blood loss >1500 mL
From Brandstrup B, Tonnesen H, Beier-Holgersen R, et al: Effects of intravenous fluid restriction on postoperative complications: Comparison of two perioperative fluid regimens—a randomized assessor-blinded multicenter trial. Ann Surg 238:641-648, 2003.
postoperative pulmonary function and exercise capacity, reduced neurohormonal stress response, and improvements in nausea, general sense of well-being, thirst, dizziness, drowsiness, fatigue, and balance function.
MANAGEMENT For the patients described in the case synopses, there is enough class I evidence from randomized clinical trials to propose appropriate approaches to perioperative fluid therapy (although one clinical trial for each condition would be insufficient to support formal standards or guidelines). For the 72-year-old man having transverse colectomy, a reasonable option is to manage fluids as in the trial conducted by Brandstrup and colleagues. Using that approach, the patient would receive no preload and minimal crystalloid during induction. Postinduction hypotension, if it developed, would be treated with a pressor while awaiting the onset of surgical stimulation. Maintenance fluids would consist of 5% dextrose in water, and no additional fluid would be given to cover third-space losses. All blood loss would be replaced with 6% hydroxyethyl starch in a ratio of 1:1 unless blood loss exceeded 1500 mL, in which case blood components would be given as appropriate. (For details on the management of changes in blood pressure unrelated to blood loss and other perturbations, such as oliguria, the original publication by Brandstrup’s group should be consulted.) In addition, it is essential to note that in patients undergoing colon surgery, laparoscopic cholecystectomy, or other surgery, it may be necessary to modify the preoperative fluid management plan. For the 35-year-old woman undergoing laparoscopic cholecystectomy, the fluid strategy would be diametrically opposite. Infusing 40 mL/kg of crystalloid over the course of the case would likely exceed what such patients typically receive, but the available evidence suggests that this approach is associated with improved postoperative symptoms. Also, there are important differences between laparoscopic cholecystectomy and colon surgery: ●
Postoperative cardiovascular, pulmonary, infectious, and wound complications occur much less commonly with laparoscopic cholecystectomy than with colon surgery. Thus, the goals of fluid therapy may be quite different for the two types of surgery.
●
In contrast to colon surgery, in which fluid sequestration and blood loss are common, laparoscopic cholecystectomy is associated with minimal fluid sequestration and usually minimal blood loss. Also, based on Brandstrup’s study, it is likely that replacement of blood loss with colloid limits postoperative hypovolemia.
So far, clinical trials have examined the influence of relative extremes of fluid therapy in only two types of surgery. It is likely that subsequent trials will examine more intermediate fluid restriction in colon surgery and less liberal fluid administration in laparoscopic cholecystectomy.
PREVENTION Prevention of the complications of insufficient or excessive perioperative fluid administration requires a multifaceted, flexible approach. A reasonable starting point for the fluid management of individual patients is to plan to replicate a strategy that has been effective in a prospective, randomized clinical trial in a similar population of patients undergoing the same procedure. In addition, each perioperative fluid plan must take into account the physiologic status of the individual patient. If no trials are available for identical surgical procedures, fluid management is based on trials in similar patients and adjusted for the invasiveness of the planned surgery (e.g., amount of tissue manipulation and trauma leading to increased third-space losses, amount of associated bleeding). Also, ambulatory patients without cardiovascular, pulmonary, or renal disease could reasonably be managed with a strategy similar to that used by Holte and coworkers in patients undergoing laparoscopic cholecystectomy. Data reported by Yogendran and associates suggest that such a strategy is advantageous, although improved outcomes in their trial were attained with less isotonic crystalloid preload (20 mL/kg). In patients undergoing major surgical procedures other than bowel surgery, the fluid strategy used by Brandstrup’s group might be used; bowel surgery may impose some procedure-specific constraints. One possible refinement of fluid management in major surgical procedures is better monitoring of fluid requirements. In that regard, studies in which esophageal Doppler monitoring (EDM) was used to measure descending aortic flow are provocative. EDM also quantifies the percentage of time that the descending aortic flow is systolic (i.e., corrected
Ch016-X2215
8/12/06
3:21 PM
Page 65
Chapter 16
Further Reading Arieff AI: Fatal postoperative pulmonary edema: Pathogenesis and literature review. Chest 115:1371-1377, 1999. Brandstrup B, Tonnesen H, Beier-Holgersen R, et al: Effects of intravenous fluid restriction on postoperative complications: Comparison of two perioperative fluid regimens—a randomized assessor-blinded multicenter trial. Ann Surg 238:641-648, 2003. Gan TJ, Soppitt A, Maroof M, et al: Goal-directed intraoperative fluid administration reduces length of hospital stay after major surgery. Anesthesiology 97:820-826, 2002. Hirsch EF: United States Navy surgical research Republic of Vietnam 19661970: A retrospective review. Mil Med 152:236-240, 1987.
Perioperative Fluid Management
65
Holte K, Klarskov B, Christensen DS, et al: Liberal versus restrictive fluid administration to improve recovery after laparoscopic cholecystectomy: A randomized, double-blind study. Ann Surg 240:892-899, 2004. Knight RJ: Resuscitation of battle casualties in South Vietnam: Experiences at the First Australian Field Hospital. Resuscitation 2:17-31, 1973. Lipsitz LA: Orthostatic hypotension in the elderly. N Engl J Med 321: 952-957, 1989. Morris JA Jr, Mucha P Jr, Ross SE, et al: Acute posttraumatic renal failure: A multicenter perspective. J Trauma 31:1584-1590, 1991. Perel A: Assessing fluid responsiveness by the systolic pressure variation in mechanically ventilated patients. Anesthesiology 89:1309-1310, 1998. Rooke GA, Schwid HA, Shapira Y: The effect of graded hemorrhage and intravascular volume replacement on systolic pressure variation in humans during mechanical and spontaneous ventilation. Anesth Analg 80:925-932, 1995. Shires GT, Brown FT, Canizaro PC: Distributional changes in extracellular fluid during acute hemorrhagic shock. Surg Forum 11:115, 1960. Shires GT, Coln D, Carrico J, et al: Fluid therapy in hemorrhagic shock. Arch Surg 88:688-693, 1964. Shires GT, Williams J, Brown F: Acute changes in extracellular fluid associated with major surgical procedures. Ann Surg 154:803-810, 1961. Stoneham MD: Less is more . . . using systolic pressure variation to assess hypovolaemia. Br J Anaesth 83:550-551, 1999. Tavernier B, Makhotine O, Lebuffe G, et al: Systolic pressure variation as a guide to fluid therapy in patients with sepsis-induced hypotension. Anesthesiology 89:1313-1321, 1998. Venn R, Steele A, Richardson P, et al: Randomized controlled trial to investigate influence of the fluid challenge on duration of hospital stay and perioperative morbidity in patients with hip fractures. Br J Anaesth 88:65-71, 2002. Yogendran S, Asokumar B, Cheng DC, et al: A prospective randomized double-blinded study of the effect of intravenous fluid therapy on adverse outcomes on outpatient surgery. Anesth Analg 80:682-686, 1995. Zaloga GP, Hughes SS: Oliguria in patients with normal renal function. Anesthesiology 72:598-602, 1990.
PHARMACOLOGY
flow time). For example, Gan and colleagues randomized 100 patients undergoing surgery in which the predicted blood loss was greater than 500 mL to fluid management based on conventional criteria versus EDM (the treatment group). In the latter, 6% hydroxyethyl starch was given in 200-mL increments to increase corrected flow time if it was less than 0.35 second. The treatment group had a shorter hospital length of stay and resumed eating solid food more quickly. Venn and associates randomized 90 patients having repair of proximal femoral fractures to one control and two treatment groups: (1) conventional fluid management (control), (2) repeated challenges with colloid guided by central venous pressure monitoring, or (3) the same colloid challenges guided by EDM. Both treatment groups had significantly fewer episodes of intraoperative hypotension and were discharged from the hospital sooner than the controls. Importantly, noninvasive EDM was equivalent to more invasive central venous pressure monitoring for assessing intraoperative fluid requirements.
■
Ch017-X2215
8/12/06
3:21 PM
Page 66
ANESTHETIC DRUGS
Volatile Anesthetics: Organ Toxicity
17
Evan D. Kharasch Case Synopsis A 53-year-old woman has laser excision of vocal cord papillomas under anesthesia with halothane and spontaneous ventilation. She has had several prior excisions, including one a month earlier, all with halothane; all were uneventful. However, 1 week after this surgery, she develops fever, nausea, and malaise, along with severe jaundice and markedly elevated serum transaminase concentrations.
PROBLEM ANALYSIS Definition Organ toxicity caused by volatile anesthetics is the result of alterations in cellular structure or function that persist beyond the period of anesthetic administration and elimination. Of greatest concern with volatile anesthetics are hepatic toxicity and renal toxicity. Not discussed here, but worthy of mention, is the potential for volatile inhalational anesthetics to interact with desiccated carbon dioxide absorbents to form potentially toxic compounds, such as carbon monoxide and compound A. Pulmonary and renal toxicity can occur, and fires and explosions have also been reported. (For more details, see the works by Baum and Woehlck listed under “Further Reading.”) HEPATIC TOXICITY Hepatic toxicity occurs most commonly after halothane administration, but it has also been observed with less frequency after enflurane, isoflurane, sevoflurane, and desflurane. Halothane causes two types of liver damage: ● ●
Fulminant hepatic necrosis (“halothane hepatitis”) Mild subclinical hepatotoxicity
Fulminant hepatic necrosis is clinically characterized by fever and jaundice, with grossly elevated serum transaminase levels. Liver biopsies show massive centrilobular necrosis. Today, fulminant hepatic necrosis is considered an immune phenomenon that is initiated by oxidative metabolism of halothane to an intermediate. This subsequently binds to liver proteins and induces trifluoroacetylation, which renders the proteins antigenic. These antigens stimulate the formation of antibodies that, on re-exposure to halothane (or enflurane, isoflurane, or desflurane), initiate immunemediated hepatic necrosis. Such necrosis is rare, occurring in 1 in 6000 to 35,000 persons after halothane administration and in 2 in 1 million persons after enflurane; there have been a few reports of cases after isoflurane and one confirmed case after desflurane. Hepatic dysfunction after sevoflurane 66
administration has also been reported, but it is not thought to represent immune-mediated necrosis, and the relationship to anesthesia is unknown. Mild hepatotoxicity occurs commonly after halothane administration (approximately 25% of cases) but not after the administration of other volatile anesthetics. It is characterized by mild, transient elevations in serum transaminase and glutathione-S-transferase concentrations and altered postoperative drug metabolism. However, clinically evident hepatocellular disease is not a characteristic of mild hepatic toxicity. Rather, it is attributed to reductive (anaerobic) halothane metabolism, with reactive metabolites causing lipid peroxidation and binding to cytochrome P-450. The two forms of hepatic anesthetic toxicity are thought to be unrelated. ACUTE RENAL FAILURE Acute renal failure is a common perioperative problem, but it is now rarely the direct result of volatile anesthetics. Several terms require definition: ●
●
●
●
●
Renal failure is a reduction in renal function sufficient to cause alterations in serum biochemistry; it may be oliguric, nonoliguric, or polyuric. Renal insufficiency is a lesser reduction in renal function with normal serum biochemistry. Oliguria is urine output less than 20 mL/hour (in a 70-kg adult) and implies renal failure. Nonoliguric renal failure is more common than oliguric failure, and it is thought to represent a milder renal insult. Polyuria is urine output greater than 100 mL/hour (in a 70-kg adult).
Both oliguric and nonoliguric renal failure may be postrenal (obstructive), prerenal (renal hypoperfusion due to hypovolemia, hypotension, decreased renal blood flow, or cardiovascular surgery), or intrinsic (caused by nephrotoxins such as aminoglycosides, myoglobin, hemoglobin, radiocontrast media, or nonsteroidal anti-inflammatory agents). Polyuric renal failure with reduced concentrating ability is due to either central diabetes insipidus (insufficient antidiuretic
Ch017-X2215
8/12/06
3:21 PM
Page 67
Chapter 17
Recognition Fulminant hepatic necrosis manifests clinically as fever, nausea, anorexia, chills, malaise, and rash that appear 3 to 6 days postoperatively, followed by severe jaundice that occurs 6 to 10 days postoperatively. Laboratory manifestations include grossly elevated serum transaminase levels, hyperbilirubinemia, and prolonged prothrombin time, but these are not specific for the disease. Pathologic findings include centrilobular and midzonal necrosis, but again, these findings are not specific. Mild hepatotoxicity after halothane is usually clinically silent, consisting of only mild, reversible increases in liver enzymes (aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase, and glutathione-S-transferase) on laboratory studies. These elevations appear 1 to 2 days postoperatively and usually resolve within days. However, levels may remain elevated for up to 2 weeks. A specific diagnosis of anesthetic-related hepatitis is difficult at best. Both the clinical presentation and the morphologic features strongly resemble those of viral hepatitis. Indeed, the incidence of occult perioperative hepatitis (viral, infectious, alcoholic) is 1 in 700, and in 30% of these cases, postoperative jaundice develops; this is far greater than the incidence of anesthetic-related fulminant hepatitis. Positive serologic markers for hepatitis A, B, C, or D or other infectious agents (e.g., cytomegalovirus, Epstein-Barr virus) may help exclude anesthesia as the cause of postoperative hepatitis, but negative serologic findings are inconclusive, especially if infection is recent. A few laboratories can detect antitrifluoroacetylated protein antibodies in serum, which favors a diagnosis of anesthetic-related hepatitis. However, the assay lacks sufficient specificity and is not routinely available. Hepatitis C is the most common cause of postoperative hepatitis, but hepatic ischemia, other drugs, transfusion, and cholestasis should also be excluded. The clinical characteristics of renal insufficiency and acute renal failure were listed earlier. Differentiation of central and nephrogenic diabetes insipidus is based on response to water deprivation and vasopressin. The cause of oliguric
Volatile Anesthetics: Organ Toxicity
67
renal failure is determined by the BUN-creatinine ratio, urine sodium and osmolality, urine-plasma osmolality, urineplasma creatinine, fractional excretion of sodium, and response to volume challenge. The diagnosis of renal failure specific to a volatile anesthetic is extremely rare in the postmethoxyflurane era.
Risk Assessment Clinical risk factors for fulminant hepatic necrosis include the following: ● ● ● ● ●
Repeated halothane exposure Prior history of postanesthetic fever or jaundice Obesity Female sex Middle age
Halothane is oxidatively metabolized by cytochrome P-450 2E1. Thus, enzyme induction (alcohol, isoniazid, obesity) increases antigen formation and increases risk, whereas enzyme inhibition (disulfiram) reduces metabolism. Multiple, repeated exposures at short intervals (<6 weeks) is the greatest risk factor for halothane hepatitis. Children are at greatly diminished risk, for unknown reasons, even after repeated halothane exposure. Liver disease itself is not a risk factor for halothane hepatitis. Clinical risk factors for mild hepatotoxicity are those that increase reductive halothane metabolism. Halothane is reduced anaerobically by P-450 3A4 and 2A6; thus, enzyme induction (e.g., by barbiturates, phenytoin, valproic acid) increases metabolism, as does reduced hepatic blood flow. The latter is further reduced by halothane. Although enflurane, isoflurane, and desflurane also cause neoantigen formation, the degree of such formation is far less than with halothane, so the risk of hepatitis with these agents in halothane-sensitized patients is far less. The only clearly identified clinical risk factors for postoperative renal failure are the following: ●
● ●
Poor preoperative renal function (increased BUN or creatinine levels) Advanced age Cardiac failure
Treatment and prevention of hypovolemia and preoperative hydration are primary goals in ameliorating the cardiovascular and renal blood flow effects of volatile anesthetics in general. Mechanical ventilation and positive endexpiratory pressure are other factors peripherally related to volatile anesthetics that diminish renal function. Although not pertinent to contemporary anesthesia, certain inducers of drug metabolism (barbiturates, isoniazid, ethanol) potentiate methoxyflurane metabolism and toxicity.
Implications Fulminant hepatic necrosis after halothane is fatal in nearly half of all cases. There are no known clinical implications of mild hepatotoxicity. Perioperative acute renal failure accounts for half of all patients who require acute dialysis and is associated with a 50% mortality rate. This has remained unchanged for decades.
PHARMACOLOGY
hormone secretion, usually due to pituitary dysfunction) or nephrogenic diabetes insipidus (renal unresponsiveness to antidiuretic hormone). Anesthesia-related renal insufficiency is often prerenal and is caused by hypotension or altered renal perfusion. It is limited to the duration of the anesthetic and is reversible. Renal failure specifically attributable to anesthetic agents has been observed only with methoxyflurane, which can cause vasopressin-resistant polyuria, hypernatremia, hyperosmolality, and dehydration; it also increases blood urea nitrogen (BUN) and creatinine levels. Methoxyflurane nephrotoxicity is due to dose-related methoxyflurane metabolism. Associated plasma fluoride concentrations range from greater than 50 to 80 μM. A mild but reversible concentrating defect following prolonged enflurane use has been noted. Direct nephrotoxicity has not been observed with enflurane, isoflurane, desflurane, or sevoflurane, even with systemic fluoride concentrations far exceeding 50 μM. The role of systemic fluoride concentrations as a factor in nephrotoxicity has been discounted.
■
Ch017-X2215
68
8/12/06
3:21 PM
Section 1
■
Page 68
Pharmacology
MANAGEMENT There is no specific management for either fulminant hepatic necrosis or mild hepatotoxicity. No therapy is needed for mild hepatotoxicity, whereas only supportive therapy and orthotopic liver transplantation are available for hepatic necrosis. Treatment for acute renal dysfunction includes restoration of normovolemia and renal blood flow; administration of mannitol, loop diuretics (controversial), dopamine, and fenoldopam (experimental); and dialysis.
PREVENTION No measures for the prevention of mild hepatotoxicity are necessary. The only fail-safe method of preventing fulminant hepatic necrosis is total avoidance of halothane, enflurane, isoflurane, and desflurane in patients previously exposed to halothane. Hepatitis is rare in children and in adults with only a single exposure to halothane. A conservative approach is to avoid halothane in patients with known risk factors for fulminant necrosis, especially recent halothane anesthesia. The ultraconservative approach is to avoid halothane altogether. The single most effective measure to prevent postoperative renal failure is to minimize renal ischemia by maintaining
renal perfusion. Maintenance of adequate hydration is essential. Mannitol may be an effective prophylactic.
Further Reading Baden JM, Mazze RI: Polyuria. In Gravenstein N, Kirby RR (eds): Complications in Anesthesiology, 2nd ed. Philadelphia, LippincottRaven, 1996, pp 493-498. Baum JA, Woehlck HJ: Interaction of inhalational anaesthetics with CO2 absorbents. Best Pract Res Clin Anaesthesiol 17:63-76, 2003. Brown BR: Inhalation anesthesia and hepatic injury. In Gravenstein N, Kirby RR (eds): Complications in Anesthesiology, 2nd ed. Philadelphia, Lippincott-Raven, 1996, pp 701-710. Dooley JR, Mazze RI: Oliguria. In Gravenstein N, Kirby RR (eds): Complications in Anesthesiology, 2nd ed. Philadelphia, LippincottRaven, 1996, pp 479-491. Gut J, Christen V, Frey N, et al: Molecular mimicry in halothane hepatitis: Biochemical and structural characterization of lipoylated autoantigens. Toxicology 97:199-224, 1995. Novis BK, Roizen MF, Aronson S, et al: Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg 78: 143-149, 1994. Pearson JD, Gelman S: Liver complications after anesthesia. In Benumof JL, Saidman LJ (eds): Anesthesia and Perioperative Complications. St. Louis, Mosby–Year Book, 1992, pp 413-433. Prough DS, Zaloga G: Hypovolemia and renal dysfunction. In Benumof JL, Saidman LJ (eds): Anesthesia and Perioperative Complications. St. Louis, Mosby–Year Book, 1992, pp 434-465. Ray DC, Drummond GB: Halothane hepatitis. Br J Anaesth 67:84-99, 1991. Woehlck HJ: Sleeping with uncertainty: Anesthetics and desiccated absorbent. Anesthesiology 101:276-278, 2004.
Ch018-X2215
8/12/06
3:21 PM
Page 69
REGIONAL ANESTHESIA & PAIN PHARMACOLOGY MANAGMENT
18
Nitrous Oxide: Neurotoxicity Claudia Praetel Case Synopsis Two weeks after surgery for prostate adenoma, a 69-year-old man developed ascending paresthesia of the limbs, severe ataxia, tactile sensory loss in the limbs and trunk, and absent tendon reflexes. After a second surgical intervention, the patient became confused. Four months after onset, the patient demonstrated paraplegia, severe weakness of the upper limbs, cutaneous anesthesia sparing the head, and confusion.
PROBLEM ANALYSIS Definition Nitrous oxide (N2O) has been safely used for anesthesia for almost 140 years, since it first became available in compressed gas cylinders in 1868. However, there are increasing reports of the neurotoxic potential of N2O associated with recreational use, with chronic occupational exposure in unscavenged environments, and after exposure during general anesthesia. A small subset of patients routinely seen during preoperative anesthetic assessment may indeed be at high risk for postoperative neurologic deterioration if exposed to N2O. Schilling postulated that N2O may precipitate neurologic disease in patients with unrecognized vitamin B12 deficiency. The patient described in the case synopsis was diagnosed with previously unrecognized pernicious anemia with subacute combined degeneration of the spinal cord after exposure to N2O anesthesia. Marié and coworkers published this case report in 2000. During the past 20 years, numerous welldocumented case reports have substantiated this potentially devastating complication. Table 18-1 highlights recent reports of neurologic complications after N2O in both children and adults.
Lack of methionine can also result in defective myelination and demyelination. Neurologic sequelae include paresthesias, peripheral neuropathy, and subacute combined degeneration of both the posterior and lateral columns of the spinal cord. Subacute combined degeneration is reversible if diagnosed and treated early with cobalamin. Psychological symptoms such as memory loss, disorientation, and depression have been described. These conditions may be observed with or without macrocytic changes in erythrocytes.
Risk Assessment Inhibition of methionine synthase by N2O anesthesia does not cause a problem in healthy individuals with sufficient vitamin B12 stores. However, any patient with even subclinical deficits of vitamin B12 is at increased risk for the development of myeloneuropathy because occult cobalamin deficiency, combined with subsequent N2O exposure, compounds inhibition of the methionine synthesis pathway. Insufficient availability of cobalamin may have the following causes: ●
●
Recognition N2O is a potent oxidant. It irreversibly oxidizes methylcobalamin through inhibition of the methionine synthesis pathway, thereby inactivating the active form of vitamin B12. The latter is essential for methionine synthase, the key enzyme for converting homocysteine to methionine (an essential amino acid) using tetrahydrofolate (the bioactive form of folate) as the methyl source. Therefore, insufficient availability of either cobalamin1 or folate results in a decrease of methionine, with the accumulation of homocysteine. N2O also directly inactivates methionine synthase, possibly due to the production of free radicals. Inhibition of methionine synthase activity has deleterious consequences for DNA synthesis, leading to megaloblastic changes in all rapidly dividing cells, macrocytosis in erythroid precursors, and ineffective erythropoiesis.
●
Inadequate intake (e.g., alcoholics, long-term strict vegetarians, breast-fed infants of vitamin B12-deficient mothers) Impaired absorption (e.g., gastric atrophy, long-term use of drugs that interfere with acid production, Crohn’s disease, lack of intrinsic factor due to autoimmune destruction of parietal cells or after surgery such as gastrectomy and gastric bypass) Rare congenital disorders (e.g., deficiencies of transcobalamin II, familial selective vitamin B12 malabsorption)
Folate deficiency is very rare due to the dietary fortification of wheat and corn grains with folic acid. Inherited defects in folate metabolism (5,10-methylenetetrahydrofolate reductase deficiency) are a contraindication to N2O exposure. 1 The terms cobalamin and vitamin B12 are used interchangeably as generic terms for all the cobalamides active in human beings. Preparations of vitamin B12 for therapeutic use contain either cyanocobalamin or hydroxocobalamin, because only these derivatives remain active following storage.
69
Ch018-X2215
8/12/06
70
3:21 PM
Section 1
Table 18–1
■
■
Page 70
Pharmacology
Selected Case Reports of Neurologic Complications after Nitrous Oxide (N2O) Anesthesia
Reference
Demographics
Onset Time and Symptoms
Findings
Selzer et al
3 mo old; excisional biopsy (45 min); 4 days later, tumor resection (270 min), for a total N2O exposure time of 315 min 8 mo old; laparoscopic orchiopexy; N2O exposure of 180 min
25 days: hypotonia, ataxic ventilation, absent reflexes
Methylenetetrahydrofolate reductase deficiency; died 46 days postoperatively
6 days: hypotonia, fine motor tremor, athetoid movements
Profound dietary cobalamin deficiency (<20 pg/mL); hyperhomocysteinemia; normal folate levels; megaloblastic abnormalities in bone marrow Severe dietary cobalamin deficiency (<45 pg/mL); normal folate levels; MRI revealed diffuse cerebral atrophy Cobalamin deficiency (135 pmol/L); borderline anemia; abnormal Schilling test; MRI revealed signal changes of posterior spinal columns; SSEP showed severe spinal cord conduction disturbance; EMG and NCS showed mixed polyneuropathy Normal cobalamin level (<166 pmol/L); low folate; macrocytic, hyperchromic anemia; bone marrow exam revealed megaloblastic hematopoiesis; MRI showed signal changes in posterior columns along cervical cord segments: EMG and NCS showed mild demyelinative polyneuropathy Macrocytic anemia; MRI revealed signal changes in posterior and lateral spinal columns
Felmet et al
McNeely et al
4 mo old; repair of cranisynostosis; N2O exposure of 80 min
3 wk: hypotonia, lethargy, feeding difficulty, severe acidosis, dehydration 2 mo: gait imbalance, lower extremity paresthesias
Ilnicziky et al (case 1)
57-yr-old man; cranial artery bypass; duration of N2O exposure unspecified
Ilnicziky et al (case 2)
52-yr-old man; gallbladder removal; duration of N2O exposure unknown
1 wk: paresthesias in both feet, ascending to trunk and upper extremities; weakness and clumsiness in all limbs
Sesso et al
63-yr-old woman; gallbladder removal; N2O exposure of 80 min
1 day: rapidly ascending paresthesias in hands/feet 2 mo: moderate tabetic-spastic gait, with impaired proprioception and sensation
EMG, electromyography; MRI, magnetic resonance imaging; NCS, nerve conduction velocity study; SSEP, somatosensory evoked potentials.
Implications A recently published multicenter study in Great Britain examined blood samples of 1562 patients aged 65 to 74 years and 75 years or older. Among men, 11% and 24%, respectively, were at high risk of vitamin B12 deficiency; the corresponding numbers were slightly lower for women (9% and 17%, respectively). Similar results were reported for the United States. This high prevalence of borderline or low vitamin B12 concentrations in the elderly (due to the decline in digestive efficiency, atrophic gastritis, and the ubiquitous use of acid-reducing drugs) is particularly worrisome because the clinical presentation varies considerably and rarely includes all the classic features. Hematologic signs of macrocytosis and anemia are often missing. Apparently, a dissociation of neurologic and hematologic findings is common. Cobalamin deficiency in young adults is uncommon, except among strict long-term vegetarians. The potential risks of N2O are increased in children with enzyme disorders and noncompliance with vitamin supplements, as described in a patient with phenylketonuria. There is growing evidence that markers such as holotranscobalamin II, methylmalonic
acid, and total serum homocysteine constitute a better index of early cobalamin deficiency and allow the differentiation between storage depletion and functional deficiency. Presently, these tests are very expensive and are not used as routine assays to investigate functional vitamin B12 status. Low cobalamin status is significantly correlated to increased plasma homocysteine, which is recognized as an independent atherothrombotic risk factor. The latency in onset of neurologic symptoms following exposure to N2O may confound the true incidence of this anesthesia-related complication.
MANAGEMENT The preoperative risk assessment should include careful attention to the following: ● ●
● ●
Hematologic abnormalities (e.g., anemia, macrocytosis) Increased prevalence of subclinical vitamin B12 deficiency in the elderly Rare genetic enzyme disorders Diet (strict vegetarian or vegan)
Ch018-X2215
8/12/06
3:21 PM
Page 71
Chapter 18
● ●
● ● ●
●
History of gastric or small bowel surgery (e.g., gastric bypass in the morbidly obese, resection of the terminal ileum in Crohn’s disease) Inflammatory bowel disease Long-term use of antacids, histamine (H2) receptor antagonists, or proton pump inhibitors (e.g., aluminum and magnesium hydroxide, ranitidine, omeprazole) Severe depression in the elderly Unexplained neurologic symptoms Previous exposure to inhaled anesthesia (including N2O) that was associated with postoperative neurologic complications Increased prevalence of folate deficiency in patients with chronic liver disease or malabsorption syndromes, longterm use of anticonvulsants (e.g., valproic acid, phenytoin), and antimetabolite therapy (e.g., methotrexate)
PREVENTION Avoidance of N2O anesthesia in patients with an elevated risk of cobalamin deficiency appears prudent in view of the possibly serious neurologic sequelae. The fact that subclinical or clinical deficits are not always accompanied by hematologic changes deserves special emphasis. Routine N2O use may be detrimental to patients with marginal cobalamin status. Vitamin pretreatment of at-risk patients is an option, but an impractical one, because anesthesiologists generally see patients immediately before surgery. Optimal management of patients with confirmed or suspected cobalamin deficiency includes an anesthetic regime devoid of N2O. N2O-induced postoperative neurologic complications are preventable with
Nitrous Oxide: Neurotoxicity
71
a proper focus on the recognition of preexisting vitamin B12 deficiency as outlined here.
Further Reading Badner NH, Freeman D, Spence JD: Preoperative oral B vitamins prevent nitrous oxide-induced postoperative plasma homocysteine increase. Anesth Analg 95:787, 2002. Clarke R, Refsum H, Birks J, et al: Screening for vitamin B12 and folate deficiency in older persons. Am J Clin Nutr 77:1241-1247, 2003. Deleu D, Hanssens Y, Louon A: Nitrous oxide-induced cobalamin deficiency. Arch Neurol 58:134-135, 2001. Felmet K, Robins B, Tilford D, Haflick SJ: Acute neurologic decompensation in an infant with cobalamin deficiency exposed to nitrous oxide. J Pediatr 137:427-428, 2000. Hadzic A, Glab K, Sanborn KV, Thys DM: Severe neurologic deficit after nitrous oxide anesthesia. Anesthesiology 83:863-866, 1995. Herrmann W, Geisel J: Vegetarian lifestyle and monitoring of vitamin B12 status. Clin Chim Acta 326:47-59, 2002. Ilniczky S, Jelencsik, Kenéz J, Szirmai I: MR findings in subacute combined degeneration of the spinal cord caused by nitrous oxide anaesthesia— two cases. Eur J Neurol 9:101-104, 2002. Marié RM, Le Biez E, Busson P, et al: Nitrous oxide anesthesia-associated myelopathy. Arch Neurol 57:380-382, 2000. McNeely JK, Buczulinski B, Rosner DR: Severe neurological impairment in an infant after nitrous oxide anesthesia. Anesthesiology 93:1549-1550, 2000. Nunn JF: Clinical aspects of the interaction between nitrous oxide and vitamin B12. Br J Anaesth 59:3-13, 1987. Royston BD, Nunn JF, Weinbren HK, et al: Rate of inactivation of human and rodent methionine synthase by nitrous oxide. Anesthesiology 68:213-216, 1988. Schilling RF: Is nitrous oxide a dangerous anesthetic for vitamin B12-deficient subjects? JAMA 255:1605-1606, 1986. Selzer RR, Rosenblatt DS, Laxova R, Hogan K: Adverse effect of nitrous oxide in a child with 5,10-methylenetetrahydrofolate reductase deficiency. N Engl J Med 349:45-50, 2003. Sesso RM, Iunes Y, Melo AC: Neuropathy following nitrous oxide anesthesia in a patient with macrocytic anaemia. Neuroradiology 41:588-590, 1999.
PHARMACOLOGY
●
■
Ch019-X2215
8/12/06
3:22 PM
Page 72
19
Intrathecal Opiates Lisa Thannikary and Bhiken Naik Case Synopsis An otherwise healthy 26-year-old woman undergoes cesarean section for delivery of a breech infant. Spinal anesthesia is used, consisting of hyperbaric bupivacaine (12 mg) with preservative-free morphine (0.3 mg). The surgery is uneventful, and the infant has Apgar scores of 9 and 9 at 5 and 10 minutes, respectively. The patient remains in the recovery room for 2 hours and is then transferred to the floor. She is treated with diphenhydramine 50 mg intravenously (IV) for generalized pruritus 4 hours after surgery and promethazine 25 mg IV for vomiting 7 hours after surgery. Ten hours after surgery, she is found to be somnolent, with a respiratory rate of 6 breaths per minute, and is minimally responsive to deep tactile stimulation.
PROBLEM ANALYSIS Definition Intrathecal administration of opioids is an effective means of providing analgesia. A combination of opioids and local anesthetics is often administered intrathecally in an effort to reduce drug dosages while limiting the side effects of both classes of drugs. Morphine is commonly chosen for intrathecal administration, because a single dose may provide analgesia for up to 24 hours. Side effects of intrathecal opioids include early and late respiratory depression, nausea and vomiting, pruritus, sedation, and urinary retention (Table 19-1). Early respiratory depression occurs in the first 2 hours after intrathecal administration and is believed to be due to vascular uptake and redistribution. This occurs more often with lipophilic opioids such as fentanyl and sufentanil than with less lipophilic opioids such as morphine. Delayed respiratory depression occurs 6 to 12 hours after intrathecal administration and is believed to be the result of rostral spread of the opioid in the cerebrospinal fluid. The target receptors are likely located in the respiratory center of the brainstem. However, the occurrence of clinically significant respiratory depression is very low, typically less than 0.5%. Pruritus, either generalized or localized, occurs frequently in patients receiving intrathecal opioids. Although
Table 19–1
■
the mechanism is not fully understood, histamine release is not postulated to be a causative factor. Nausea and vomiting are believed to be due to rostral spread of the opioid in the cerebrospinal fluid. The opioid stimulates the vomiting center and the chemoreceptor trigger zone in the fourth ventricle. Sedation is believed to result from opioid spread through the cerebrospinal fluid to the thalamus, limbic system, or cerebral cortex. Sedation may be exacerbated by hypercarbia with carbon dioxide narcosis. Urinary retention is believed to be due to inhibition of sacral parasympathetic outflow. This results in relaxation of the bladder detrusor muscle and the concomitant inability to relax the sphincter.
Recognition The most serious complication of intrathecal opioid administration is delayed respiratory depression because it usually occurs when the patient is no longer under an anesthesiologist’s or intensivist’s care. In the operating room, labor suite, recovery room, or critical care unit, patients are more closely monitored than they are on the floor. It is also important to recognize that respiratory depression is often a late finding. Increasing somnolence, bradypnea, and smaller tidal volumes are early signs of respiratory compromise. Late signs are hypoxia, unresponsiveness, and cardiopulmonary arrest.
Cause and Treatment of Complications of Intrathecal Medications
Complication
Cause
Treatment
Early respiratory depression Late respiratory depression Pruritus Nausea, vomiting
Rapid vascular uptake and redistribution Rostral CSF spread to brainstem respiratory center Unknown (unlikely due to histamine release) Rostral CSF spread to vomiting center or chemoreceptor trigger zone in fourth ventricle Inhibited sacral parasympathetic outflow Rostral spread in CSF to thalamus, limbic system, or cortex; hypercarbia
Ventilatory support, naloxone Ventilatory support, naloxone Naloxone, antihistamines, propofol Naloxone, antiemetics, droperidol, transdermal scopolamine Naloxone (large doses), urinary catheterization Naloxone
Urinary retention Sedation
CSF, cerebrospinal fluid.
72
Ch019-X2215
8/12/06
3:22 PM
Page 73
Chapter 19
Risk Assessment Careful selection of patients for the administration of intrathecal opioids is important. Patients at increased risk for respiratory depression include those who are debilitated or elderly, suffer from coexisting respiratory disease, and are placed in Trendelenburg’s position following intrathecal opioid injection. Also, patients receiving hydrophilic opioids, large or frequent doses of opioids, large-volume injections, and concomitant parenteral or oral sedatives are at increased risk for respiratory depression.
Implications Anesthesiologists commonly administer intrathecal opioids to provide postoperative analgesia. It is important to remember that side effects of intrathecal opioids can occur after the patient has left the anesthesiologist’s care. Good communication with the nursing staff caring for the patient is crucial for the prevention of many complications.
MANAGEMENT The immediate treatment for neuraxial opiate-induced respiratory depression is ventilatory support until the opiate is metabolized or pharmacologically antagonized. The patient must be ventilated with positive-pressure mask ventilation and 100% oxygen. Tracheal intubation and mechanical ventilation may be necessary in some patients. Opiate reversal is accomplished with small doses (40 to 80 μg) of parenteral naloxone. Repeated naloxone doses or infusions may be necessary because its half-life is shorter than that of intrathecal morphine. Also, advanced cardiovascular life support is required for patients with cardiac arrest due to narcotic-caused respiratory depression. Arterial blood gas measurements for carbon dioxide concentrations are helpful to ascertain the degree of inhibition of respiration or the adequacy of ventilation. Finally, narcotics administered by other routes (intravenous, oral, epidural, intramuscular) must be discontinued.
Intrathecal Opiates
73
PREVENTION The best way to prevent delayed respiratory depression in patients receiving spinal opioids is to not give parenteral opioids or other sedating medications until at least 24 hours after intrathecal administration. Pruritus and nausea are common side effects of intrathecal opioids and can be treated effectively with naloxone. If other drugs are used for the treatment of pain or side effects, it is important to use nonsedating ones, such as nonsteroidal anti-inflammatory drugs for patients with pain. Good communication between anesthesia and nursing personnel is essential to prevent and treat adverse sequelae of intrathecal opioid administration. Nursing staff must be educated about intrathecal opioid side effects and their appropriate management. One effective measure is to use a preprinted order signed by the anesthesiologist stating that the patient received intrathecal opioids and should not receive further sedating drugs for at least 24 hours without clearance from the anesthesia staff. Signs posted above the head of the patient’s bed indicating that intrathecal opioids have been used may also be helpful. Monitoring the patient at frequent intervals is critical to prevent significant respiratory depression. The patient must be assessed for rate and quality of respirations and level of sedation. For very high-risk patients, the usual floormonitoring interval may not be adequate. If so, the patient may have to be admitted to a unit where more staff are available to monitor the patient more closely. Pulse oximetry monitoring with data telemetry to a centralized nursing station is also helpful but may not be available to all patients or in all hospitals.
Further Reading Ballantyne JC, Loach AB, Carr DB: Itching after epidural and spinal opiates. Pain 33:149-160, 1988. Brill S, Gurman GM, Fisher A: A history of neuraxial administration of local analgesics and opioids. Eur J Anaesthesiol 20:682-689, 2003. Gustafsson LL, Schildt B, Jacobsen K: Adverse effects of extradural and intrathecal opiates: Report of a nationwide survey in Sweden. Br J Anaesth 54:479-485, 1982. Ready LB: Acute perioperative pain. In Miller RD (ed): Anesthesia, 5th ed. Philadelphia, Churchill Livingstone, 2000, pp 2323-2350. Reiz S, Westberg M: Side effects of epidural morphine. Lancet 2:203-204, 1980. Sinatra RS: Acute pain management and acute pain services. In Cousins MJ, Bridenbaugh PO (eds): Neural Blockade in Clinical Anesthesia and Management of Pain, 3rd ed. Philadelphia, Lippincott-Raven, 1998, pp 793-835.
PHARMACOLOGY
Further, intrathecal opioids can impair the ventilatory response to carbon dioxide, which can exacerbate respiratory depression. A high index of suspicion and early recognition of delayed respiratory depression are paramount to timely and effective management. Otherwise, there may be fatal or permanent injuries.
■
Ch020-X2215
8/12/06
3:22 PM
Page 74
20
Barbiturates: Porphyrias Christoph N. Seubert Case Synopsis An anxious 24-year-old woman presents with nausea, vomiting, and abdominal pain and is scheduled for an exploratory laparotomy. The past medical history indicates a negative exploratory laparotomy 2 years ago. The patient’s blood pressure is 150/90 mm Hg and pulse is 105 beats per minute. The physical examination reveals abdominal tenderness. Electrolyte levels and white blood cell count are normal. With direct questioning about family history, the patient declares that her mother may have had porphyria.
PROBLEM ANALYSIS Definition Although barbiturates are widely used in anesthetic practice, they may cause an acute attack in susceptible patients with inducible porphyria. Porphyrias are a heterogeneous group of genetic disorders wherein genetic, physiologic, and environmental factors interact to cause disease. Although porphyrias can be classified on the basis of the underlying genetic defects involved in hemoglobin synthesis, the simple clinical division into inducible-acute and noninduciblechronic forms remains useful. An example of the latter is porphyria cutanea tarda (PCT), the most common form of porphyria. Apart from the friability of the patient’s skin and the association with hepatitis C, human immunodeficiency virus (HIV), and alcohol abuse, PCT presents no anesthetic concerns and does not restrict the choice of drugs. In contrast, all patients with acute porphyrias are at risk for porphyric crisis, particularly in the perioperative period. Drugs administered in the perioperative period for the condition requiring surgery, stress, or fasting may precipitate acute attacks of porphyria. If the attack goes untreated or unrecognized, it may be fatal. Conversely, control of precipitating factors or prompt treatment can avert or mitigate the attack and allow the safe conduct of surgery. Acute porphyrias, therefore, present important anesthetic concerns. Porphyrin synthesis occurs in all cells and is of particular importance in the bone marrow and liver. Porphyrins are essential components of proteins involved in the utilization, transport, and storage of oxygen. These proteins include the ubiquitous cytochrome oxidases of the respiratory chain, the hepatic cytochrome P-450 enzymes, and transport proteins such as hemoglobin. Synthesis of porphyrins involves a series of enzymes (Fig. 20-1). Genes for key enzymes of porphyrin synthesis are duplicated in the genome, allowing for separate regulation of heme synthesis in the bone marrow and the liver. In the liver, most heme is used for the production of cytochrome P-450 enzymes. Heme synthesis and P-450 production are regulated in a coordinated fashion. The four acute porphyrias are acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), and δ-aminolevulinic acid dehydratasedeficient porphyria (ADP) (Table 20-1). The gene defects 74
that underlie the acute porphyrias are loss-of-function mutations and typically reduce enzyme activity by half. This reduction results in a pattern of inheritance that is either recessive for the rare ADP or dominant with variable penetrance for the three more frequent acute porphyrias. Although the location of the defective hepatic enzyme in the synthetic pathway for heme varies among the acute porphyrias (see Fig. 20-1), all four may present with acute attacks that are similar in terms of symptoms and treatment. It is not known why enzymatic defects in chronic or erythropoietic porphyrias do not lead to acute attacks. HCP and VP may cause accumulation of excess porphyrins in the skin, where excitation by ultraviolet light causes blistering and scarring skin lesions.
Recognition Acute attacks of inducible porphyria are difficult to recognize in the perioperative setting because symptoms may be nonspecific and varied. Typical symptoms are summarized in Table 20-2. Attacks rarely occur before puberty and seldom recur throughout adult life. They last for several days and are characterized by intense abdominal pain that is steady and poorly localized. The pain intensity contrasts sharply with the paucity of physical findings, sometimes resulting in emergent exploratory laparotomy. Nausea, vomiting, and decreased bowel sounds are common but do not dominate
Glycine + Succinyl CoA ALA Synthetase
negative feedback
Aminolevulinic Acid (ALA)
Heme
Porphobilinogen
Protoporphyrin
Hydroxymethylbilane
Protoporphyrinogen
Uroporphyrinogen
Coproporphyrinogen
Figure 20–1
■
Heme synthesis.
Ch020-X2215
8/12/06
3:22 PM
Page 75
Chapter 20
■
75
Barbiturates: Porphyrias
Acute-Inducible Porphyrias Neurovisceral Symptoms
Photosensitivity
Autosomal recessive
++
–
Autosomal dominant Autosomal dominant Autosomal dominant
+++ ++ ++
– + +
Type
Incidence
Inheritance
δ-Aminolevulinic acid dehydratasedeficient porphyria (ADP) Acute intermittent porphyria (AIP) Hereditary coproporphyria (HCP) Variegate porphyria (VP)
Exceedingly rare (only 7 cases reported) 1:10,000 (higher in Scandinavia) Rare (1:1 million) 1:300,000 (higher in South Africa)
the clinical picture; fever, leukocytosis, and abdominal tenderness are usually absent. Acute attacks of inducible porphyria may involve the peripheral nervous system in the form of a proximally accentuated motor weakness. This weakness occasionally occurs after resolution of the abdominal pain and may resemble Guillain-Barré syndrome, without the characteristic albumin increase in cerebrospinal fluid. Cranial nerves and sensory nerves may be affected, and progression of neurologic involvement to respiratory and bulbar paralysis and death is possible. In a quarter of patients the central nervous system may be involved, resulting in psychiatric symptoms such as anxiety, hallucinations, and paranoia. Generalized seizures may occur as a neurologic manifestation of central nervous system involvement or as a manifestation of severe hyponatremia caused by inappropriate secretion of antidiuretic hormone or vomiting. If acute porphyria is suspected, the diagnosis can be confirmed by screening for and quantifying the porphyrin precursors δ-aminolevulinic acid and porphobilinogen in urine. Daylight can convert the colorless porphobilinogen to porphyrins, causing a darkening and red to purple discoloration of the urine. Resolution of symptoms is usually rapid, but weakness may persist for days or months. In asymptomatic patients, the perioperative diagnosis of acute porphyria relies on a detailed family history. Because the more frequent forms are all inherited as autosomal
dominant diseases, many susceptible patients know of blood relatives with a diagnosis of acute porphyria. In contrast, laboratory investigations may be negative because the patient’s metabolic situation is compensated. Positive diagnosis of porphyria therefore belongs in the hands of a specialist.1
Risk Assessment The prevalence of acute porphyrias (see Table 20-1) is difficult to estimate because as many as 80% of affected patients may never experience an acute attack in their lifetimes. The prevalence of AIP is estimated to be about 1 in 10,000 in North America but may be as high as 1 in 1000 in Scandinavia or in people of Scandinavian descent. Clinically, AIP accounts for three quarters of acute attacks. VP is less prevalent, except in South Africans of Dutch descent; more than 20,000 cases have been traced to a single immigrant couple. HCP is rare, with an estimated prevalence of 1 in 1 million. Only seven cases of ADP have been reported. More important to risk assessment than prevalence data is the fact that acute attacks are always multifactorial. Even prior uneventful exposure to porphyrinogenic drugs does not rule out a diagnosis of acute porphyria. A high index of suspicion is therefore justified if the constellation of symptoms (see Table 20-2) fits that of an acute attack of porphyria.
Implications Table 20–2
■
Symptoms of a Porphyric Crisis
Parameter Peripheral nervous system Sensory Motor Autonomic Central nervous system Psychiatric Endocrine Neurologic Miscellaneous Laboratory
Symptom
Failure to diagnose and treat an acute attack of porphyria confers up to a 10% risk of mortality. Such failure not only prolongs the attack but also puts the patient at risk of further morbidity from the following: ●
Abdominal pain Proximally accentuated weakness; may involve cranial nerves and respiratory muscles Tachycardia; hypertension Anxiety; hallucinations; paranoia SIADH Seizures Nausea, vomiting Increased ALA and PBG in urine; light-exposed urine turns dark red or pink
ALA, δ-aminolevulinic acid; PBG, porphobilinogen; SIADH, syndrome of inappropriate secretion of antidiuretic hormone.
●
●
●
●
●
Further up-regulation of hepatic heme synthesis, because of decreased glucose intake Progression of motor involvement to include respiratory muscles and cranial nerves Residual paresis that persists even after resolution of the attack Seizures, which may be treated with porphyrinogenic drugs Exposure to porphyrinogenic drugs for other supportive treatment Unwarranted surgery
1 Information can be found on the American Porphyria Foundation Web site: www.porphyriafoundation.com.
PHARMACOLOGY
Table 20–1
■
Ch020-X2215
76
8/12/06
3:22 PM
Section 1
■
Page 76
Pharmacology
MANAGEMENT Perioperative care of patients with porphyria involves more than the avoidance of barbiturates. Preoperative assessment should identify whether symptoms of an acute attack are present. In the absence of an acute attack, the anesthetic prescription should consist of nonporphyrinogenic drugs. Details, as well as additional measures to minimize the risk of an acute attack, are discussed later. If the preoperative assessment suggests an acute attack of porphyria, both symptomatic and specific therapies should be instituted in an appropriate inpatient setting.
Acute Attack of Porphyria in the Perioperative Period Therapy for acute attacks of porphyria consists of three interventions: (1) administration of hematin and (2) administration of glucose, both of which inhibit δ-aminolevulinic acid synthase and thus correct the metabolic abnormality; and (3) identification and removal of the precipitating factor to decrease enzyme induction. Hematin (Panhematin, Ovation Pharmaceuticals, Deerfield, Ill) contains alkaline heme from processed human red blood cells. It is a lyophilized powder that is best reconstituted in albumin to form a stable solution and minimize thrombophlebitis and anticoagulation. Depending on the severity of an attack, hematin is given at a dose of 3 to 4 mg/kg for up to 4 days. Hematin replenishes the hepatic heme pool and normalizes the activity of the heme synthesis pathway by providing negative feedback (see Fig. 20-1). Given the mortality risk and the potential for severe or protracted neurologic symptoms with acute attacks of porphyria, hematin therapy should be initiated as early as possible. Glucose, at a dose of 300 to 400 g/day, is less effective than hematin but has been shown to decrease the excretion of porphyrin precursors. Furthermore, fasting and lowcarbohydrate diets can precipitate acute attacks. Although glucose is effective when administered enterally, the nausea and decreased intestinal motility accompanying an acute attack make parenteral administration more feasible. Finally, identification and removal of precipitating factors should include a careful assessment of the patient’s drug therapy to determine the safety implications of such drugs in a patient with suspected acute porphyria (Table 20-3). Given that the causes of an acute attack may be multifactorial, complete removal of all precipitating factors may not be possible. Supportive therapy focuses on the symptoms associated with the attack. Pain is treated with opiates, and electrolyte imbalances are corrected. Cranial nerve involvement may require aspiration prophylaxis, whereas involvement of respiratory muscles may require mechanical ventilation or close monitoring in an intensive care unit. Seizures present a particular challenge because barbiturates, phenytoin, and some other antiseizure drugs are potent triggers for an acute attack. Hyponatremia should be excluded as a cause of seizures, and midazolam or clonazepam can be used safely to stop seizure activity.
Table 20–3
■
Unsafe/Avoid Barbiturates Etomidate Phenytoin Valproic acid Succinimides Pyrazolones Clindamycin Erythromycin Doxycycline Sulfonamides Amiodarone
Safety of Drugs in Patients with Acute Porphyria Use with Caution/ Avoid Ketorolac Macrolides Tetracyclines Quinolones Hydralazine Calcium channel blockers
Probably Safe Opiates Neuromuscular blockers Glycopyrrolate Atropine Neostigmine Naloxone Midazolam Flumazenil Nitrous oxide Halothane Local anesthetics Procainamide β-Blockers Scopolamine Diphenhydramine Chlorpromazine
This list is incomplete, and unlisted drugs cannot be assumed to be safe. These categories are intended to provide guidance and not to replace the clinical judgment of the prescribing physician. Some drugs are categorized based on clinical experience, irrespective of the presence or absence of warnings in the package insert. Porphyrics should be treated with the minimum number of drugs necessary.
Anesthetic Management of Patients with Acute Porphyria Assessment of the safety profile of drugs in porphyria is difficult. On the one hand, drugs are the most frequent precipitating factor of acute attacks. On the other hand, not every exposure of susceptible patients to porphyrinogenic drugs results in an acute attack. Information about drug safety in porphyria is derived from three sources, listed in order of decreasing clinical applicability: (1) actual human cases that suggest a temporal or causal relationship, (2) animal models of induced porphyria, and (3) cell culture. The last two sources tend to overstate the risks to patients and frequently provide conflicting information.2 Volatile anesthetics, for example, are porphyrinogenic in animal models, but clinical experience with halothane and isoflurane suggests that they are safe to use. Many drugs can be used with caution, provided they are indicated and the potential benefits outweigh the risks. The anesthetic plan for patients with porphyria should avoid agents that are known to precipitate acute attacks (see Table 20-3). For general anesthesia, propofol is considered the induction agent of choice, whereas barbiturates and etomidate should be avoided. Muscle relaxants and opioids are safe. As stated earlier, volatile agents appear safe, although data on sevoflurane and desflurane are limited. Local and regional anesthesia can be used safely in patients with porphyria, but during an acute attack, autonomic instability, psychiatric symptoms, weakness, and hypovolemia
2 More detailed drug information and lists of safe and potentially unsafe drugs can be found on the following Web sites: http://web.uct.ac.za/depts/porphyria/professional/prof%20index.htm and http://www.porphyries.com.fr.
Ch020-X2215
8/12/06
3:22 PM
Page 77
Chapter 20
PREVENTION Perioperative prevention of acute attacks in patients with acute porphyria requires careful planning and good communication among all caregivers. Admission on the night before surgery allows prophylactic administration of glucose, thus minimizing the impact of the preoperative fast. Reassurance and premedication can relieve anxiety and stress. Drug administration should be minimized, and each drug should be assessed for its risk of precipitating an acute attack. Because a delayed porphyric crisis may develop 3 to
Barbiturates: Porphyrias
77
5 days after the precipitating event, discharge instructions should stress the symptoms of a porphyric crisis as reportable postoperative complaints. The workup for symptoms should include screening for and quantification of the urinary porphyrin precursors δ-aminolevulinic acid and porphobilinogen. Such an integrated approach allows for the safe conduct of surgery in patients with acute porphyria.
Further Reading Dover SB, Plenderleith L, Moore MR, et al: Safety of general anesthesia and surgery in acute hepatic porphyria. Gut 35:1112-1115, 1994. Elder GH, Hift RJ, Meissner PN: The acute porphyrias. Lancet 349:1613-1617, 1997. Harrison GG, Meissner PN, Hift RJ: Anesthesia for the porphyric patient. Anaesthesia 48:417-421, 1993. James MFM, Hift RJ: Porphyrias. Br J Anaesth 85:143-153, 2000. Palmieri C, Vigushin DM, Peters TJ: Managing malignant disease in patients with porphyria. Q J Med 97:115-126, 2004.
PHARMACOLOGY
may present relative contraindications. Clinical experience suggests that both amide- and ester-type local anesthetics are safe, even though lidocaine increases δ-aminolevulinic acid synthase activity in tissue culture.
■
Ch021-X2215
8/12/06
3:32 PM
Page 78
21
Ketamine Lisa Thannikary and Bhiken Naik Case Synopsis A 68-year-old man is brought to the operating room emergently for exploratory laparotomy after suffering a gunshot wound to the abdomen. He is tachycardiac with a heart rate of 114 beats per minute and hypotensive with a blood pressure of 86/47 mm Hg. He was resuscitated with 2 L of crystalloid in the emergency room. Although he was not intubated, he was unable to give any history owing to acute ethanol intoxication. A rapid-sequence induction with cricoid pressure is performed with intravenous ketamine (3 mg/kg) and succinylcholine (1.5 mg/kg). Intubation occurs without difficulty. Following intubation, the patient’s blood pressure decreases precipitously to 65/33, and an ST segment depression of 2 mm is noted in lead V5. The patient is treated with intravenous fluids and ephedrine, with minimal improvement in blood pressure. A transesophageal echocardiogram shows decreased myocardial contractility.
PROBLEM ANALYSIS Definition Ketamine is a phencyclidine derivative used for the induction of anesthesia; it provides anterograde amnesia as well as intense analgesia. It is the only induction agent that stimulates the sympathetic nervous system centrally, which can lead to an increase in blood pressure and heart rate of approximately 30% from baseline values. These hemodynamic effects are seen after 3 to 5 minutes of intravenous injection and slowly decrease to predrug levels after about 20 minutes. The cardiovascular stimulating effects can be blunted by the prior administration of benzodiazepines or concomitant use of inhalation agents. The mechanisms for the increase in hemodynamic variables are complex. Ketamine is believed to stimulate the central nervous system directly, leading to increased sympathetic outflow. Increased plasma levels of epinephrine and norepinephrine that occur after injection of the drug are also believed to play a role in increasing the heart rate and blood pressure. Ketamine has direct negative inotropic effects, however, that are usually overshadowed by the sympathetic stimulation. These negative inotropic effects are usually seen with depletion of endogenous catecholamine stores or with exhaustion of the sympathetic nervous system compensatory mechanisms in patients who are critically ill or in shock.
Recognition If a patient has an attenuated or blunted response to an induction dose of ketamine, the possibility of depleted catecholamine stores or exhausted sympathetic nervous system compensatory mechanisms, with unmasking of the direct myocardial depressant effects of ketamine, must be considered.
Risk Assessment Clinical scenarios in which the negative inotropic effects of ketamine can be unmasked include the following: ● ●
Prolonged critical illness Uncompensated shock
78
● ● ● ●
Inadequate volume resuscitation Underlying ischemic heart disease Chronic β-blocker therapy Cocaine use
Implications Ketamine antagonizes N-methyl-D-aspartate receptors. It also interacts with μ, δ, and κ opioid receptors, as well as with monoaminergic receptors, muscarinic receptors, and voltage-sensitive calcium channels. It produces dissociative anesthesia resembling a cataleptic state in which the patient is noncommunicative but appears awake. Because ketamine is a phencyclidine derivative, emergence delirium is possible, but this can be reduced with concomitant use of benzodiazepines. Ketamine has a rapid onset of action, a relatively short duration of action, and high lipid solubility. It does not bind significantly to plasma proteins and is initially distributed to highly perfused tissues, such as the brain. Ketamine rapidly crosses the blood-brain barrier owing to its high lipid solubility. Ketamine’s pharmacokinetic characteristics (Table 21-1), coupled with its sympathomimetic effects, make it an ideal induction agent for patients who are hemodynamically unstable.
Table 21–1
■
Pharmacokinetic Properties of Intravenous Ketamine
Parameter
Value
pKa Protein binding (%) Distribution half-life (min) Distribution volume at steady state (L/kg) Clearance (mL/kg/min) Elimination half-life (hr) Breakdown product
7.5 12 11-16 2.5-3.5
Elimination
12-17 2-4 Norketamine (20%-30% potency of ketamine) Renal
Ch021-X2215
8/12/06
3:32 PM
Page 79
Chapter 21
■
Ketamine
79
PREVENTION
MANAGEMENT
It is important to recognize risk factors that may lead to hypotension with the use of ketamine. In these patients, an alternative induction agent should be used.
Before induction of anesthesia, anesthesiologists should attempt to identify patients who might be at risk for developing a hypotensive response to ketamine. Patients with hypovolemic or hemorrhagic shock should be volume-resuscitated before induction, if possible. Invasive monitoring, including central venous pressure, pulmonary artery catheter, or transesophageal echocardiography, can be used in the perioperative period to optimize filling pressures and contractility. If the patient remains hypotensive after induction—despite adequate fluid resuscitation—an inotropic agent or pressor (or both) may be needed to ensure adequate perfusion pressure to the vital organs. The optimal inotropic agent in these patients is a direct-acting sympathomimetic, such as epinephrine or norepinephrine.
Further Reading Reich DL, Silvay G: Ketamine: An update on the first 25 years of clinical experience. Can J Anaesth 36:186-197, 1989. Rogers RJ: Intravenous anesthetic agents. In Kirby RR, Gravenstein N, Lobato EB, et al (eds): Clinical Anesthesia Practice. Philadelphia, WB Saunders, 2002, pp 636-637. Stoelting RK: Nonbarbiturate induction drugs. In Stoelting RK (ed): Pharmacology and Physiology in Anesthetic Practice. Philadelphia, Lippincott-Raven, 1999, pp 148-155. Tweed WA, Minuck MS, Mymin D: Circulatory response to ketamine anesthesia. Anesthesiology 37:613-619, 1972.
PHARMACOLOGY
Caution should be exercised, however, when using ketamine in the aforementioned high-risk patients.
Ch022-X2215
8/12/06
3:33 PM
Page 80
22
Nonbarbiturate Anesthetics Harshdeep Wilkhu, Kevin P. Chan, E. Price Stover, and John L. Atlee Case Synopsis A 53-year-old, 75-kg man with no significant past medical history or allergies is scheduled for a screening colonoscopy. During anesthetic induction he receives a bolus of propofol (80 mg) with additional propofol (170 mg) titrated in divided doses over the course of the procedure. The patient maintains spontaneous ventilation throughout the procedure. Upon completion of the procedure, the patient is responsive to verbal commands and is transferred to the recovery room. Ten minutes after arrival, the patient develops gross arrhythmic jerking of all limbs that appears to be a grand mal seizure.
PROBLEM ANALYSIS Definition In addition to ketamine (see Chapter 21), nonbarbiturate anesthetics include midazolam, etomidate, and propofol. Midazolam is more commonly used as a sedative-anxiolytic than as an intravenous (IV) anesthetic induction agent. Both etomidate and propofol are used as IV induction agents; the former is often preferred for patients with or at risk for hemodynamic instability.
Recognition MECHANISM
OF
ACTION
Midazolam is a benzodiazepine that increases the frequency of chloride channel opening by facilitating γ-aminobutyric acid (GABA) receptor binding, and it has an inhibitory effect on neural function. GABA is the principal central nervous system neuroinhibitory transmitter.
Table 22–1
■
Etomidate is an imidazole derivative. It inactivates the reticular activating system and may also increase GABA receptor availability. Propofol is an alkylphenol. It is presumed to act on GABA receptors in the central nervous system to increase the frequency of chloride channel opening. Thus, propofol too has a neuroinhibitory action. PHARMACOKINETICS Midazolam is water soluble in a buffered acid medium (pH = 3.5) and highly lipophilic at physiologic pH. Other pharmacokinetic data for propofol, etomidate, and midazolam are listed in Table 22-1. Etomidate is water soluble and is dissolved in 35% propylene glycol. Its short duration of action is the result of redistribution after an initial distribution time of 3 minutes. It is metabolized by the liver into inactive metabolites that are excreted by the kidneys (85%) and in the bile (13%). Age decreases its clearance, whereas in cirrhosis, clearance is normal but the volume of distribution and elimination half-time are doubled.
Pharmacokinetic Data for Propofol, Etomidate, and Midazolam Drug
Parameter
Propofol
Etomidate
Midazolam
Distribution half-life (min)
2-8
3-10
Elimination half-life (hr) Biotransformation Metabolites Excretion IV induction dose IV sedation dose IV maintenance dose
0.5-1.5 Hepatic; extrahepatic (lungs) Inactive Renal 1-2.5 mg/kg 10-75 μg/kg/min 50-150 μg/kg/min
Initial: 3 Late: 29 2-5 Hepatic Very weakly active Renal (85%); bile (13%) 0.2-0.5 mg/kg 5-8 μg/kg/min 10 μg/kg/min (with N2O-opiate)
80
1-4 Hepatic Inactive Renal 0.1-0.2 mg/kg 0.5-1 mg incremental dosing 0.05-0.1 μg/kg/min
Ch022-X2215
8/12/06
3:33 PM
Page 81
Chapter 22
HEMODYNAMIC
AND
OTHER EFFECTS
Midazolam has little effect on hemodynamic parameters (Table 22-2). At a dose of 0.2 mg/kg, midazolam appears to be safe in patients with cardiovascular disease. Any increase in heart rate is likely a reflex-caused response to modestly decreased stroke volume and blood pressure, with reduced sympathetic tone secondary to anxiolysis. Hypovolemia accentuates these effects. In contrast, midazolam can cause apnea and decrease the ventilatory response to carbon dioxide (CO2), especially after bolus dosing. Also, midazolam is commonly given with an opiate (e.g., fentanyl, alfentanil) for sedation in the preoperative or ambulatory surgery holding area. Such opiates potentiate midazolam’s effect on respiration, so patients receiving this combination of drugs must be closely monitored for signs of respiratory insufficiency. Etomidate does not affect sympathetic activity or baroreflex function. It confers reliable hemodynamic stability in patients with or without cardiac disease. The myocardial oxygen (O2) supply-demand ratio is maintained. A slightly negative inotropic effect occurs with its solvent (propylene glycol), which likely explains any observed hemodynamic changes (see Table 22-2). In hemorrhagic shock models,
Table 22–2
■
Nonbarbiturate Anesthetics
etomidate is associated with increased survival compared with thiopental. However, some studies suggest that the cardiovascular depression with etomidate is similar to that with propofol. Finally, etomidate is less likely to cause apnea or decrease the ventilatory response to CO2 than is midazolam. Propofol has potent cardiovascular depressant effects. It decreases mean arterial pressure by as much as 40% due to myocardial depression and vasodilatation. Preload and afterload are reduced secondary to decreased venous return and systemic vascular resistance, respectively. This is brought about by propofol’s action to reduce sympathetic tone and directly relax vascular smooth muscle. However, the myocardial O2 supply-demand balance is maintained. Propofol also impairs the vasoconstrictor reflex in acute hemorrhage. Propofol has neuroexcitatory side effects that range from mild, involuntary myoclonic limb movements to grand mal seizures; their timing is quite variable and may occur with induction, in the recovery room, or even many days afterward. However, most neuroexcitatory events related to propofol occur during induction or emergence from anesthesia, when both plasma and cerebral concentrations of the drug are in a dynamic state of flux. They also occur in a variety of scenarios: lengthy or short, major or minor surgical procedures; with or without a prior history of neurologic events.
Risk Assessment When choosing a nonbarbiturate anesthetic for short outpatient procedures, there are several options, including midazolam, etomidate, propofol, and ketamine (see Chapter 21). The most commonly used drug is propofol, owing to its rapid onset of action and recovery and lack of serious side effects. However, when choosing among these nonbarbiturates as IV induction agents, one must consider whether any of the following is present or possible: ● ●
Hypovolemia or circulatory shock Cardiovascular disease
Hemodynamic, Respiratory, and Other Effects of Propofol, Etomidate, and Midazolam Drug
Parameter
Propofol
Etomidate
Midazolam
Heart rate Mean arterial pressure Systemic vascular resistance Mean pulmonary artery pressure Cardiac index Stroke volume Myocardial contractility Apnea Ventilatory response to CO2 Bronchodilatation Nausea and vomiting Analgesia Pain on injection
↓ ↓↓ ↓↓ 0 ↓↓ ↓↓ 0/↓ ↑↑↑ ↓↓↓ + in COPD Decrease Minimal Severe
0/↑ 0/↓ 0/↓ 0/↑ 0/↑ 0/↓ 0/↓ ↑ ↓ 0 Increase Minimal Possible
0/↑ 0/↓ 0/↓ 0 0/↓ 0/↓ 0/↓ ↑↑ ↓↓ 0 Minimal Minimal Minimal
COPD, chronic obstructive pulmonary disease.
81 PHARMACOLOGY
Propofol is highly lipophilic and is formulated in a soybean oil–egg yolk–lecithin emulsion. Pharmacodynamic properties of propofol are dependent on the plasma concentration of the drug. The induction dose of propofol in adults is 1 to 2.5 mg/kg, producing blood concentrations of 2 to 6 μg/mL. Awakening is rapid even after prolonged infusions and typically occurs at plasma concentrations of 1.0 to 1.5 μg/mL. Steady-state propofol blood concentrations are generally proportional to infusion rates. The context-sensitive half-time of propofol is minimally influenced by infusion duration, owing to rapid metabolic clearance. Biotransformation occurs in the liver. Clearance exceeds hepatic blood flow, suggesting the existence of extrahepatic metabolism. Metabolites are secreted in the urine. Hepatic or renal dysfunction does not reduce the clearance of the parent drug.
■
Ch022-X2215
8/12/06
82
● ● ●
● ●
3:33 PM
Section 1
■
Page 82
Pharmacology
Respiratory insufficiency Central nervous system injury or impairment Hepatic or renal impairment and any related pharmacokinetic implications Drug interactions Full stomach or history of acid reflux
MIDAZOLAM As earlier noted, midazolam has minimal adverse cardiovascular effects and appears to be safe in patients with coronary or heart disease (at doses of 0.2 mg/kg); however, it has the potential to aggravate respiratory insufficiency (see Table 22-2). Other considerations include the following: ●
●
●
●
●
●
Hepatic biotransformation with inactive metabolites; renal excretion Slight reduction in cerebral O2 consumption, with little or no decrease in cerebral blood flow Small decrease in intracranial pressure (ICP); small increase in seizure threshold Maintains cerebral autoregulation; large decrease in intraocular pressure (IOP) Slower loss of consciousness and longer recovery period for return of cognitive functions Potential for coughing, hiccups, or involuntary skeletal muscle movements when used for induction of anesthesia
ETOMIDATE Etomidate has generally supportive and beneficial effects on both cardiovascular and cerebral function. However, as noted earlier, there is a slightly negative inotropic effect with its solvent (propylene glycol). Etomidate has minimal effects on ventilation and does not trigger histamine release. It is not an analgesic. Similar to the effects of midazolam, coughing, hiccups, or involuntary skeletal muscle movements (nonepileptogenic) may occur if etomidate is used for anesthetic induction. Although grand mal seizures have occurred with etomidate, it induces electroencephalographic burst suppression at high doses. Other considerations are the following: ● ● ●
●
●
● ●
●
Increased incidence of nausea and vomiting Irritation at peripheral vein injection site Clinically significant adrenocortical inhibition with prolonged infusions May reduce IOP, but this is counteracted by myoclonus, mydriasis, or coughing Unlikely to cause apnea or impair the ventilatory response to CO2 Hepatic metabolism; inactive metabolites; renal elimination Initial distribution half-life of 3 minutes and redistribution half-life of about 30 minutes Elimination half-life of 3 to 5 hours
inotropic effects are due to reduced myocardial intracellular calcium availability, caused by Ca2+ influx inhibition. Overall, propofol decreases sympathetic more than parasympathetic activity, leading to parasympathetic dominance. Propofol produces dose-dependent respiratory depression that acts in synergy with opioids and benzodiazepines. Further, it has a high potential to impair the ventilatory response to CO2 and cause apnea (see Table 22-2). Continuous infusions reduce both the tidal volume and the frequency of breathing; opiates potentiate this effect. Propofol has a bronchodilating effect, and it decreases the intraoperative incidence of bronchospasm with reactive airways disease. In February 2001 the Food and Drug Administration noted that abrupt discontinuation of propofol after prolonged infusion may result in agitation, tremulousness, and hyperirritability in pediatric patients. This led to a pediatric exclusivity labeling change: propofol is not indicated for prolonged use in the pediatric intensive care unit. Other effects to consider are the following: ●
●
● ●
●
●
●
●
Coughing, hiccups, and involuntary skeletal muscle movements with induction Vein irritation and pain on injection (lidocaine helps reduce this, but slow, incremental, “desensitizing” injections are more reliable)1 Antiemetic, antipruritic, and anxiolytic properties Reports of delayed seizures, hallucinations, and opisthotonos Formerly, anaphylactic reactions and bacterial growth were possible with the lipid solvent (less of a problem with the current formulation) Hepatic and possible extrahepatic biotransformation, with inactive metabolites and renal (85%) and bile (13%) excretion Reduction in cerebral O2 consumption, blood flow, and ICP and IOP No effect on seizure threshold, and not an analgesic
Implications The delayed onset of neurologic excitatory events (especially with etomidate or propofol) has serious implications for ambulatory surgery (outpatient) anesthesia practice. When patients are discharged home 1 to 2 hours after surgery or other procedures, they are at serious risk of harm to themselves or others. The patient or family can be traumatized during a seizure, and loss of the airway during this event can have dire consequences. Adverse neurologic sequelae also increase health care costs because many of these patients must be admitted to an intensive care unit to rule out serious pathology and undergo costly diagnostic studies (e.g., magnetic resonance imaging, computed tomography, electroencephalography). In addition, consultant care may be requested for these events.
PROPOFOL Propofol reduces systemic blood pressure by vasodilatation and negative inotropic effects. The inhibition of efferent sympathetic activity results in vascular smooth muscle relaxation and blood pressure reduction. Propofol’s negative
1 We have found that 1-, 2-, and 3-mL “desensitizing” increments of propofol spaced 30 to 45 seconds apart, followed by an IV “push” of the remaining induction dose, are effective at reducing the discomfort associated with propofol induction. Lidocaine (50 mg) can be either mixed with or given before propofol.
Ch022-X2215
8/12/06
3:33 PM
Page 83
Chapter 22
MANAGEMENT Selection of an appropriate nonbarbiturate IV induction agent must take the following issues into consideration: ●
Hypovolemia or hypotension due to hemorrhage ● Restore intravascular volume (preload) and use blood or blood products as needed. ● Optimize ventilation and oxygenation. ● Restore acid-base balance. ● Consider the use of vasoactive drugs. ● Initiate invasive monitoring, transesophageal echocardiography, or both, if needed. ● Choose a nonbarbiturate anesthetic and method of delivery according to the aforementioned considerations.
●
Airway management ● Use awake intubation followed by an IV induction agent or inhalational anesthetic. ● Assess the need for rapid or modified rapid-sequence intubation.
●
Increased ICP ● Choose an IV induction agent accordingly (propofol or etomidate decreases ICP). ● Consider hypocapnia, mannitol, and corticosteroids (see also Chapters 174 and 182).
Neuroexcitatory Events Initially, no treatment may be necessary because the majority of neuroexcitatory events resolve spontaneously. Benzodiazepines are the drugs of choice for events that do not resolve spontaneously. They depress spinal reflexes and reduce the spontaneous electrical activity in all regions of the brain and spinal cord. All benzodiazepines elevate the seizure threshold and thus are considered anticonvulsants. These drugs are quite safe and are rarely fatal, unless taken concomitantly with other sedatives. Second-line therapy for neuroexcitatory events is a barbiturate. This family of drugs depresses the activity of all excitable central nervous system tissue. In general, barbiturates possess a low therapeutic index, along with low selectivity. Hence, they must be dosed cautiously.
PREVENTION Avoidance of complications with nonbarbiturate IV induction agents requires attention to the following issues: ●
●
Hypovolemia and Airway Management
Increased Intracranial or Intraocular Pressure Midazolam, etomidate, and propofol exert a beneficial decrease in ICP, in contrast to ketamine, which increases
83
ICP and can produce emergence delirium. However, slower emergence with midazolam can hinder early postoperative neurologic assessment. Both midazolam and propofol decrease IOP. Etomidate has the same effect, but it can be counteracted by myoclonic activity, mydriasis, and cough caused by etomidate. Ketamine increases IOP.
●
Resuscitation begins with securing a compromised airway, optimizing O2 delivery, restoring intravascular volume, and correcting acidosis. A rapid-sequence induction is usually necessary to minimize the risk of aspiration. In the case of a difficult airway or an unstable cervical spine, awake intubation is indicated in a cooperative patient. The choice of an IV anesthetic is dictated by its cardiovascular, cerebrovascular, and pharmacokinetic effects (see Tables 22-1 and 22-2). Of the agents discussed here, etomidate is probably the safest agent for patients with significant hypovolemia or blood loss. However, regardless of which agent is selected, its dose must be reduced in the presence of significant hemorrhage or reduced intravascular volume, because either of these conditions will increase the amount of drug delivered to the heart or brain due to redistribution of blood flow to vital organs.
Nonbarbiturate Anesthetics
●
Volume repletion and administration of blood or blood products, if indicated Appropriate selection of the IV anesthetic induction agent. Consider time of onset and emergence, amnesia, analgesia, coronary and cerebral perfusion, systemic blood pressure, myocardial and cerebral O2 consumption, onset of apnea, and effects on ICP and IOP. Slow titration and adjustment of induction doses. Careful titration to effect generally prevents abrupt, deleterious changes in blood pressure, unless a rapid-sequence induction is indicated. If so, a vasopressor may be needed for the patient to tolerate the induction. Doses of IV induction agents should be adjusted based on the patient’s age, ideal weight, and hepatic and renal function. Side effects of and relative contraindications to the various IV anesthetic induction agents
For the patient described in the case synopsis, prevention of future neuroexcitatory events suggests that propofol (or etomidate) should not be administered to him in the future. This advice might also apply to patients with a history of neuroexcitatory events. However, no single diagnosis or combination of diagnoses has been implicated as the cause of such events. The seeming rarity of major neuroexcitatory events with administration of propofol or etomidate, along with the lack of reported long-term adverse sequelae, has resulted in their continued use in ambulatory and inpatient settings, especially propofol. The overall risk-benefit ratio for propofol is extremely low, and the decision whether to use the drug should not be based on reports of rare associated neurologic phenomena.
PHARMACOLOGY
Patients with cardiovascular disease or hypovolemia are at increased risk for cardiovascular collapse and myocardial ischemia or infarction after IV anesthesia induction (greatest risk with propofol, followed by midazolam and then etomidate). Hemorrhagic shock results in lactic acidosis, and hepatorenal lactate clearance must be maintained. End-organ perfusion in general must be preserved. Also, the risk of irreversible brain or ocular injury must be carefully evaluated during the selection of a rapid IV induction agent.
■
Ch022-X2215
84
8/12/06
3:33 PM
Section 1
■
Page 84
Pharmacology
Further Reading Dearlove JC, Dearlove OR: Cortical reflex myoclonus after propofol anaesthesia. Anaesthesia 57:834-835, 2002. Reves JG, Glass PSA, Lubarsky DA, et al: Intravenous nonopioid anesthetics. In Miller RD (ed): Miller’s Anesthesia, 6th ed. Philadelphia, Churchill Livingstone, 2005, pp 317-378.
Strachan AN, Raithatha HH: Propofol myoclonus. Can J Anaesth 43:536-537, 1996. Sutherland MJ, Burt P: Propofol and seizures. Anaesth Intensive Care 22:733-737, 1994. Walder B, Tramer MR, Seeck M: Seizure-like phenomena and propofol: A systematic review. Neurology 58:1327-1332, 2002.
Ch023-X2215
8/12/06
3:34 PM
Page 85
PHARMACOLOGY
ANESTHETIC ADJUNCTS
23
Succinylcholine Eugene B. Freid Case Synopsis A 32-year-old woman undergoes emergent open reduction of bilateral femoral fractures sustained in a fall. Past history is pertinent only for mild, hemiparetic, static encephalopathy as a result of meningitis in infancy. Rapid-sequence induction of anesthesia with 20 mg of etomidate and 80 mg of succinylcholine is uneventful. At the end of the 2-hour procedure, she is clinically weak, with four diminished twitches and moderate fade on a train-of-four. She is extubated 1 hour after completion of surgery. Evaluation reveals a pseudocholinesterase activity of 95% and a dibucaine number of 25, which is consistent with an abnormal genetic variant of pseudocholinesterase.
PROBLEM ANALYSIS Definition The onset and offset characteristics of succinylcholine provide distinct advantages over other neuromuscular blocking drugs. Unfortunately, succinylcholine also has a number of well-described complications related to its mechanism of action or pharmacokinetics or that occur as an idiosyncratic effect (Table 23-1). Observations show that hyperkalemia and cardiac arrest develop soon after succinylcholine administration to patients with thermal injury, trauma, upper and lower motor neuron injuries, and various myopathies (Table 23-2). Prolonged relaxation may occur after succinylcholine administration because of the development of a phase II blockade or decreased metabolism. After a single large dose, repeated doses, or a prolonged continuous infusion of succinylcholine, the postjunctional receptor may not respond
normally to acetylcholine, even after the receptor-nicotinic channel has repolarized. This is termed a phase II block and is preferred to the terms dual block and nondepolarization block because phase II block does not imply a specific mechanism. Under normal circumstances, the short duration of the effect of succinylcholine is the result of rapid hydrolysis by pseudocholinesterase. Ninety percent of an intravenous dose of succinylcholine is rapidly hydrolyzed to a nearly inactive metabolite in the plasma and liver by pseudocholinesterase. Neuromuscular blockade terminates by the diffusion of succinylcholine from the end plate into the extracellular fluid because there is no pseudocholinesterase at the motor end plate. Pseudocholinesterase influences the onset and duration of action by controlling the rate of hydrolysis in plasma. A prolonged duration of succinylcholine neuromuscular block may occur when quantities of normal pseudocholinesterase are decreased or when an atypical or abnormal variant of pseudocholinesterase is present.
˜
Table 23–1
■
Complications of Succinylcholine Administration
Cardiovascular Tachycardia (ganglionic stimulation) Bradycardia, sinus arrest, junctional rhythm Hyperkalemia Fasciculations; myalgia* Myoglobinuria, elevated plasma creatine phosphokinase Sustained muscle contraction (myotonic dystrophy, congenital myotonia) Malignant hyperpyrexia Masseter muscle rigidity Prolonged relaxation Phase II block Inadequate pseudocholinesterase activity Increased intraocular pressure* Increased intracranial pressure Increased intragastric pressure* Histamine release
Table 23–2
■
Conditions Predisposing to Exaggerated Potassium Release with Succinylcholine
Thermal injury Traumatic injury Neurologic disease Spinal cord trauma Hemiparesis, lower motor neuron lesions Multiple sclerosis Stroke Guillain-Barré disease Encephalitis Central nervous system trauma Myopathy, muscular dystrophy Disuse atrophy Tetanus
*May be reduced with succinylcholine pretreatment (defasciculation).
85
Ch023-X2215
86
8/12/06
3:34 PM
Section 1
■
Page 86
Pharmacology
Recognition T-wave elevation, QRS complex prolongation and a sinusoidal QRS waveform (see Chapter 14, Fig. 14-2), and arrhythmias (ventricular tachycardia or fibrillation) occurring shortly after succinylcholine administration are the characteristic alterations seen on the electrocardiogram (ECG) in patients with hyperkalemia and exaggerated potassium (K+) release. Measurement of serum K+ concentrations confirms hyperkalemia. However, if the ECG is abnormal, treatment should precede confirmation of serum K+ concentrations. Prolonged relaxation after succinylcholine is indicated by apnea and neuromuscular weakness or paresis. The diagnosis is confirmed by characteristic findings on peripheral nerve stimulation, including a train-of-four (T4/T1) of less than 0.3 and the presence of fade and post-tetanic facilitation. The presence of low levels of normal pseudocholinesterase, or atypical or abnormal forms of pseudocholinesterase, leads to variable prolongation of neuromuscular blockade (Table 23-3). The presence of abnormal pseudocholinesterase is frequently recognized only after moderately or very prolonged blockade occurs in an otherwise healthy patient who received a normal dose of succinylcholine. Nerve monitoring characteristics typical of a phase II block should be expected when abnormal pseudocholinesterase is present due to the large concentration of unmetabolized succinylcholine at the neuromuscular junction.
Risk Assessment POTASSIUM RELEASE Under normal conditions, depolarization of skeletal muscle occurs at acetylcholine receptors at the motor end plate. Fluxes in sodium (Na+) and K+ after succinylcholine typically lead to an increase in serum K+ concentrations of up to 0.5 mEq/dL. In a number of pathologic conditions, however, exaggerated K+ release following succinycholine causes plasma K+ concentrations to rise excessively (see Table 23-2). In patients with denervation states, up-regulation of acetylcholine receptors leads to muscle supersensitivity. In effect, the entire muscle membrane acts as a motor end plate.
Table 23–3
■
The increased zone of permeability to Na+ and K+ leads to exaggerated movement of these ions after the administration of succinylcholine and consequent increased efflux of K+ from the myocytes into the extracellular fluid. The timing of the development of exaggerated K+ release with succinylcholine administration depends on the nature of the injury and follows the timing of the development of acetylcholine receptor supersensitivity. Typically, it begins 5 to 15 days after thermal injury or trauma, peaks at 20 to 60 days, and persists for up to 3 months. In patients with upper and lower motor neuron disease, it begins at 7 days and persists for about 6 months. Pretreatment with a nondepolarizing relaxant does not reliably abolish the hyperkalemic response. In infants and children, myopathy may be clinically unapparent and may be diagnosed only after succinylcholine-hyperkalemic cardiac arrest. In contrast, patients with static encephalopathies (e.g., cerebral palsy) typically do not have exaggerated K+ release after succinylcholine, because their nervous system damage is remote and stable. PHASE II BLOCK Clinically relevant phase II block can occur with total succinylcholine doses as low as 4 mg/kg in some patients, with either repeat dosing or continuous infusions. Such block may be evident with tetanic stimulation in highly sensitive (“fine”) muscle groups (e.g., extraocular muscles) before it occurs in the larger muscles involved in respiration. Development of tachyphylaxis, which manifests as an increase in the amount of infused succinylcholine, often occurs concurrently with the development of clinically relevant phase II block. PSEUDOCHOLINESTERASE Low pseudocholinesterase activity occurs in the newborn and the elderly; with pregnancy, liver disease, malignancy, or thermal injury; and with the use of certain medications (glucocorticoids, estrogens, echothiophate, bambuterol, phenelzine, and cyclophosphamide) and organophosphate pesticides. Pseudocholinesterase levels may drop precipitously
Characteristics of Normal, Atypical, and Abnormal Pseudocholinesterase
Pseudocholinesterase Type
Genotype
Duration of Clinical Block
Homozygous normal Heterozygous dibucaine Heterozygous fluoride Heterozygous silent Dibucaine fluoride Dibucaine silent Fluoride silent Homozygous dibucaine (atypical) Homozygous fluoride Homozygous silent
Eu Eu Eu Ea Eu Ef Eu Es Ea Ef Ea Es Ef Es Ea Ea Ef Ef Es Es
Normal Slightly prolonged Slightly prolonged Slightly prolonged Moderately prolonged Very prolonged Moderately prolonged Very prolonged Slightly prolonged Very prolonged
Dibucaine No.
Fluoride No.
80 60 75 80 50 20 65 20 65 —
60 50 50 60 50 20 35 20 35 —
Adapted from Pantuck EJ, Pantuck CB: Prolonged apnea following succinylcholine administration. In Azar I (ed): Muscle Relaxants. New York, Marcel Dekker, 1987, pp 206-229.
Ch023-X2215
8/12/06
3:34 PM
Page 87
Chapter 23
Succinylcholine
87
medicine specialist for an occult myopathy should be performed.
Prolonged Block Treatment for prolonged relaxation includes ensuring an adequate airway and gas exchange until phase II block is no longer evident (neuromuscular function monitoring) and adequate muscle strength is present. Pure phase II block is reversible with anticholinesterase. However, the block caused by succinylcholine overdose or with atypical or abnormal pseudocholinesterase is mixed (phase I and phase II block). In this case, anticholinesterase therapy may lengthen the duration of phase I block. Most practitioners simply continue ventilatory support until the block wanes and muscle strength has returned to its baseline level. With prolonged block due to atypical or abnormal pseudocholinesterase, ventilatory support must be continued until muscle strength returns. Although banked blood and plasma contain active pseudocholinesterase, the risk associated with their transfusion outweighs the possible benefit of reversing prolonged block. Patients suspected of having atypical or abnormal pseudocholinesterase should be tested for pseudocholinesterase activity and type and made aware of their condition. There should be a note in the patient’s chart indicating an “allergy” to succinylcholine, and the patient should wear a MedicAlert bracelet.
Implications The consequences of succinylcholine-induced hyperkalemia include arrhythmias and cardiac arrest. Prolonged relaxation after succinylcholine requires airway management and mechanical ventilation (with sedation) until the neuromuscular weakness subsides. Patients with atypical or abnormal pseudocholinesterase also demonstrate prolonged metabolism of mivacurium and ester local anesthetics. Because red blood cell esterase hydrolyzes esmolol, its metabolism is unaffected in patients with atypical or abnormal pseudocholinesterase.
MANAGEMENT Hyperkalemia Ventricular tachyarrhythmias and fibrillation are treated with standard advanced cardiovascular life support protocols. In addition, hyperkalemia must be aggressively treated with hyperventilation, calcium salts (chloride or gluconate), sodium bicarbonate, and epinephrine. Hyperventilation, bicarbonate, and β-adrenergic receptor agonists help drive K+ intracellularly, and calcium reduces the cellular effects of high K+ concentrations in the heart. Milder degrees of hyperkalemia are treated with hyperventilation, calcium salts, sodium bicarbonate, and parenteral or inhaled β-adrenergic receptor agonist therapy (albuterol or terbutaline). Glucose and insulin can also be used, but because their effects are more delayed, they are not considered first-line therapy. For children with hyperkalemic cardiac arrest, a postoperative evaluation by a neurologist or physical and rehabilitation
PREVENTION One way to prevent complications with succinylcholine is to avoid it altogether, unless there is a compelling indication for or advantage to its use. This is especially true in young children, who might have clinically unapparent myopathies. Rarely, an unexpected hyperkalemic response may occur, but with the avoidance of succinylcholine in at-risk patients, this should be quite unusual. With the availability of short- and intermediate-acting nondepolarizing agents, the need for large doses or infusions of succinylcholine should be uncommon. If repeated doses or infusions of succinylcholine are used, keeping the total dose under 5 to 6 mg/kg will help. During the preoperative evaluation, a family history of prolonged weakness or delay in awakening from anesthesia should be elicited. There are some geographic regions in which pseudocholinesterase exists because of its hereditary nature. In these regions, preoperative laboratory screening for pseudocholinesterase activity may be useful.
Further Reading Goldhill DR, Martyn JA Jr: Succinylcholine-induced hyperkalemia. In Azar I (ed): Muscle Relaxants. New York, Marcel Dekker, 1987, pp 93-113. Jensen FS, Viby-Mogensen J: Plasma cholinesterase and abnormal reaction to succinylcholine: Twenty years’ experience with the Danish Cholinesterase Research Unit. Acta Anaesth Scand 39:150-156, 1995. Larach MG, Rosenberg H, Gronert GA, et al: Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Am J Anesth 24:241-247, 1997.
PHARMACOLOGY
after plasmapheresis. Low levels of normal pseudocholinesterase generally do not prolong succinylcholine block to a clinically significant degree; this occurs only when normal pseudocholinesterase activity is reduced by at least 75% (normal, 4.9 to 12 IU/mL). In contrast, in patients with genetically atypical or abnormal pseudocholinesterase, the delay in return of normal neuromuscular function can range from mild (10 to 15 minutes) to severe (2 to 4 hours), depending on the variant. The difference among normal, atypical, and abnormal pseudocholinesterase variants is shown in the laboratory with compounds (e.g., dibucaine, fluoride) that inhibit benzoylcholine hydrolysis by pseudocholinesterase. The most common forms of abnormal pseudocholinesterase are the dibucaine-resistant and atypical variants (Eu Ea and Ea Ea, respectively). The homozygous atypical form (Ea Ea) occurs in 1 in 3200 patients, and the heterozygous form (Eu Ea) occurs in 1 in 480 patients. Dibucaine inhibits benzoylcholine hydrolysis by normal pseudocholinesterase by more than 70%; it inhibits benzoylcholine hydrolysis by the atypical (Ea Ea) form by less than 30%. Other forms of pseudocholinesterase include fluoride-resistant variants and a “silent” variant that shows neither dibucainenor fluoride-induced inhibition. Table 23-3 summarizes the characteristics of normal, atypical, and abnormal pseudocholinesterase variants.
■
Ch023-X2215
88
8